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Abstract 
Insulin and IGF-1 are small circulating peptides known to regulate bone mineral density 
and formation in vertebrates through the activation of intracellular PI-3K and MAPK 
signalling pathways. Vanadium/vanadate has recently been shown to regulate 
proliferation and differentiation of mammalian bone-derived cell lines also through the 
activation of both pathways. In this study, proliferative and mineralogenic effects of 
insulin, IGF-1 and vanadate have been investigated using fish bone-derived cell lines 
VSa13 (chondrocyte-like) and VSa16 (osteoblast-like). Short-term treatments of VSa13 
cells with two different forms of vanadate in solution (meta- and decavanadate) 
reavealed that metavanadate (i) results in faster and higher accumulation of vanadate in 
the cell, and (ii) has a lower toxicity than decavanadate when administered in vitro to 
the cells. Chronic treatments with both solutions were found to partially mimic the 
effects of both factors, e.g. stimulated VSa13 cell proliferation, as IGF-1, and prevented 
ECM mineralization, as insulin. Treatments with wortmannin and PD98959 
demonstrated the involvement of MAPK and PI-3K\Ras\ERK pathways in proliferative 
and mineralogenic effects, respectively. These data are consistent with recent 
observations in mammalian ATDC5 cells (chondrocytes) suggesting the conservation of 
mechanisms of action throughout evolution. Vanadate was also shown not only to 
interfere with regulatory pathways but also to inhibit alkaline phosphatase activity, a 
key enzyme in bone formation. In Vsa16 cells, similar effects have been observed on 
proliferation, using IGF-1 (i.e. stimulation), and ECM mineralization, using both IGF-1 
and vanadate (i.e. inhibition), suggesting conservation of mechanisms across bone cell 
types. In parallel to this work, 3 spliced variants of seabream proIGF-1 (IGF-1a, 1b and 
1c) were identified and associated to a different mode of action (local and systemic) in 
adult tissues and during development, as previously observed in mammals. Variants 1a 
 iv
and 1b were also proposed to play a role in fish osmoregulation. Altogether, results 
presented here indicate a conservation of mechanisms between fish and mammals, 
further demonstrating the suitability of fish systems to study vertebrate insulin-like 
effects in bone. 
 
Keywords 
Insulin-like activity; vanadate; intracellular signalling; in vitro mineralization; bone-
derived cell lines; vertebrate bone formation; teleost fish Sparus aurata; Pro-insulin-like 
growth factor 1 (proIGF-1); E domain; alternative splicing.  
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Resumo 
Insulina e IGF-1 são pequenos péptidos circulantes conhecidos por regular a densidade 
mineral e formação óssea em vertebrados através da activação vias de sinalização 
celular PI-3K e MAPK. Por sua vez, demonstrou-se recentemente que o 
vanádio/vanadato regula a proliferação e diferenciação de linhas celulares derivadas do 
osso de mamíferos através mesmas vias. Neste estudo, os efeitos proliferativos e 
mineralogénicos da insulina, IGF-1 e vanadato foram investigados em linhas derivadas 
do osso de peixe: VSa13 (tipo condrócito) e VSa16 (tipo osteoblasto). Tratamentos 
agudos com metavanadato (espécies n-méricas 1 a 5) nas células VSa13 revelaram uma 
acumulação mais rápida e mais elevada de vanádio, bem como uma toxicidade mais 
baixa do que decavanadato (n = 1 ou 10). Tratamentos crónicos com ambas as soluções 
estimularam a proliferação das VSa13, tal como a IGF-1, e preveniram a mineralização, 
tal como a insulina. Tratamentos com wortmanina e PD98959 demonstraram o 
envolvimento das vias MAPK e PI-3K\Ras\ERK nos efeitos proliferativos e 
mineralogénicos, respectivamente. Os dados obtidos são consistentes com observações 
recentes nas células de mamífero ATDC5 (condrócitos) sugerindo uma conservação de 
mecanismos ao longo da evolução. Aparentemente o vanadato não só terá interferido 
com as vias de sinalização mas também com a actividade da fosfatase alcalina, uma 
enzima muito importante na formação óssea. Nas células VSa16 foram observados 
efeitos semelhantes na proliferação através de tratamentos com IGF-1 (estimulação), e 
na mineralização através de tratamentos com vanadato e IGF-1 (inibição), sugerindo 
uma conservação de mecanismos através dos tipos celulares de osso. Em paralelo, neste 
trabalho foram identificadas em seabream 3 variantes da proIGF-1 (IGF-1a, 1b e 1c) e 
associadas a diferentes modos de acção (local e sistémico) em tecidos de adultos e 
durante o desenvolvimento, tal como previamente demonstrado em mamíferos. 
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Propôs-se também que em peixes as variantes 1a e 1b estariam relacionadas com uma 
adaptação a diferentes salinidades. Em geral, os resultados aqui apresentados indicam 
uma conservação de mecanismos em vertebrados, demonstrando a importância dos 
sistemas derivados de peixes no estudo dos efeitos semelhantes à insulina no osso. 
 
Palavras-chave 
Actividade tipo insulina; vanadato; sinalização intracelular; mineralização in vitro; 
linhas celulares derivadas de osso; formação óssea em vertebrados; teleósteos (Sparus 
aurata); Pro-insulin-like growth factor 1 (proIGF-1); domínio E; “splicing” alternativo. 
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1. Introduction 
1.1. Insulin-like activity in mammals 
In mammals, insulin and IGFs belong to a protein family composed of at least eight 
members, including relaxin and four insulin-like peptides [1]. Insulin is a small 
circulating peptide known for its metabolic effects and therapeutic properties in 
diabetes, through regulation of glucose levels in blood [2]. This peptide was first 
purified from bovine pancreas and injected in diabetic patients in 1922, but major 
advances in this therapy only arrived in 1978 when Genentech started to produce 
recombinant human insulin in E. coli. Insulin-like growth factors 1 and 2 (IGF-1 and 
IGF-2) are circulating peptides that share a high sequence similarity with insulin and 
that are known for its growth related and anti-apoptotic properties [3]. Like insulin but 
with more recent history, IGF-1 is currently being tested in clinical trials for the therapy 
of diabetes (type 1 and 2) and growth failure disorders. Companies are seeking United 
States of America Food and Drug Administration (FDA) approval for its 
commercialization.   
 
1.1.1. Insulin and insulin-like growth factors 
Insulin, IGF-1 and IGF-2 are synthesized as pre-pro-peptides. IGF-1 and IGF-2 
pro-peptides (proIGFs) contain 5 domains (B, C, A, D and E) and are processed by the 
proteolytic removal of E domain [3]. Similarly, insulin pro-peptide (proinsulin) contains 
3 domains (B, C and A) and is processed by the proteolytic removal of C domains [4]. 
ProIGFs and proinsulin are processed by SPC1 (furin) in the Golgi apparatus [5,6] 
forming mature peptides of approximately 70 and 51 residues (7.5 and 5.8 kDa), 
respectively. While B, C and A domains of proIGFs are structurally similar to those of 
Chapter I - Introduction 
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proinsulin in terms of amino acid composition, IGFs D domain has no equivalent 
domain in insulin (Figure 1.1) [3].  
 
Figure 1.1 – Processing of IGF and insulin pro-peptides by intracellular peptidase and 2D structure of 
mature peptide. Adapted from Berg et al, 2002, and http://dailymed.nlm.nih.gov/dailymed/fda/. [7] 
 
1.1.2. Insulin and IGF biological effects 
The physiological roles of insulin and IGFs are mainly associated in vertebrates to 
metabolism (glucose, amino acid and lipid), prenatal and postnatal growth, and 
regulation of tissue remodelling (bone) [2,3,8-10]. Insulin is mainly produced in β-cells 
of pancreatic islets of Langerhans under stimulation of circulating glucose and amino 
acids. After being released into bloodstream it readily decreases the circulating levels of 
glucose mainly through its action: (i) in liver, after stimulation of gluconeogenesis and 
glycogenolysis processes, and (ii) in muscle and adipose tissue, after stimulation of 
glucose uptake (mainly through glucose transporter-4, GLUT-4) and consumption [10]. 
Disorders associated to insulin deficiency or resistance, diabetes type I (incapacity to 
Chapter I - Introduction 
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produce insulin by pancreatic cells) and type II (both incapacity to produce insulin and 
tissue inability to respond to this hormone), are mainly characterized by the failure to 
regulate blood glucose levels [2,10]. Besides metabolic effects, insulin is also known to 
produce anabolic effects, such as lipid, protein and DNA synthesis, and to generally 
promote cell proliferation and differentiation during development [2]. Humans lacking 
active insulin receptors (IR), i.e. exhibiting Donohue syndrome, present severe growth 
retardations, adiposity, abnormal glycemia and β-cell failure to produce insulin [1]. 
IGF-1 and IGF-2 are both known to have important roles during development but 
also to act independently with a distinct spatio-temporal distribution [3]. IGF-1 is 
mainly produced in the liver under the stimulation of growth hormone (GH), which is 
secreted by the pituitary gland. In return, IGF-1 decreases GH secretion through its 
action in hypothalamus [3,9,11]. Although liver is responsible for most of circulating 
IGF-1 in vertebrates, approx. 260 ng/ml in mice [12], local production by specific 
tissues, through autocrine/paracrine processes, assumes an important role in 
organogenesis during postnatal growth [12]. IGF-2, which is highly expressed in 
various tissues (resulting in a 3-4 fold higher concentration in serum compared to 
IGF-1), has been shown to be particularly important during early embryogenesis but 
less determinant during postnatal growth [3,13]. Through its effects on either 
proliferation/differentiation of progenitor cells, metabolism or anabolism, several 
tissues/organs/systems have been shown to be regulated by IGFs: (i) central nervous 
system [14,15]; (ii) bone (this will be further discussed later in this chapter) [16-23]; 
(iii) skeletal muscle [24]; (iv) mammary gland; (v) adipose tissue [25,26]; (vi) pancreas 
(pancreatic β-cell proliferation and insulin release) [27-29]; and (vii) reproductive 
system [3]. Most of the tissues/organs/systems regulated by IGF-1 were shown to be 
affected in patients exhibiting Laron syndrome (LS), a disorder characterized by GH 
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resistance (due to GH receptor defects) and consequent reduced levels of circulating 
IGF-1. The main phenotype of patients with LS (Figure 1.2) [30] is: skeletal 
underdevelopment (patients also frequently develop osteoporosis at young age), sparse 
hair, obesity, muscle underdevelopment, hypoglycaemia and smaller/disproportioned 
bodies.. 
 
Figure 1.2 – Laron syndrome (LS) phenotype. A and B, lateral view of a 4-year-old male with LS: low 
height, slight obesity, small chin, saddle nose and protruding forehead. C, 5-year-old male exhibiting LS 
with defective teeth formation. D, hands of a 4-year-old male with LS (left) and 2-year-old male (right). 
E, lateral view of a 45-year-old male with LS exhibiting the same phenotype as in A-D and with sparse 
hair and occipital alopecia. Adapted from Laron, 2002. 
 
The only effective known treatment for LS is the supplementation with exogenous 
IGF-1, which results in: (i) higher glucose (in young age) and lower cholesterol levels in 
blood; (ii) increased liver and bone alkaline phosphatase (ALP) activity; and 
(iii) reduced adipose tissue and increased muscle strength. 
Finally, IGF-1 has been also shown to be related to lifespan and aging but this issue 
is still highly controversial. Nevertheless, IGF-1 receptor (IGF-1R) +/- mice knockout 
studies have suggested an interesting increase in oxidative stress tolerance associated to 
a higher lifespan [31]. 
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1.1.3. Insulin, IGF-1 and IGF-2 receptors and IGF binding proteins 
Biological effects associated with insulin and IGFs are promoted through their 
binding to specific membrane receptors, IR, IGF-1R and IGF-2R (Figure I.3). While IR 
and IGF-1R are both tyrosine kinase receptors (TKR), IGF-2R is a cation-independent 
mannose-6-phosphate receptor (CI-MPR). CI-MPRs are transmembrane glycoproteins 
with long extracellular domains that are implicated in lysosomal degradation [32]. In 
that sense, there has been some controversy concerning IGF-2R specific role in 
mediating IGF-2 effects, but evidences seem to indicate that this receptor is probably 
responsible for clearing circulating IGF-2 [3]. IGF-2 effects are thought to be promoted 
through its binding to a IR splicing variant (IR-A) and IGF-1R [33,34]. However, 
IGF-1, which may also bind to IR with a high affinity [1], can also bind to IGF-2R with 
a very low affinity (~100 times less than IGF-2), thus being cleared from circulation 
[33]. IR and IGF-1R are composed by 4 subunits: two α (extracellular) and 
two β (transmembrane) subunits linked by disulfide bridges [35,36]. β subunits exhibit 
intrinsic PTK activity resulting in auto-phosphorylation of tyrosine residues upon 
binding of specific peptides to the α subunits. Three of these residues are located near 
the PTK catalytic site of β subunit and are responsible for a conformational change and 
consequent activation: catalytic region becomes accessible to peptide substrates and 
MgATP [35,37-39]. 
IGF binding proteins (IGFBPs), which are also part of the IGF system, form a 
family of at least six members, and exhibit a high affinity for IGFs (higher than 
receptors) in circulation, but display a very low or inexistent affinity for insulin [40]. 
The main functions of IGFBPs are to: (i) carry IGF to cells/tissues; (ii) extend IGF 
half-life; (iii) modulate IGF availability; and (iv) modulate IGF binding to receptors and 
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its activities [40]. Additionally, there have been some evidences indicating additional 
IGFBPs effects on cell function (e.g. cell migration) through its interaction with specific 
receptors and independently of its binding to IGFs [40]. Although IGFBPs were 
originally thought to limit IGFs effects, recent studies have shown that, on the contrary, 
they are able to potentiate IGFs effects. It has been proposed that IGFBPs bind IGFs 
with high affinity in serum in order to transport them to the target tissues. This affinity 
would hypothetically be decreased by IGFBP/IGF complex interaction with ECM or 
IGFBPs proteolysis by specific proteases [40]. 
 
Figure 1.3 – Scheme illustrating insulin (Ins), IGF-1 and IGF-2, their specific receptors 
and binding proteins. α and β represent the subunits of insulin and IGF-1 receptors; 
Circled P represents phosphorylation of β subunit; GP indicates glycoprotein of 
IGF-2R. Adapted from Florini et al., 1996. 
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1.1.4. Insulin and IGF intracellular signalling 
Binding of insulin and IGF to α subunits of IR and IGF-1R initiates intracellular 
signalling events that result in biological effects [2,41]. Two main signalling pathways 
can be activated through this mechanism: phosphatidylinositol-3 kinase (PI-3K) and 
mitogen-activated protein kinases (MAPK) [10,41] (Figure 1.4). Briefly, either insulin 
receptor substrates (IRS) or Shc (SH2-containing collagen-related) proteins bind to 
receptor’s tyrosine kinases and become phosphorylated/activated (Figure 1.4). While 
activated Shc forms a complex with GRB-2 (growth factor receptor-bound protein 2) 
adapter and Sos (Son of sevenless), a guanidine nucleotide exchange protein, IRS forms 
a complex with GRB-2 and PI-3K. Consequently, either Shc/GRB-2/Sos complex 
consecutively activates Ras (rat sarcoma viral oncogene) and MAPK, or 
IRS/GRB-2/PI-3K complex activates protein kinase B or C (PKB or PKC) (Figure 1.4).
 
 
Figure 1.4 – Insulin (Ins) and insulin-like 
growth factor 1 and 2 (IGF) intracellular 
signalling pathways. α and β represent the 
subunits of insulin and IGF-1 receptors; Circled 
P represents phosphorylation of β subunit and 
signalling peptides. Filled arrows indicate 
activation by protein/complex; dashed arrow 
indicates PI-3K\Ras\ERK pathway. IRS-1, 
GRB-2, PKB and PKC indicate activated 
intermediates in PI-3K pathway. Shc, Sos, 
GRB-2 (also intermediate in PI-3K), Ras, MEK 
(MAPK/ERK kinase) and 
ERK (extracellular-regulated kinase) indicate 
intermediate proteins in MAPK pathway. 
Adapted from Tiago et al. 2008.
Chapter I - Introduction 
 9
Until recently, it was widely accepted that MAPK and PI-3K pathways were 
responsible for proliferation/differentiation effects and metabolic/anti-apoptotic effects, 
respectively. However, recent data have revealed that each of these pathways can 
generate both responses [10,41,42]. In that sense, proliferative effects induced by 
MAPK were shown to result from downstream activation of transcription factors while 
the same effects are mediated by PI-3K through PKC activation. In both cases, growth 
responses start with activation of AP-1 family of transcription factors (including c-fos 
and c-jun) [2]. Alternatively, GRB-2/IRS/PI-3K complex was shown to be capable of 
activating MAPK through Ras, thus generating a PI-3K\Ras\ERK pathway (Figure 1.4) 
[2,41]. MAPK pathway was shown to mediate anti-apoptotic effects (usually associated 
to PI-3K action) in experiments using cell lines in which IRS (essential intermediate of 
PI-3K pathway) were absent [43].  
Although IR and IGF-1R generate similar intracellular signalling events, insulin and 
IGFs promote in most cases distinct effects [1]. In general, studies using IR, IGF-1R 
and IGF-2R knock-out mice suggested that only IR can mediate insulin signal while 
IGF-1R absence can be compensated by IGFs binding to IR (in particular IGF-2). Thus, 
important questions have arisen concerning what features in each receptor trigger the 
distinct effects. Evidences obtained from studies in which specific residues of IGF-1R 
were mutated suggested that differential phosphorylation of tyrosine residues in 
receptor β subunit may be responsible for differences in signal transduction. Apparently, 
C-terminal tyrosines are specifically associated to mitogenic effects, while 
juxtamembrane tyrosines regulate both PI-3K and MAPK signalling activation [10,41]. 
In fact, a major difference between IR and IGF-1R is precisely located in the C-terminal 
region, in which a quartet of serines is present in IGF-1R and shown to be essential for 
maximal activation of MAPK pathway [44,45]. Finally, tyrosine kinase activity of IR is 
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apparently down-regulated after phosphorylation of serine/threonine in the β subunits. 
Following this idea, it has been suggested that activation of serine kinases (e.g. PKC) 
through either IGF-1 or other hormones and cytokines actions, could constitute a 
negative feedback regulatory mechanism of insulin signalling, or be associated to 
insulin resistance disorder (type II diabetes) [46].  
 
1.1.5. Vanadium and its insulin-like activity 
Vanadium, an essential element in organisms 
Vanadium is a trace element that has been shown to be essential for biological 
activity in various organisms. In plants and algae, vanadium is directly involved in 
specific enzyme activities, acting as a cofactor in vanadium-nitrogenases and 
vanadate-dependent haloperoxidases [47-49]. In mammals, reduced doses of vanadium 
are associated with poorly developed animals, higher rates of spontaneous abortion or 
mortality and bone malformations [50]. Vanadium natural intake by human is 
approximately 10 µg V per day, mainly through vegetables, fruits, eggs, fish, beverages 
(beer and wine). Vanadium is absorbed in the upper gastrointestinal tract and it mainly 
accumulates in bones (ribs and carpal bones), kidney, spleen, ovary and uterus [50]. 
Biological effects of vanadium in vertebrates derive essentially from its capacity to 
interfere with several key enzymes, such as ATPases, phosphorylases, phosphatases 
(alkaline, acid and protein phosphatases) and ribonucleases [48]. This interference, in 
particular with phosphatases, has been attributed to vanadium oxidation states VV and 
VIV (vanadate and vanadyl, respectively), which exhibit some analogy with phosphate 
although to different extents (strong for vanadate and weak for vanadyl). Inhibition of 
phosphatases by vanadate was attributed to the formation of good transition state 
analogues during enzymatic catalysis [48,51] and a similar mechanism was proposed 
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for vanadyl although its geometry of coordination is somewhat different to that of 
phosphate [48].  
An important feature of vanadate resides in its capacity to form different oligomeric 
species (monomeric to decameric species according to pH and concentration [52]; 
Figure 1.5), and to promote distinct effects depending on that oligomerization [53-57].  
 
Figure 1.5 – Molecular structure of vanadate oligomers. V1, V2 and V10 indicate monomeric, dimeric 
and decameric vanadate species, respectively; HV1 indicates protonated monomeric vanadate (HVO42-); 
V4L and V4C indicate linear and circularized tetrameric vanadate species, respectively; V, O and H 
indicate vanadium, oxygen and hydrogen atoms, respectively. V1, V2 and V4 representations were 
adapted from Amado et al., 1993; V10 representation was adapted from Howarth and Jarrold, 
1978.[52,58] 
 
These distinct effects were demonstrated using in vitro and in vivo systems 
[53,59,60]. For example, decameric species were shown, in fish, to induce higher 
oxidative stress and haemoglobin oxidation, to stimulate antioxidant enzyme activities 
and to generate more tissue damages than other oligomeric species [54,61,62]. In 
contrast, monomeric species apparently accumulated at higher rates and doses in cardiac 
muscle, red blood cells and plasma [63]. Decameric species also revealed stronger 
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inhibition and affinity for ATPases, in particular myosin and sarcoplasmic reticulum 
Ca2+-ATPase [53,55,64,65].  
 
Vanadium insulin-mimetic properties 
The most important biological effect of vanadium is probably insulin mimicking. It 
was first demonstrated in the early 80’s, when vanadate and vanadyl treatments applied 
to isolated rat adipocytes [66,67] were shown to stimulate hexose transport, glucose 
oxidation and lipogenesis, as insulin [68]. Additional in vivo studies showed that 
vanadate oral administration to streptozocin-treated diabetic rats resulted in the 
reduction of blood glucose to normal levels [69,70], confirming its ability to mimic 
insulin. Vanadate was consequently proposed as a powerful therapeutic agent for 
diabetes mellitus (insulin-dependent). However, the therapeutic use of vanadate has 
been seriously hampered by its relatively high toxicity at administered doses [71,72]. 
Recent efforts have therefore focused on the discovery of chelating agents, which would 
reduce vanadyl and vanadate toxicity while preserving its insulin-like properties [73].  
Insulin- and IGF-like properties of vanadium have been associated to specific 
inhibition of protein tyrosine phosphatases (PTPases) and consequent activation of 
receptor-associated PTK, including that of IR (Figure 1.6) [72,74-76]. Alternatively, 
non-receptor PTKs, e.g. IRS-1 or cytosolic PTK, are also putative targets in this 
mechanism [77].  
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Figure 1.6 – Insulin (Ins) and insulin-like growth factor 1 and 2 (IGF) intracellular signalling pathways, 
and putative regulation by vanadium. α and β represent the subunits of insulin and IGF-1 receptors; 
Circled P represents phosphorylation of β subunit and signalling peptides; V indicates vanadium. Filled 
arrows indicate activation by previous protein/complex; dashed arrow indicates 
PI-3K\Ras\ERK pathway; intersected line (┬) indicates inhibition or inactivated. IRS-1, GRB-2, PKB 
and PKC indicate activated intermediates in PI-3K pathway. Shc, Sos, GRB-2 (also intermediate in 
PI-3K), Ras, MEK and ERK indicate intermediate proteins in MAPK pathway. Adapted from Tiago et al. 
2008. [78] 
 
1.2. Insulin-like activity in vertebrate bone 
Vertebrate linear bone growth is a process tightly regulated by numerous and 
complex cellular signalling pathways, which are regulated by various growth factors 
and hormones [79-81], including insulin and IGFs [82,83]. In vivo and in vitro 
experiments have demonstrated an association of insulin and IGFs with osteogenesis 
[84-86], bone mineral density and bone formation rate [20,22,87-90]. These processes 
are highly dependent on the effects promoted during development by three major 
skeleton specific cell types: the chondrocyte, the osteoblast and the osteoclast. 
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1.2.1.  Skeleton formation 
Vertebrate skeleton is composed of cartilage and bone tissues, which are mainly 
formed by 3 major cell types: chondrocytes (cartilage specific), osteoblasts and 
osteoclasts (both bone specific) [91]. However, bone and cartilage cell types have 
different progenitor cells. Chondrocytes and osteoblasts derived from mesenchymal cell 
lineage and osteoclasts derived from monocyte cell lineage (Figure 1.7).  
 
Figure 1.7 – Chondrocyte, osteoblast and osteoclast differentiation, its precursors and regulation. OPG 
indicates osteoprotegerin, RANKL indicates receptor activator of NF-kB ligand, TNF-α indicates tumor 
necrosis factor alpha, Wnt indicates wingless-int-1 oncogene, DKK-1 indicates Dickkopf-1 (inhibitor of 
Wnt); arrows indicate activation and intersected line (┬) indicates inhibition. From Goldring and 
Goldring, 2007. [92] 
 
After being completely formed, the skeleton is mostly made of bone tissue. 
Nevertheless, specific processes during development involve formation of cartilage 
templates in intermediary steps. Such events occur during endochondral ossification in 
long bones, which involve: (i) mesenchymal stem cells condensation; (ii) differentiation 
of condensed stem cells into chondrocytes to form a cartilaginous template; (iii) 
chondrocyte proliferation; (iv) chondrocyte differentiation through a process named 
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hypertrophy; (v) ECM calcification by hypertrophic chondrocytes; (vi) chondrocyte 
apoptosis; (vii) vascularisation and degradation of calcified ECM by chondroclasts; 
(viii) condensation of osteoblast progenitor cells; (ix) osteoblast differentiation 
(Figure 1.8) [91]. During hypertrophy, chondrocyte cells produce type II collagen, 
which are randomly oriented fibers that confer tensile strength, and aggrecan, which is a 
proteoglycan that provides a solid base for the ECM [93]. Hypertrophic chondrocytes 
no longer produce type II collagen but instead they synthesize type X collagen. 
 
Figure 1.8 – Representation of growth plate column in long bones. From top to the bottom are 
represented are represented non-differentiated cells, then proliferating non-hypertrophic chondrocytes and 
finally hypertrophic chondrocytes with calcified ECM. Adapted from Karsenty et al., 2002 
 
Endochondral ossification is controlled by several growth factors and transcription 
factors that regulate differentiation and proliferation of cells: Sox5, 6 and 9 (initial 
differentiation), Ihh (Indian hedgehog; proliferation and terminal differentiation), 
C-type natriuretic peptide (proliferation), fibroblast growth factor (FGF) receptor 3 
(growth arrest), Wnt (wingless-int-1 oncogene; non-hypertrophic to hypertrophic 
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transition), Runx2 and parathyroid hormone related protein (terminal differentiation), 
and IGF-1 (proliferation and terminal differentiation) [91].  
During flat bones formation, intramembranous ossification process takes place, 
involving condensation of mesenchymal stem cells and differentiation into osteoblasts. 
Differentiation of osteoblasts, whether in endochondral or intramembranous 
ossification, is also controlled by various growth and transcriptions factors, and in that 
sense Ihh and FGF-18 growth factors, and Cbfa1/Runx2 transcription factor seem to 
play key roles. Other factors, such as bone morphogenic proteins (BMPs), transforming 
growth factor-β and IGF, are also strongly implicated in proliferation and differentiation 
of osteoblasts, although their mode of action, either through direct or indirect pathways, 
remains uncompletely understood [91].  
Differentiated osteoblasts are organized in bone as part of multicellular units named 
osteons, which synthesize a dense cross-linked type I collagen based matrix into which 
hydroxyapatite minerals (Ca10(PO4)6(OH)2) are deposited [94]. This process is assisted 
by several proteins, including the tissue non-specific ALP (TNAP; which cleaves 
pyrophosphate, an inhibitor of ECM mineralization), osteopontin (also named bone 
sialoprotein; an extracellular structural protein) and osteocalcin (OC, also named bone 
Gla protein – BGP – a calcium-binding protein essential for correct mineral maturation) 
[93,94]. Nevertheless, recent results demonstrate that coexpression of TNAP and 
fibrillar collagen (e.g. type I collagen)  is apparently sufficient for ECM mineralization 
to occur [94].  
In general, bone growth, regeneration and homeostasis occurs through a process 
involving sequential osteoblast and osteoclast differentiation (and cell death) which, 
through their specific activities, will form or resorb the mineralized matrix, respectively 
[93]. In this process, osteoclast formation is induced by the release of receptor activator 
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nuclear factor κB (NF-κB)  proteins by osteoblasts, which are in turn stimulated by 
parathyroid hormone, vitamin D and several cytokines [93].  
 
1.2.2. Insulin and IGF in vitro effects in bone-derived systems 
IGFs are the most abundant growth factors in bone, where they have an 
autocrine/paracrine mode of action [81]. In addition, insulin and IGFs also assume 
important roles in bone through an endocrine mode of action [3]. In vitro, insulin and 
IGF (particularly IGF-1) have been shown to induce proliferation [95,96], 
differentiation (measured through ALP activity) [97-100], collagen synthesis (in 
combination with the inhibition of collagen degradation)  [21,23,101-105] and 
anti-apoptotic effects [106] in osteoblast and osteoblast-like cell cultures (e.g. mouse 
primary osteoblasts and pre-osteoblastic cells MC3T3-E1, and human osteosarcoma 
cells MG63). Both MAPK and PI-3K pathways were shown to mediate mitogenic and 
anti-apoptotic effects (see also section 1.1.4) but ERK activation seems to be central in 
these effects. Evidences suggest that activation of MAPK pathway is essential for 
osteoblast differentiation through IGF-1 effects. Although data concerning insulin-like 
activity in chondrocytes or osteoclasts is somewhat limited, evidences point towards 
IGF-1 stimulation of: (i) proliferation [107,108], differentiation [109] and matrix 
synthesis in chondrocytes [19]; and (ii) differentiation of osteoclasts [97,110]. Studies 
developed in mouse ATDC5 chondrocyte cells have suggested that ERK activation 
triggers chondrocyte proliferation while inhibiting its differentiation [108]. Osteoclast 
formation and activity is apparently induced by both IGF-1 and IGF-2 in isolated rat 
osteoclast cultures but only in the presence of osteoblast cells (co-culture with primary 
osteoblast cultures or MG63 pre-osteoblast cells) [110]. 
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1.2.3. Insulin and IGF in vivo effects in bone 
Insulin and IGFs exhibit distinct effects in vivo on chondrocytes, osteoblasts and 
osteoclasts, as already stated in a previous section describing their in vitro effects. These 
in vivo effects have been studied by reverse genetics through knockout and 
overexpression (constitutive or restricted to osteoblasts) experiments in mice. Resulting 
phenotypes, summarized in Table I.1, clearly associate IGF-1, but not IGF-2, to bone 
formation rate and mineral density [3].  
 
Table 1.1 – Mouse with mutations in IGF system and respective bone phenotype. Adapted from Dupont 
and Holzenberger, 2003.  
Model Phenotype Reference 
IGF-1 overproduction in osteoblasts in 
early development 
↑ Bone formation 
↑ mineral density [20] 
IGF-1 constitutive knockout ↓ Mineral density, short bones [9] 
IGF-2 constitutive knockout No delay in ossification [111] 
IGF-1R conditional knockout in 
osteoblasts 
↓ mineralization rate, 
↓ mineral density [16] 
IRS-1 constitutive knockout ↓ Bone formation [112] 
 
Mice with altered IGF-1 and IGF-1R gene expression exhibit mineralization defects, 
demonstrating an important role for IGF-1 signalling during in vivo mineralization of 
the osteoblast ECM [16,20]. Experiments involving specific disruption of IRS-1 gene 
(see previous section) confirm a role of IGF signalling in osteoblast differentiation and 
additionally demonstrate important functions in osteoclastogenesis and bone turnover 
regulation [112]. Furthermore, IGF-1 effects during endochondral ossification have 
been linked to both stimulation of proliferation [113] and hypertrophy [19] of 
chondrocytes. Surprisingly, no significant bone-related phenotypes have been observed 
in IGF-2 knockout mice, suggesting a secondary role for this peptide in that 
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tissue [111]. In humans, low levels of IGF-1 in serum (resulting from a polymorphism 
in IGF-1 gene promoter) have been tentatively associated with a higher susceptibility to 
osteoarthritis and osteoporosis  [114,115]. In a similar way, studies regarding insulin 
have mainly attempted to link type I diabetic condition in mice and human with 
particular bone-related phenotypes [82,87]. In streptozocin-treated mice (induced 
diabetes) intramembranous ossification was apparently accompanied by decreased gene 
expression of important transcription factors (e.g. Runx2). As a result, differentiation of 
osteoblasts was seriously hampered and a significant decrease in synthesis of bone 
matrix proteins such as OC and type I collagen [82] has been observed. In humans, 
diabetes is generally associated with an increased risk of fracture and osteoporosis. 
Histological studies have revealed lower levels of osteocalcin and decreased bone 
matrix formation rate [87]. 
 
1.2.4. Vanadate and its effects in bone 
While adipose tissue has been the focus of most studies related to insulin-like 
properties of vanadium, bone has more recently emerged as a system of interest as a 
result of various observations: (i) vanadium has been shown to promote bone-related 
insulin-like effects [18,47,116,117], (ii) it accumulates in mammalian bones [118] 
and (iii) it affects bone formation if absent from diet [50,119]. In fact, bone is the main 
tissue for vanadium storage in mammals, e.g. approximately 2.4 µg V/g dry matter in 
goat carpal bones against only 1.6 µg V/g dry matter in kidney (the second highest 
concentration of vanadium in tissues) [50]. This accumulation has been proposed to be 
due to vanadium substitution of phosphate anions in the hydroxyapatite lattice and also 
to be related to a detoxification process [120,121]. However, severe malformations 
occurring in bone of animals (e.g. in the forelegs of goats) lacking vanadium (Figure 
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1.9) suggested a mechanism involving specific interaction with growth factors 
signalling, in particular those known to control bone development: platelet-derived 
growth factor (PDGF), fibroblast growth factors (1 and 2), insulin, IGFs, transforming 
growth factors β (1, 2 and 3), and various BMPs [79,116]. In fact, vanadate action 
closely resembled insulin and IGF due to its specific effects on osteoblast 
differentiation, interference with TKR and specific regulation of insulin/IGF associated 
signalling [122].  
 
Figure 1.9 – Newborn vanadium-deficient goat with severely deformed forelegs. In Anke et al., 2004. 
 
Vanadium effects in bone-derived systems in vitro 
Primary culture from rat and chicken calvaria were the first in vitro systems used to 
investigate vanadium insulin-like effects in bone [117,123], in particular the inhibition 
of ALP activity and the stimulation of type I collagen synthesis [122]. Two mammalian 
cell lines, MC3T3-E1 (developed from newborn mouse calvaria, composed of 
pre-osteoblasts and able to mineralize its ECM [124]) and UMR106 (developed from rat 
osteosarcoma, composed of differentiated osteoblasts and unable to mineralize its ECM) 
were later shown to be particularly useful in understanding cellular mechanisms of 
vanadium, insulin- and IGF-like effects. In early studies, vanadium salts (i.e. vanadate, 
vanadyl, hydroperoxo- and peroxovanadium) have been shown to (i) affect osteoblast 
cell differentiation (monitored through the measurement of ALP activity) [125] 
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and stimulate cell proliferation at low doses (i.e. below 25 µM), and (ii) severely impair 
growth at higher doses [126]. Later on, other vanadium complexes (i.e. vanadium 
oxalate, citrate, tartrate and nitrilotriacetate) were tested on MC3T3-E1 and UMR106 
cells proliferative and mineralogenic ability, revealing effects similar to those observed 
for vanadate [127] but still associated with a high cytotoxicity. Promising results arose 
recently from a new generation of vanadium complexes (i.e. 
bis(maltolato)oxovanadium(IV), bis(maltolato) dioxovanadium(V), vanadyl/aspirin, 
vanadyl/trehalose and vanadyl/ascorbate). These complexes have revealed a lower 
cytotoxicity while exhibiting effects similar to those promoted by vanadium salts (in 
particular vanadate). They have also allowed a better characterization of cellular 
mechanisms associated with bone-related vanadium effects, e.g. (i) strong inhibition of 
PTPase, (ii) stimulation of phosphorylation of tyrosine residues and insulin/IGF 
signalling cascade intermediates [128,129]; and (iii) activation of MAPK and PI-3K 
signalling pathways (analyzed using pathways inhibitors) [130-133]. In summary, while 
stimulation of cell proliferation and type-I collagen synthesis were shown to be 
mediated by insulin-dependent mechanisms, inhibition of ALP activity was apparently 
insulin-independent [122]. Since ALP and collagen are critical intermediates in ECM 
mineralization (vide supra section 1.2.1), it is likely that vanadium biological effects in 
bone depend greatly on its effect on these proteins. Nevertheless, the involvement of 
signalling mechanisms in these effects is still poorly understood and will need to be 
further investigated.  
 
1.3. Fish as a model organism to study vertebrate bone formation 
Fish systems have recently emerged as a promising alternative to more classical 
models (i.e. mammalian systems such as mouse, rat or mouse) to investigate vertebrate 
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development and various studies using Danio rerio (zebrafish) have demonstrated the 
suitability of fish models (see review by McGonnell and Fowkes [134]). Important 
features have recently demonstrated the suitability of fish to study vertebrate 
skeletogenesis, including: (i) the presence of fish orthologs for most mammalian genes, 
(ii) the strong resemblance of biochemical and physiological processes between fish and 
mammals and (iii) their important similarities in organ morphology and systems 
composition. In addition, fish systems present various technical advantages such as 
large progeny, external reproduction and fast growth. 
Skeleton formation has been an important subject of study in fish. Interest in fish 
bone investigation has greatly increased after the detection of pathologies in zebrafish 
similar to those found in human systems: (i) chihuahua mutation in type 1 collagen 
gene can model human osteogenesis imperfecta and (ii) cranial neural crest formation in 
zebrafish can model human craniofacial birth defects [134,135]. Moreover, and from an 
economical point of view, the presence of a high rate of skeletal abnormalities in 
aquaculture fish species has also contributed to increase the interest in fish 
skeletogenesis. In that sense, skeletal development of aquaculture fish species has been 
extensively characterized in recent years [136]: important bone markers, such as matrix 
Gla protein (MGP), BMP-2, osteopontin, osteocalcin, etc, have been identified (gene 
and/or protein) and their role in fish tissue mineralization and bone formation has been 
investigated [137-141]. Conversely, important efforts have been made towards the 
development of biochemical, molecular and cellular biology tools from fish systems: 
the genomes of zebrafish, Japanese and green spotted pufferfish, Japanese medaka and 
stickleback have been sequenced and are available (e.g. at Ensembl sequence database –
 www.ensembl.org), microarrays containing thousands of genes have been constructed 
and cell lines have been developed. Remarkably, despite numerous fish cell lines being 
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available, none was derived from bone, and therefore suitable to study mechanism of 
tissue mineralization, until the recent development in our laboratory of two cell lines 
derived from the vertebra of the marine teleost fish Sparus aurata (gilthead 
seabream) [142].  
 
1.3.1. Fish bone-derived cell lines: VSa13 and VSa16 cells 
VSa13 and VSa16 (Figure 1.10) are bone-derived cell lines with chondrocytic and 
osteoblastic properties, respectively, and capable of mineralizing their ECM under 
appropriate conditions, although to different extents and rates [142]. 
 
Figure 1.10 – Phase contrast micrographs of VSa13 (left) and VSa16 cells (right). Cells were cultured in 
Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum, 2 mM glutamine and 
1% antibiotics and antimycotics. Pictures were obtained using a Zeiss Axiovert 25 microscope and an 
Olympus C-3030 Zoom digital camera. Bar = 100 µm. 
 
During ECM mineralization, both cell types deposit calcium/phosphate nodules with 
chemical composition similar to that of hydroxyapatite (demonstrated by X-Ray 
diffraction), and this process has been quantified / analyzed using staining techniques 
specific for phosphate (von Kossa) or for calcium (Alizarin red) [136,142]. Both cell 
lines express MGP and osteocalcin genes in a mutually exclusive manner (i.e. MGP is 
only expressed in VSa13 cells where it is down-regulated during mineralization and 
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osteocalcin is only expressed in VSa16 where it is upregulated during mineralization), 
further demonstrating their relation with distinct bone cell types (i.e. chondrocyte-like 
and osteoblast-like respectively)  [143]. [143]. Finally, both cell lines produce alkaline 
phosphatase and fibrilar collagen in quantity suitable for in vitro studies of ECM 
mineralization. 
 
1.4. Objective 
The effects of insulin, IGF-1 and vanadate on bone metabolism/formation are still 
poorly understood and have been exclusively characterized using classical mammalian 
systems. There are only few data available concerning other vertebrates, and none for 
fish. We proposed to characterize insulin, IGF-1 and vanadate effects on VSa13 
(chondrocyte-like) and VSa16 (osteoblast-like) cell proliferation and ECM 
mineralization, and investigate intracellular signalling mechanisms, as well as important 
bone-related targets (i.e. ALP activity and collagen synthesis), involved in proliferative 
and mineralogenic effects. Ultimately, a comprehensive knowledge of IGF system in 
seabream (and fish in general) is proposed through the cloning of IGF-1 transcript(s) 
and the characterization of gene expression pattern during development and in adult 
tissues. 
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2. Methods 
2.1. Preparation of peptide, vanadate, PD98059 and wortmannin solutions 
Mature peptides of bovine insulin (Sigma Aldrich) and Australian snapper 
(Sparidae: Pagrus auratus) IGF-1 (Novozymes GroPep) were solubilised in pH 2.0 
water (i.e. 1% v/v glacial acetic acid solution) at 10 µM and in pH 6.0 water 
at 0.1 mg/ml, respectively.  
Metavanadate stock solution (50 mM, pH 6.7) was prepared from ammonium 
metavanadate (NH4VO3; Riedel-de-Haen). Decavanadate stock solution was obtained 
by adjusting the pH of the former solution to 4.0, as described elsewhere [55]. Acquired 
characteristic orange color in decavanadate solution upon acidification revealed the 
presence of decameric vanadate species (V10). Decavanadate stock solution was always 
adjusted to pH 7.0 immediately before using it. Both vanadate solutions were stored at 
4°C. Although total vanadate concentration does not change, it should be noted that in 
case of decavanadate solutions the concentration in decameric vanadate species is 
effectively reduced 10-fold, meaning that stock decavanadate solutions contain 5 mM 
decameric vanadate species. However, vanadate concentrations are always given for 
monomeric vanadate (i.e. total vanadate).  
PD98059 and wortmannin (Sigma Aldrich) stock solutions were prepared in DMSO 
at 6 and 10 mg/ml, respectively. 
Milli-Q water (Millipore) was used to prepare solutions used in this work. 
 
2.1.1. Characterization of vanadate solutions in cell culture medium 
Composition of both vanadate solutions was analyzed by 51V Nuclear Magnetic 
Resonance (NMR) spectroscopy as described elsewhere [55]. Briefly, the composition 
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of vanadate solutions upon dilution into Dulbecco’s modified Eagle medium (DMEM 
#21969-035, Invitrogen; see Table AI.1in Appendix I) was analyzed in a Bruker 
AM-400 spectrometer at 105.2 MHz equipped with a 5-mm multinuclear inverse probe, 
using a 90º pulse Fourier transform technique. Spectra were acquired at room 
temperature using 0.5 ml of vanadate samples in the medium, containing at least 10 % 
D2O, under the following conditions: spectral width 45455 Hz, accumulation time 
0.05 s and relaxation delay 0.01 s. 51V NMR chemical shifts are reported relative to an 
external reference of VOCl3 (0 ppm). The relative areas of the several free or/and bound 
vanadate resonances were integrated and the line widths were obtained after subtracting 
the value (20 Hz) used in line broadening. The concentration of each vanadate 
oligomers Vx was calculated from the fractions of the total integrated areas observed in 
the recorded spectra as described (Equation 1). Symbol A corresponds to the area 
measured for the x vanadate species with the n aggregation number (number of 
vanadium atoms), At the sum of measured areas and [Vt] corresponds to total vanadate 
concentration [52]. 
[ ] [ ]
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V t
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x ×=                                                                                           (1) 
The calculated concentrations of vanadate oligomers were reproducible within 
2-4%. For quantitative measurements all spectra parameters were kept constant. 
Vanadate concentrations are always given for monomeric vanadate, i.e. total vanadium. 
Unlike metavanadate, decavanadate solutions are instable. The partial 
de-oligomerization of decameric vanadate species present at the decavanadate solutions 
upon dilution in DMEM was analyzed by ultraviolet/visible spectroscopy (Shimadzu 
UV-2401PC spectrophotometer) at 400 nm, as described elsewhere [63]. 
 
Chapter II - Methods 
 28
2.2. Fish culture 
Eggs collected from natural spawning of seabream (from January to March, 2006) 
were placed at 16ºC in a closed recirculating system with 35 ppt salinity water. Light 
was controlled with fluorescent lamps, maintaining a 12:12 hour light-dark photoperiod. 
Hatching took place 48 to 56 hours after fertilization (HAF; hatched larvae approx. size 
3 mm). Developing larvae were fed with rotifers from 96 HAF to 20 days after 
hatching (DAH; approx. size 7-8 mm) and with newly hatched Artemia nauplii from 20 
to 50 DAH (approx. size 15 mm), as described in table AIII.1 of appendix III. Rotifers 
and A. nauplii were fed with microalgae Tetraselmis suecica and Isochrysis galbana. 
Selco (INVE) was introduced into larval diet between 35 and 45 DAH through the use 
of Selco-enriched A. nauplii. Dry food was introduced into larval diet between 45 and 
70 DAH (approx. size 20 mm) through the use of Selco/dry food mixture (initially 50% 
and then 100% food). After 70 DAH, larvae were maintained on a dry food diet. 
Definitive morphology reached at approximately 90 DAH (approx. size 30 mm). 
Juvenile and adult fish were bred at 16-20ºC in 100 l seawater tanks with a 12:12 hour 
light-dark photoperiod, aeration of 100 ml/minute, and renewal flow of 1 tank/day and 
fed with artificial food (Sorgal).  
 
2.3. Cell culture maintenance 
Cultured VSa13 and VSa16 cells were maintained as described elsewhere [142]. 
Briefly, cells were cultured in DMEM (see Table AI.1 in Appendix I) supplemented 
with 1 % penicillin-streptomycin, 1 % fungizone, 2 mM L-glutamine and 10 % fetal 
bovine serum (Invitrogen), and incubated at 33 ºC in a 10 % CO2 humidified 
atmosphere. Confluent cultures were divided (1:2) every 3-4 days using trypsin-EDTA 
solution (solution T; see appendix I table AI.2). 
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2.4. RNA preparations 
2.4.1. RNA extraction from larvae and tissues 
At appropriate times, pools of at least 10 eggs/larvae/juveniles or tissues from 1 
female and 3 male adult fish (males approx. weight was 0.5 kg and female approx. 
weight was 2 kg; equal amount of male and female tissues were mixed) were sampled. 
Fish and tissue samples were washed twice in phosphate-buffered saline solution 
(PBS 1×; see Table AI.2 in Appendix I) before storage at -80ºC in at least 5 ml of Trizol 
(see Table AI.3 in Appendix I). Total RNA was extracted as described by Chomczynski 
and Sacchi [144]. Briefly, samples were ground to powder in liquid N2 (hard tissues) 
and homogenised in Trizol using a syringe with a 20 G needle. Total RNA was first 
extracted from tissue homogenate with 0.2 volume of chloroform/isoamyl alcohol 
mixture (49:1, freshly prepared) then precipitated from aqueous phase (obtained after 
15 min of centrifugation at 12000×g and 4ºC) with 1 volume of 100% isopropanol. 
After 1 h at -30ºC, total RNA was finally pelleted by centrifugation at 12000×g (15 min, 
4ºC). RNA pellets were washed twice with ice-cold 75% ethanol and re-suspended in 
RNase-free MilliQ water. Total RNA concentration was determined by 
spectrophotometry at 260 nm using GeneQuant spectrophotometer (Pharmacia). Quality 
of all RNA samples was assessed on agarose-formaldehyde gels. 
 
2.4.2. RNA preparation from cultured  cells 
Total RNA was extracted from cultured cells using a method adapted from 
Chomczynski and Sacchi [144]. Cells were washed with PBS 1×, scraped from plates, 
homogenized in 5 ml of solution D (see Table AI.3 in Appendix I) using a syringe with 
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a 20 G needle (to shear genomic DNA). Total RNA was first extrated from cell 
homogenate with 0.1 volume of 2 M sodium acetate pH 4 (mixed by inversion), 
1 volume of phenol pH 4 (mixed by inversion) and 0.2 volume of chloroform/isoamyl 
alcohol mixture (49:1, freshly prepared), then precipitated from aqueous phase 
(obtained after 15 min centrifugation at 10000×g and 4ºC) with 1 volume of 100% 
isopropanol. After 1 h at -30ºC, total RNA was finally pelleted by centrifugation 
(30 min at 10000×g, 4ºC). RNA pellets were solubilized in solution D and RNA was 
again precipitated, washed with ice-cold 75 % ethanol, air dried and finally sollubilized 
in RNase-free MilliQ water. Total RNA concentration was determined by 
spectrophotometry at 260 nm using GeneQuant spectrophotometer (Pharmacia). Quality 
of all RNA samples was assessed on agarose-formaldehyde gels. 
 
2.5. Construction of genomic and complementary DNA libraries 
2.5.1. Construction of genomic DNA library 
Seabream genomic DNA was prepared from a pool of tissues using DNeasy Tissue 
kit (QIAGEN) according to manufacturer instructions, then digested with PvuII or ScaI 
endonucleases. Libraries were constructed using GenomeWalker Universal kit 
(Clontech BD Biosciences) according to manufacturer instructions. 
 
2.5.2. Construction of complementary DNA 
Full-length cDNA library were prepared using Marathon cDNA Amplification kit 
(Clontech BD Biosciences) according to manufacturer instructions. Poly(A+) RNA 
needed for library construction was purified using RNA QuickPrep Micro mRNA 
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Purification kit (Pharmacia) from total RNA extracted from seabream liver, kidney, 
brain and pituitary as described in section 2.4.  
 
2.6. DNA amplification and cloning 
Rapid amplification of cDNA ends (RACE) and amplification of full-length cDNAs 
were performed by polymerase chain reaction (PCR) using a 1:50 dilution of a 
Marathon cDNA library, Advantage Klen Taq Polymerase mix (Clontech BD 
Biosciences) and primers listed in Table AII.1 of Appendix II, according to 
manufacturer’s instructions. Amplification of genomic fragments was performed by 
PCR using GenomeWalker libraries, Advantage Klen Taq Polymerase mix and primers 
listed in Table AII.1 of Appendix II, according to manufacturer’s instructions. PCR 
products were size-separated by agarose gel electrophoresis, purified using the GFX 
PCR DNA and Gel Band Purification kit (Amersham Biosciences) and cloned into 
pCRII-TOPO vector (Invitrogen). Final fragment identification was achieved by DNA 
sequencing (Macrogen) and analyzed using BLAST facilities at NCBI 
(www.ncbi.nlm.nih.gov). 
 
2.7. Sequence reconstruction 
GenBank sequence database was searched in October 2006 using BLAST facilities 
at NCBI for sequences showing similarities to seabream IGF-1 transcripts. Species-
specific sequences were first clustered, and elements of each cluster were assembled 
using ContigExpress module of Vector NTI Suite 10 (Invitrogen) to generate, after 
manual correction, accurate consensus sequences. Virtual transcripts and alternative 
splicing events were deduced from consensus sequences using stringent overlap criteria. 
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2.8. Genomic southern analysis 
Aliquots (10 µg) of seabream genomic DNA, prepared using DNeasy Tissue kit 
were digested with 25 units of selected endonucleases (BglI, BglII, EcoRI, HindIII, PstI, 
and ScaI) and DNA fragments were size-separated on a 0.8 % (w/v) agarose gel for 10 h 
at 50 V. DNA was transferred onto a Hybond-XL nylon membrane (Amersham 
Biosciences) by capillarity blotting with standard saline citrate buffer 10× (SSC 10×; 
see composition in Table AI.6 of Appendix I). IGF-1 cDNA probe (199 bp 
corresponding to cDNA positions 357 to 555 bp) was radiolabeled with [α-32P]dCTP 
(3000 Ci/ml) using the Rediprime II kit (Amersham Biosciences) and purified from 
unincorporated nucleotides using MicroSpin G-50 columns (Amersham Biosciences). 
Hybridization of the blot was performed overnight at 42°C in ULTRAhyb solution 
(Ambion). Blots were washed 2×5 min in low stringency solution (SSC 2× and 0.1 % 
SDS) and 3×15 min in high stringency solution (SSC 0.1× and 0.1 % SDS) at 60°C, 
then autoradiographed. 
 
2.9. Quantitative real-time PCR 
Real-time PCR (qPCR) was performed using iCycler PCR system and software 
(Bio-Rad). Total RNA (1 µg) samples from seabream were treated with RQ1 
RNase-free DNase (Promega) and reverse-transcribed using moloney murine leukemia 
virus reverse transcriptase (Invitrogen) and specific reverse primers listed in 
Table AII.2 of Appendix II. The following reverse transcription reaction conditions 
were used: 3 min at 60ºC, 5 min at 4ºC, 1 h at 37ºC and 5 min at 95ºC. PCR 
amplification of cDNA fragments was performed using the iQ SYBR Green I mix (Bio-
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Rad), 10 ng of reverse-transcribed RNA and specific primers listed in Table AII.2 of 
Appendix II. The following PCR conditions were used: 4 min at 95ºC, 40-50 cycles 
(each cycle is 30 s at 95ºC, 15 s at 68ºC). Changes in gene expression were determined 
through normalization of each transcript threshold cycle with that of corresponding 
housekeeping gene (β-actin or ribosomal protein L27a (RPL27a), assumed to be 
invariant) [145]. This operation was performed using Bio-Rad RelQuant excel sheet.  
 
 
2.10. Cell viability assay 
Cytotoxic and proliferative effects on cells were assessed through cell viability 
analysis using the CellTiter 96 non-radioactive proliferation assay kit (Promega) 
according to manufacturer’s instructions (adapted from the protocol developed by 
Mosmann [146]. Briefly, tetrazolium reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; inner salt, MTS) and the 
electron-coupling reagent, phenazine methosulfate, were mixed in solution in a 20:1 
proportion. Once added to cell culture, MTS is reduced into formazan by a 
mitochondrial dehydrogenase found in metabolically active cells. Formazan formation, 
which is proportional to the number of living cells [147], was followed at 490 nm in 
96-well tissue culture dishes using a Bio-Rad Benchmark microplate reader. Incubation 
with 20 µl of reagent mixture during 1 h was determined to be the optimal after being 
observed linearity between number of cells and formazan absorbance at 490 nm 
wavelength (see Figure AIV.1 in Appendix IV,). Effects were either analyzed in 
confluent cell cultures or low-density cell cultures (starting from 1.5×103 cells/well). 
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2.11. ECM mineralization and nodule detection 
Cells were seeded in 24-well plates at 2×104 cells/well using culture conditions 
described in section 2.3. To induce ECM mineralization, cells were treated with 
50 µg/ml L-ascorbic acid (vitamin C), 10 mM β-glycerophosphate and 4 mM 
CaCl2 during 4 weeks. At appropriate times, cells were washed 3 times with ice-cold 
PBS, fixed with 10% formaldehyde (in PBS 1×) for 1 h at 4ºC, washed 3 times with 
MilliQ water, then incubated with 5% silver nitrate for 30 min under ultraviolet light. 
Relative levels of ECM mineralization were determined by densitometric analysis using 
Quantity One software (Bio-Rad). 
 
2.12. Protein quantification 
Protein concentration in cell extracts was determined using Bradford reagent (Sigma 
Aldrich) according to manufacturer’s protocol (adapted from Bradford [148]). Standards 
and samples were prepared according to Table AIII.2 of Appendix III using 2 mg/ml 
bovine serum albumin (BSA; Pierce) or 10 µl of each sample, then incubated 
approximately 10 min with reagent. Absorbance was measured at 595 nm in a Thermo 
Helios-γ spectrophotometer.  
 
2.13. ALP activity 
Cells were washed 3 times with PBS 1× and scrapped using 500 µl of 0.1% Triton 
X-100. Samples were centrifuged at 16000×g and supernatants collected and stored at 
-20 ºC until further analysis. Protein content was determined as described in section 12 
of Methods. ALP activity was measured at 37ºC through spectrophotometric analysis of 
initial rates of hydrolysis of p-nitrophenyl phosphate (Sigma Aldrich) into p-nitrophenol 
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at 405 nm, using a Shimadzu UV-2401PC spectrophotometer. The following reaction 
mixture has been used: 800 µl of ALP reaction buffer (see Table AI.4 of Appendix I), 
100 µl of p-nitrophenyl phosphate (5 mM in reaction buffer) and 100 µl of supernatant 
(used to set the reaction). ALP activity was normalized with protein content and 
presented as nmol of p-nitrophenol (considering ε = 18200 M-1 cm-1) formed per min 
and per mg of total protein. 
 
2.14. Total collagen content 
Collagen fibbers of ECM were stained using Sirius red dye as described by 
Tullberg-Reinert and Jundt (1999) [149]. Briefly, cell cultures were washed 3 times 
with PBS 1× then fixed for 1 h using Bouin’s fluid (see Table AI.5of Appendix I). After 
fixation, cells were washed with running tap water during 15 min, air dried and 
incubated 1 h (gentle agitation) with Sirius red staining solution (see Table AI.5 of 
Appendix I). Unbound dye was removed by extensive wash using 0.01 N HCl. 
Coloration was observed under an Axiovert 25 inverted light microscope (Zeiss) and 
quantified in a Bio-Rad Benchmark microplate reader at 550 nm after dye re-suspension 
in 200 µl of 0.1 N NaOH solution. 
 
2.15. Vanadium accumulation in cell extracts 
Cells were incubated with vanadate solutions during 24 h. At appropriate times, 
cultures were washed 3 times with PBS 1×, supplemented with 1 ml of MilliQ water 
and placed at -80ºC for at least 12 h. Frozen cells, thawed at room temperature, were 
scrapped from plates and transferred into 2-ml microcentrifuge tubes. Plates were 
washed with 1 ml of MilliQ water then pooled with first extract (total volume sample 
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was 2 ml). Total protein content in samples was quantified as described in section 12 of 
Methods. Remaining sample was digested at 100ºC with 30 µl of 65 % HNO3 and final 
solid residues dissolved in 5% HCl solution. Vanadium concentration was determined 
by atomic absorption spectrometry analysis using a GBC Avanta atomic absorption 
spectrometer equipped with a GBC GF 3000 graphite furnace system and a GBC PAL 
3000 auto sampler working at a furnace program of 63 s with an argon gas flow of 
3.0 l/min. The vanadium lamp was operated at 318.2 nm, with slit width of 0.2 nm, and 
the instrument was calibrated against a series of solutions containing 12.5, 25, 37.5 and 
50 ppb of vanadium. Calibrating standards were obtained by successive dilutions of a 
standard solution of vanadium 1002 ± 2 mg/l (Merck). The detection and quantification 
limits of the instrument for these analysis conditions, determined according to ISO 
8466-1, were 5 and 11 ppb, respectively. 
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3. Results 
3.1. Short exposures of vanadate oligomers differently affect VSa13 cells 
3.1.1. Spectral analysis of metavanadate and decavanadate oligomers in 
DMEM 
51V NMR spectroscopy of decavanadate-DMEM solutions (1 and 5 mM at pH 7.0), 
revealed three signals attributed to three specific vanadium atoms in V10 structure: 
V10A at -515 ppm, V10B at -498 ppm and V10C at -425 ppm (Figure 3.1 A). Similarly, 
signals detected in metavanadate-DMEM solutions (1 and 5 mM at pH 7.0) were 
attributed to mono- (V1), di- (V2), tetra- (V4) and pentameric (V5) vanadate species at -
556 , -571 , -579  and -587 ppm, respectively  (Figure 3.1 A). Monomeric NMR signal 
is clearly broadened, with a half line-width value (270 Hz) approx. 3.4-fold of normal 
value (80 Hz) [65], probably due to vanadate interactions with compounds present in 
DMEM such as glucose (25 mM) and pyruvate (1 mM), or even interactions with 
proteins from FBS, also present in culture medium [53,65]. Concerning each vanadate 
oligomers concentrations in metavanadate solutions in DMEM (1 and 5 mM), different 
profile has been observed (Figure 3.1 B). Interestingly, different profiles have been 
observed for each concentration of metavanadate in DMEM: while tetrameric species 
were predominant at 5 mM, monomeric vanadate was the most abundant at 
1 mM (Figure 3.1 B). On the contrary, the profile of decavanadate solutions was similar 
since decameric species present in the solutions increased linearly with total vanadate 
concentration (Figure 3.1 C). 
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Figure 3.1 - 51V NMR spectra of metavanadate and decavanadate solutions in DMEM. Spectra were 
performed at 22°C and pH 7.1. (A) V1 and V2 correspond to monomeric (H2VO4–) and dimeric (HV2O73– 
and H2V2O72–) vanadate species, respectively, and independently of protonation state; V4 and V5 
correspond to cyclic tetrameric (V4O124–) and pentameric (V5O155–) vanadate specie; V10A, V10B and 
V10C signals correspond different to vanadium atoms in the decameric vanadate specie (V10O286–) 
structure. (B and C) Each vanadate (V) specie concentration was calculated from the fractions of the total 
integrated areas observed in the spectra (as described in section 1.1 of Methods. For quantitative 
measurements, spectral parameters were kept constant and normalized using that of 5 mM decavanadate. 
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3.1.2. Decavanadate stability in DMEM 
51V NMR spectroscopy is an essential tool to analyze vanadate oligomers 
composition and interactions in a solution; however, it is not suitable when analyzing 
the presence of vanadate species at low concentrations (in the µM range). Consequently, 
the stability of vanadate species in culture medium were followed through 
ultraviolet/visible spectroscopy and decomposition rate was determined at 33ºC through 
the time-course analysis of the absorbance (400 nm) of a decavanadate solution 
prepared in DMEM (250 µM, meaning 25 µM decameric species). In these conditions, 
decameric species were shown to decompose through a first order kinetic (Figure III.2), 
which can be mathematically described by equation 1. In this equation, t1/2 is the 
half-life time of the reaction, [V10] is the concentration of decameric species at a given 
time, [V10]0 is the initial concentration of decameric species and k is the kinetic constant 
(which corresponds to the slope of the straight line in a first order kinetic). 
 ln ([V10]/[V10]0) = -kt (1) 
At t1/2, [A] = ½ [A]0, and substituting this values in equation 1 we obtain equation 2. 
 t1/2 = ln(2)/k (2) 
From the graphic in Figure III.2, k is 0.00462 min-1 and substituting values in equation 2 
it has been determined that t1/2 of decavanadate decomposition is approx. 150 min.  
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Figure 3.2 – Decameric species de-oligomerization kinetic in DMEM at 33ºC and pH 7.4, from 250 µM 
decavanadate solution. Before dilution in DMEM of the decavanadate stock solution (50 mM), pH was 
adjusted to 7.4; DMEM was used as absorbance blank at 400 nm; decavanadate in DMEM absorbance 
was measured during approximately 30 min using Shimadzu UV-2401PC spectrophotometer.  
 
3.1.3. Short- and long-term cytotoxic effects of vanadate oligomers in 
VSa13 cells 
Cytotoxicity of vanadate oligomers was tested in confluent cultures of VSa13 cells 
for 15 days using concentrations up to 250 µM (chronic toxicity) or for 4 h using a 
concentration of 1 mM (acute toxicity). Prolonged exposure to metavanadate or 
decavanadate similarly affected VSa13 cell viability (Figure 3.3): treatments using 
concentrations up to 7.5 µM did not decrease cell viability (a slight increase was even 
observed after 15 days) while treatments using 10 to 250 µM concentrations seriously 
affected cell viability, most of the cells being killed at the highest concentrations.  
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Figure 3.3 - Long-term effect of metavanadate and decavanadate on VSa13 cell viability. VSa13 cells 
were seeded in 96-well plates, grown in DMEM until confluence then treated with metavanadate (A) and 
decavanadate (B) using concentrations ranging from 5 to 250 µM. Cell viability was evaluated at 
appropriate times using MTS assay and is presented as the percentage of control value (set to 100%). 
Values are the mean of at least three independent experiments.  
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On the contrary, short-term exposure to metavanadate and decavanadate differentially 
affected VSa13 cell viability (Figure 3.4): while 1 mM decavanadate significantly 
reduced cell viability after 2 h, 1 mM metavanadate showed no effects. After 4 h, both 
solutions significantly reduced the cell viability to levels near 50% (ANOVA – analysis 
of variances). 
 
Figure 3.4 - Short-term effect of metavanadate and decavanadate on VSa13 cell viability. VSa13 cells 
were seeded in 96-microwell plates, grown in DMEM until confluence then treated with 1 mM 
metavanadate and decavanadate. Cell viability was evaluated at appropriate times using MTS assay and is 
presented as the percentage of control value (set to 100%). Values are the mean of at least three 
independent experiments. Asterisk indicates that values are statistically different in comparison to the 
respective control (P < 0.05; one-way ANOVA). Dashed line indicates the half-life of decavanadate in 
DMEM estimated at 2.5 h. 
 
This observation suggests that decameric vanadate species, still present in culture 
medium after 2 h, are likely to induce more toxicity effects than monomeric vanadate 
species, certainly the most abundant vanadate form found in culture medium after 4 h 
(half-life time of decavanadate in DMEM was estimated at 2.5 h) upon decameric 
vanadate desintegration. 
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3.1.4. Vanadium accumulates differently in VSa13 cells upon vanadate 
exposure 
A time-course of vanadium accumulation in VSa13 cells was determined in 
confluent cultures treated with 10 µM metavanadate or decavanadate (shown not to be 
toxic at 24 h; see Figure 3.3). After subtraction of vanadium content measured in non-
treated cells (2.54 ± 0.43 µg V/g of protein; Figure 3.5), vanadium accumulation after 
1 h of treatment was significantly higher (according to Student’s test) in cells treated 
with metavanadate (4.61 ± 0.29 µg V/g of protein) than in cells treated with 
decavanadate (3.24 ± 0.24 µg V/g of protein). A similar but more pronounced 
difference in vanadium accumulations was observed after 2 h of treatment 
(6.85 ± 0.4 µg and 3.95 ±0.1 µg V/g of protein, respectively).  Although longer 
incubation resulted in higher vanadium accumulation (approximately 18-fold increase 
above control value at 24 h), no significant differences have been observed between 
metavanadate and decavanadate treatments. These results suggest that monomeric 
species enter and accumulate more easily in VSa13 cells than decameric species. 
Furthermore, accumulation rates only become similar at longer exposures which is 
consistent with decameric molecules decomposition (t1/2 = 150 minutes). 
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Figure 3.5 - Vanadium accumulation in VSa13 cells upon vanadate exposure. VSa13 cells were seeded in 
100-mm plates, grown in DMEM until confluence then treated with 10 µM metavanadate or 
decavanadate. At appropriate times, vanadium content was determined by atomic absorption from cellular 
extract and normalized with protein content. Vanadium content measured in non-treated samples 
(2.54 ± 0.43 µg V/g of protein) was subtracted to each value. Asterisks indicate statistically significant 
differences between metavanadate and decavanadate according to Student’s test (** p < 0.005 and *** p 
< 0.001). Values are the mean of at least three independent experiments. Dashed line indicates the half-
life of decavanadate in DMEM estimated at 2.5 h. 
 
3.2. Vanadate insulin-like effects on VSa13 cells 
3.2.1. Vanadate and IGF-1 stimulate VSa13 cells proliferation 
Vanadate effect on VSa13 cell proliferation rate was investigated in dividing 
cultures. Both metavanadate and decavanadate (maximum at 7.5 µM) stimulated VSa13 
cell proliferation to a similar extent (consequently only data from metavanadate 
exposure are shown; Figures 3.6, 3.7 and 3.8). In separate experiments, IGF-1,  but not 
insulin (up to 100 nM each; concentrations used in mammalian bone-derived cell 
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systems [150,151]) stimulated VSa13 cells proliferation to an extent similar to that of 
vanadate (maximum stimulation at 10 nM) (Figures 3.6, 3.7 and 3.8).  
 
Figure 3.6 - Effect of vanadate, insulin and IGF-1 on VSa13 cells proliferation. VSa13 cells were seeded 
in 96-well plates at 1.5×103 cell/well then treated either with 7.5 µM vanadate (metavanadate or 
decavanadate), 10 nM insulin or 10 nM IGF-1. Cell proliferation was evaluated at appropriate times using 
MTS assay. Values are the mean of at least three independent experiments. 
 
These results suggest that proliferative effect of vanadate may involve IGF-1 
signalling pathway, but not that of insulin. It is worth noting that no proliferative effects 
were observed for insulin using concentrations up to 100 nM (Figure 3.7). 
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Figure 3.7 - Effect of vanadate, insulin and IGF-1 doses on VSa13 cells proliferation. VSa13 cells were 
seeded in 96-well plates at 1.5×103 cells/well then either left untreated (0) or treated with vanadate (2.5-
10 µM), insulin (1-100 nM) or IGF-1 (1-100 nM). Cell proliferation was evaluated after 8 days using 
MTS assay. Asterisk indicates values statistically different from corresponding controls (n≥3; P<0.05; 
one-way ANOVA). 
 
3.2.2. PD98059 similarly blocks vanadate and IGF-1 stimulation of VSa13 
cell proliferation 
Wortmannin and PD98059, known inhibitors of PI-3K and MAPK, respectively, 
were tested for their effect on VSa13 cell proliferation and for their capacity of reverting 
IGF-1 and vanadate stimulatory effects. Dividing cultures of VSa13 cells were treated 
for 8 days with 0.1 µM wortmannin, 100 µM PD98059 (non-toxic concentrations, see 
Figure AIV.2 of Appendix IV; added volumes of DMSO were non-toxic, data not 
shown), 10 nM insulin, 7.5 µM vanadate and/or 10 nM IGF-1. PD98059 but not 
wortmannin totally abolished vanadate and IGF-1 stimulation of cell proliferation, while 
inhibitors alone had no effect (Figure 3.8). These results provide strong evidence that 
proliferation of VSa13 cells is stimulated by micromolar concentrations of vanadate 
through the same mechanisms as IGF-1, i.e. through activation of the MAPK pathway. 
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Figure 3.8 – Effect of vanadate, insulin, IGF-1, wortmannin and PD98059 on VSa13 cell proliferation. 
VSa13 cells were seeded in 96-well plates at 1.5×103 cells/well then either left untreated or treated with 
PD98059, wortmannin, vanadate, insulin or IGF-1, alone or in combinations. Cell proliferation was 
evaluated after 8 days using MTS assay. Values are the mean of at least three independent experiments. 
Asterisk indicates values statistically different from their respective control (P<0.05; one-way ANOVA). 
 
3.2.3. Vanadate and insulin impair VSa13 ECM mineralization 
Vanadate was then tested for its ability to affect cell differentiation using VSa13 
cells cultured under mineralizing conditions for 4 weeks. ECM mineralization was 
evaluated by densitometric analysis of von Kossa staining. VSa13 cells were either 
treated with 5 µM metavanadate, 5 µM decavanadate, 10 nM insulin and 10 nM IGF-1 
separately, or in combination (Figure 3.9). Both metavanadate and decavanadate 
induced similar effects on ECM mineralization and to a similar extent, therefore only 
metavanadate results have been reported. Vanadate 7.5 µM concentration was excluded 
from this experiment due to cytotoxic effects observed after 4 weeks of treatment (data 
not shown). Insulin and vanadate, but not IGF-1, decreased ECM mineralization 
(according to ANOVA), although to different extents: 30% and 87.5%, respectively. 
Our results also indicate that mineral deposition was almost abolished by a combination 
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of both insulin and vanadate, suggesting that both agents either activate different 
pathways resulting in anti-mineralogenic effect or, on the contrary, activate the same 
pathway but through a synergistic effect, e.g. vanadate would potentiate insulin effect. 
 
Figure 3.9 - Effect of vanadate, IGF-1 and insulin on ECM mineralization. VSa13 cells were seeded in 
24-well plates, grown in DMEM until confluence then treated for mineralization. Mineralizing cultures 
were subsequently treated with 10 nM IGF-1 (IGF-1), 10 nM insulin (Ins), 5 µM vanadate (V), vanadate 
and insulin (Ins + V), or left untreated. Mineral deposition was revealed by von Kossa staining and 
evaluated by densitometric analysis. Values are the mean of at least three independent experiments. 
Asterisk indicates that values are statistically different in comparison to the respective control (P<0.05; 
one-way ANOVA). 
 
3.2.4. PD98059 and wortmannin block both vanadate and insulin effects on 
VSa13 ECM mineralization 
Wortmannin and PD98059 were then tested for their effect on ECM mineralization 
of VSa13 cells and for their capacity of reverting vanadate and insulin inhibitory effects. 
Mineralizing VSa13 cultures were treated for 4 weeks with 0.1 µM wortmannin, 
100 µM PD98059, 10 nM IGF-1, 10 nM insulin, and/or 5 µM vanadate, then evaluated 
for mineralization. As already showed in Figure 3.9, and further demonstrated in 
Figure 3.10, mineral deposition was increasingly impaired by insulin (1.4 fold), 
vanadate (8 folds) and almost abolished by a combination of both agents, while not 
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altered by IGF-1. Interestingly, ECM of PD98059-treated cells, but not that of 
wortmannin-treated cells, exhibited a significant increase in mineral deposition (3.2 
folds) suggesting an antagonist role of MAPK pathway in mineralization (Figure 3.10). 
This role was further confirmed by the reversion (100% and 72.5%, respectively) of 
insulin and vanadate anti-mineralogenic effect by PD98059. Surprisingly, wortmannin 
also reverted (100 % and 57.5%, respectively) insulin and vanadate anti-mineralogenic 
effect, suggesting also a role for PI-3K pathway in mineralization. As expected, 
impairment of mineralization by the combined effect of insulin and vanadate was 
reverted to an extent similar to that observed for vanadate alone. These results suggest 
that both MAPK and PI-3K pathways mediate vanadate and insulin anti-mineralogenic 
effect. However, vanadate anti-mineralogenic action apparently involved other 
mechanisms of action, given that neither PD98059 nor wortmannin completely revert its 
effects. ALP and collagen are important actors of ECM mineralization [94] and the 
action of vanadate on their activity and synthesis, respectively, will be evaluated in the 
next section. 
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Figure 3.10 – Effect of IGF-1, vanadate, insulin, wortmannin and PD98059 on VSa13 ECM 
mineralization. VSa13 cells were seeded in 24-well plates at 2×104 cells/well, grown until confluence 
then treated for mineralization. Mineralizing cultures were then left untreated or treated with IGF-1, 
insulin, vanadate, PD98059, or wortmannin, alone or in combinations. Mineral deposition was revealed 
after 4 weeks by von Kossa staining and evaluated by densitometry analysis. Mineralization data are 
presented as the ratio of individual values with their respective control (non-treated, treated with 
wortmannin and treated with PD98059). Values are the mean of at least three independent experiments. 
Asterisk indicates values statistically different from their respective control (P<0.05; one-way ANOVA). 
 
3.2.5. ALP activity is inhibited while collagen content is increased by 
micromolar concentrations of vanadate 
ALP activity, a marker for osteoblast differentiation shown to be crucial in 
mineralization [94], was determined in mineralizing cell cultures treated with 5 µM 
vanadate and/or 10 nM insulin, and shown to increase by 40% following ECM 
mineralization, while activity remained similar to non-mineralizing control cells upon 
vanadate treatment (Figure 3.11, left panel). In similar experiments, collagen, another 
crucial protein in mineralization [94], was shown to increase by 57% in ECM 
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mineralized cultures and by an additional 17% when those cultures were also treated 
with vanadate (Figure 3.12). The stimulation of both ALP activity and collagen 
production in mineralized cultures is consistent with their role in mineralization 
mechanisms. The inability of insulin to affect ALP activity and collagen production 
suggests that vanadate action occurs through an insulin receptor-independent manner. 
ALP activity was then measured in cellular extracts of mineralized cultures (4 weeks) in 
the presence of increasing concentrations of vanadate: activity was stimulated at low 
concentration (5 µM) while strongly inhibited at higher concentrations (from 25 to 
500 µM) of vanadate (Figure 3.11, right panel). Based on the capacity of VSa13 cells to 
accumulate vanadate (Figure 3.5) and on ALP direct inhibition only at higher vanadate 
concentrations (above 5 µM; Figure 3.11, right panel), it is likely that the mechanism 
for ALP activity down-regulation during mineralization (Figure 3.11, left panel) also 
involves higher vanadate concentrations (i.e. above 5 µM). 
 
Figure 3.11 – ALP activity in mineralized cell cultures treated with insulin and vanadate. VSa13 cells 
were seeded in 24-well plates at 2×104 cells/well, grown until confluence then treated for mineralization. 
Mineralizing cultures were left untreated or treated with insulin and/or vanadate. ALP activity was 
measured in cell extracts after 4 weeks of treatment (left panel) or assayed in the presence of increasing 
concentration of vanadate (right panel). ALP activity was always measure in times lower than 5 minutes. 
Values are the mean of at least three independent experiments. Asterisk indicates values statistically 
different from their respective control (P<0.05; one-way ANOVA). 
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On the contrary, the increase of total collagen content in vanadate-treated mineralized 
cultures (most probably the result of increased type X collagen synthesis as observed in 
differentiated ATDC5 chondrocytes cells [91,93]) can hardly explain the decrease of 
ECM mineralization since increased collagen production is rather likely to benefit ECM 
mineralization. 
 
Figure 3.12 – Collagen content in mineralized cell cultures treated with insulin and/or vanadate. VSa13 
cells were seeded in 24-well plates at 2×104 cells/well, grown until confluence then treated for 
mineralization. Mineralizing cultures were left untreated or treated with insulin and/or vanadate. Total 
collagen content was determined after 4 weeks of treatment through Sirius red staining. Values are the 
mean of at least three independent experiments. Asterisk indicates values statistically different from their 
respective control (P<0.05; one-way ANOVA). 
 
3.3. Insulin-like effects on VSa16 cells  
3.3.1. Proliferation of VSa16 cells is stimulated by IGF-1 but not by vanadate 
Dividing cultures of VSa16 cells were treated for 8 days with 10 nM insulin, 
10 nM IGF-1, 7.5 µM vanadate or left untreated, then cell proliferation was evaluated 
using the MTS assay and compared to that of VSa13 in similar experiments. Results 
illustrated in Figure 3.13 showed that cell proliferation of both cell lines was stimulated 
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by IGF-1, although to a different extent (20% over control in VSa13 cells and 11% over 
control in VSa16 cells), while unaltered by insulin. This observation suggests that, 
unlike insulin, IGF-1 exhibits strong mitogenic activity in fish bone-derived cells. 
Vanadate, in contrast to what has been observed for VSa13 cells, did not stimulate 
VSa16 cell proliferation (Figure 3.13), suggesting that vanadate mitogenic activity in 
fish bone-derived cells is cell type specific. 
 
Figure 3.13 - Effect of vanadate, insulin and IGF-1 on VSa13 and VSa16 cells proliferation. Cells were 
seeded in 96-well plates at 1.5×103 cell/well then treated either with 10 nM insulin, 10 nM IGF-1 or 
7.5 µM vanadate. Cell proliferation was evaluated after 8 days using MTS assay. Values are the mean of 
at least three independent experiments. Asterisk indicates values statistically different from their 
respective control (P<0.05; one-way ANOVA). 
 
3.3.2. Vanadate and IGF-1 impair ECM mineralization in VSa16 cells 
VSa16 cells were cultured under mineralizing conditions for 4 weeks and treated 
with 5 µM metavanadate, 10 nM insulin or 10 nM IGF-1. While insulin, but not IGF-1, 
significantly (ANOVA analysis) inhibited ECM mineralization in VSa13 cells, IGF-1, 
but not insulin, inhibited ECM mineralization in VSa16 cultures to a similar 
extent (i.e. 27% inhibition; figure 3.14). Altogether, these results suggest similar roles 
for insulin and IGF-1 in distinct bone-derived cells (osteoblast versus chondrocyte). 
Finally, vanadate was also shown to promote similar effects in both VSa13 and VSa16 
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cells, i.e. strong inhibition (88% and 66% of control mineralizing cells, respectively) 
without affecting cell viability (data not shown), respectively. Our results suggest that 
vanadate effects in involve similar mechanisms as in VSa13 cells, i.e. signalling 
pathway(s) activated by either insulin or IGF-1, or ALP activity inhibition. 
 
Figure 3.14 - Effect of vanadate, IGF-1 and insulin on ECM mineralization of VSa13 and VSa16 cells. 
Cells were seeded in 24-well plates, grown in DMEM until confluence then treated for mineralization. 
Mineralizing cultures were subsequently treated with 10 nM insulin (Ins), 10 nM IGF-1 (IGF-1), 5 µM 
vanadate (V), or left untreated. N.D. means non-detected. Mineral deposition was revealed by von Kossa 
staining and evaluated by densitometric analysis. Values are the mean of at least three independent 
experiments. Asterisk indicates that values are statistically different in comparison to the respective 
control (P<0.05; one-way ANOVA). 
 
3.4. Alternative splicing of seabream IGF-1 transcript: Distribution and role of 
the splicing variants 
3.4.1. Cloning of seabream IGF-1 transcripts 
A 155 bp fragment was first amplified by 2 rounds of RACE-PCR using Marathon 
primers MarAP1 and MarAP2 combined with reverse primer IGF-1RV1 (see 
Table AII.1 of Appendix II), designed according to the partial sequence published by 
Duguay and colleagues [152]. This fragment was sequenced, identified as the 5’ end of 
IGF-1 cDNA, and then used to design the forward specific primer IGF-1FW1 (see 
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Table AII.1 of Appendix II). Using this primer and Marathon primer MarAP1, two 
fragments of 2204 and 2285 bp were amplified by PCR. Both fragments were 
sequenced and identified as full-length IGF-1 cDNAs, then termed IGF-1a (longer 
transcript; GenBank accession number AY996779) and IGF-1b (shorter transcript; 
GenBank accession number EF688015). The comparison of both sequences identified a 
region of 81 bp present in IGF-1a but absent in IGF-1b (Figure 3.15) and localized 
between positions 492 bp and 572 bp in the sequence coding for IGF-1 E domain. 
Specific primers were designed in order to detect additional IGF-1 transcripts. Using 
primer sets IGF-1FW1 / MarAP1 and IGF-1FW2 / IGF-1RV2 (see Table AII.1 in 
appendix II), a third fragment was amplified, IGF-1c (GenBank accession number 
EF688016). The comparison of IGF-1c sequence with that of IGF-1a identified a region 
of 117 bp present only in IGF-1a (Figure 3.15) and localized between positions 492 bp 
and 608 bp in the sequence encoding IGF-1 E domain. No polyadenylation signal has 
been clearly identified but a putative one has been underlined in Figure 3.13. All 
transcripts identified in this study as seabream IGF-1 encode peptides containing the six 
canonical domains [153] but exhibiting different sizes for the E domain: 74, 47 and 35 
aa for IGF-1a, 1b and 1c, respectively. 
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Figure 3.15 - Seabream IGF-1 full-length cDNA and deduced amino acid sequences. Light grey box and 
black letters indicate the signal peptide; dark grey box and black letters indicate the B domain; dark grey 
box and white letters indicate the C domain; white box indicates the A domain; light grey box and white 
letters indicate the D domain; black box and white letters indicate the E domain; asterisks indicate the 
stop codon; black arrows set the boundaries of the 81-bp alternatively spliced region present in IGF-1a 
transcript but absent in transcripts IGF-1b and IGF-1c (alternative GT donor splice site is bold-
underlined); grey arrows set the boundaries of the 36-bp alternatively spliced region present in transcripts 
IGF-1a and IGF-1b but absent in transcript IGF-1c; putative polyadenylation signal sequence is 
underlined. 
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3.4.2. IGF-1 gene occurrence and structure 
In order to determine whether previously identified transcripts originated from 
alternative splicing of a single IGF-1 gene or from several genes, seabream genome was 
analyzed by Southern blot. Probe was designed within putative exon 3 (determined by 
comparison of seabream cDNA with available IGF-1 genes from zebrafish, salmon and 
flounder), which is present in all 3 transcripts and does not contain restriction sites for 
the endonucleases used to digest DNA. A single signal was detected in each lane of the 
hybridized blot (Figure 3.16), suggesting the presence of a single copy of IGF-1 gene in 
seabream genome and consequently that the various IGF-1 transcripts obtained 
correspond to alternatively spliced variants. 
 
Figure 3.16 - Southern blot analysis of seabream genomic DNA. A 199-bp radiolabeled probe specific 
for exon 3 was used for hybridization; restriction enzymes used to digest genomic DNA (BglI, BglII, 
EcoRI, HindIII, PstI and ScaI) are indicated above each lane; DNA marker sizes are indicated in the right. 
 
Using primers IGF-1FW3 and IGF-1FW4, designed immediately upstream of 
alternatively spliced regions, in combination with GWAP1 and GWAP2 primers, 
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respectively (see Table AII.1 of Appendix II), a genomic fragment of approximately 
4600-bp was amplified, sequenced and identified as partial seabream IGF-1 gene 
(GenBank accession number DQ118098). This genomic fragment was compared with 
each of the transcripts using the Spidey mRNA-to-genomic alignment tool at NCBI, 
allowing the reconstruction of partial IGF-1 gene structure (Figure 3.17). Exon 3 
(partial), exon 4 and exon 5 (containing 3’UTR) were identified, coding for domains A 
(partial), D and E, respectively (Figure 3.17 A). 
 
Figure 3.17 - Schematic representation of seabream partial IGF-1 gene and related cDNAs. (A) Exons 
and domains are represented by boxes; introns are represented by solid thick lines; light grey boxes 
indicate exon 3 and related domains, dark grey boxes indicate exon 4 and related domains and white 
boxes indicate exon 5 and related domains; boxes with dashed lines indicate putative alternative 
transcripts; alternative splicing events in exon 3 and exon 4 are represented by solid and dashed lines; 
primers used for qPCR amplification of alternative transcripts are indicated above IGF-1a cDNA; 
(B) qPCR fragments and primers used to amplify them; first primer set is specific for IGF-1a transcript 
and amplifies a 258-bp fragment; second primer set is specific for IGF-1a and IGF-1b transcripts and 
amplifies a 201-bp fragment; third primer set amplifies a 134-bp fragment common to all three 
transcripts. 
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Alternatively spliced regions were localized within exon 3 and exon 4 and shown to 
be removed through 2 different splicing mechanisms: (i) alternative donor site (two 
functional GT donor sites were localized 81 bp from each other) at the 3’ extremity of 
exon 3 and (ii) alternative skipping of the entire exon 4. In all cases, the phase of intron 
insertion was conserved (phase 0; [154]) thus maintaining the same reading frame. 
 
3.4.3. Expression of IGF-1 transcripts during development and in adult 
seabream 
Relative expression of alternatively spliced transcripts was measured by qPCR in 
developing and adult seabream using three sets of variant-specific primers (see 
Table AII.2 of Appendix II and Figure 3.17): set 1 (IGF-1ABC) to amplify all isoforms, 
set 2 (IGF-1A) to amplify IGF-1a, and set 3 (IGF-1AB) to amplify simultaneously 
IGF-1a and IGF-1b (Figure 3.17 B). IGF-1b relative gene expression was determined by 
subtracting values from set 2 to those from set 3 while relative levels of IGF-1c gene 
expression were determined by subtracting values from set 3 to those of set 1 
(Figures 3.18 and 3.18). IGF-1c was shown to be expressed at basal levels in 
unfertilized eggs and during early development (embryo) while strongly up-regulated 
(around 30-fold) in hatched larvae. Levels of IGF-1c expression remained high in 
juvenile fish. IGF-1a transcript was first detected in larvae at 20 DAH, exhibiting 
intermediate levels of expression that remained stable throughout larval and juvenile 
development. IGF-1b transcript was detected soon after hatching but levels remained 
low throughout larval and juvenile development. All 3 transcripts clearly exhibited 
different patterns of gene expression during development (different onset and extent), 
suggesting different roles during this particular physiological stage in fish. 
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Figure 3.18 - Relative IGF-1 gene expression during seabream development measured by qPCR. IGF-1 
gene expression was normalized using housekeeping gene β-actin; asterisks indicate that transcripts were 
not detected; U/E means unfertilized eggs; values are the mean of at least three independent qPCR 
experiments; insert illustrates the onset and extent of gene expression for each IGF-1 transcripts 
throughout seabream development. 
 
Differences in transcript levels were also observed in adult tissues. IGF-1c was by 
far the most expressed transcript in all adult tissues, exhibiting highest levels of 
expression in liver, adipose tissue and pancreas, and moderate levels in brain, gall 
bladder, spleen and most of the calcified tissues, including poorly calcified branchial 
arches and gills. Both IGF-1a and IGF-1b were poorly expressed in most tissues 
analyzed, with the exception of liver. While high expression of IGF-1c transcripts in 
liver, adipose and pancreas is probably related to a systemic mode of action, lower 
levels of all transcripts in the remaining tissues could be associated to 
autocrine/paracrine regulation. 
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Figure 3.19 - Relative IGF-1 gene expression in seabream tissues measured by qPCR. IGF-1 gene 
expression was normalized using housekeeping gene RPL27a; asterisks indicate that transcripts were not 
detected; values are the mean of at least three independent qPCR experiments. 
 
3.4.4. IGF-1 alternative splicing in vertebrates 
In order to understand the occurrence of IGF-1 variants in seabream, orthologous 
sequences have been searched within GenBank sequence data base using Blast facilities 
at NCBI. Positive search results were considered to be members of the IGF-1 family if 
they showed significant sequence similarity to any of the previously identified members 
and if this similarity extended throughout the protein. Our search identified various 
sequences previously identified as IGF-1 and ESTs with similarities to previously 
characterized sequences, from which we could identify or reconstruct 52 IGF-1-related 
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cDNAs (Figure AIV.3 of Appendix IV). A total of 154 complete or nearly complete 
sequences (all with a complete E domain) have been identified from 41 species 
representing most classes of vertebrates (i.e. mammals, birds, amphibians and bony 
fish). One was identified in a cartilaginous fish (Squalus acanthias) but the homology 
within the E domain was weak making the identification dubious. Consequently, these 
sequences were not included in our analysis of alternative splicing in vertebrate IGF-1 
gene. While sequences of all available bony fish, birds and amphibians were analyzed, 
only sequences from human and mouse were processed for mammals since almost 
nearly complete sets of sequences exist for both species. Our analysis identified 4 
alternatively spliced IGF-1 transcripts in bony fish: three variants exhibited a splicing 
identical to those found in seabream and one was differently spliced (only exon 4 was 
alternatively spliced) and termed IGF-1d according to the nomenclature used in this 
study (Figure 3.17). A single transcript, spliced as seabream IGF-1c, was identified in 
birds and amphibians. Finally, three IGF-1 variants were identified in mammals, one 
spliced as seabream IGF-1c (IGF-1-Ea), and two variants specific to this taxonomic 
group: IGF-1-Eb, which includes exons 4 and 5 in the E domain, and IGF-1-Ec, which 
includes exons 4, partial 5 and 6 [155].  
Analysis of the distribution of IGF-1 variants revealed that (i) IGF-1a transcript was 
specific of the Acanthopterygii and Protacanthopterygii, (ii) IGF-1b transcript was 
mainly found in Ostariophysi (also observed in few Acanthopterygii and 
Protacanthopterygii, (iii) IGF-1c was identified only in seabream and Salmonidae to 
date, and (iv) IGF-1d, the rarest variant, was exclusively found in Salmonidae 
(Oncorhynchus kisutch and Oncorhynchus mykiss). In general, only 6 Osteichthyes 
species expressed multiple IGF-1 variants, and the four fish-related transcripts were 
never simultaneously expressed, although some Salmonidae, if not all, are likely to have 
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the 4 of them. IGF-1c/Ea was shown to be the only variant common to all vertebrate 
taxa (Figure 3.20). On the contrary, other variants were shown to be specific for a taxon: 
IGF-1a, IGF-1b and IGF-1d were only observed in bony fish, and IGF-1-Eb and 
IGF-1-Ec were found exclusively in mammals. IGF-1c was not only the common 
variant in all analyzed classes, but also shown to be the only one present in amphibians 
and birds. IGF-1c/Ea pro-peptide is likely to play systemic role in fish as shown in 
mammals (or would have acquired this role throughout evolution), while other 
pro-peptides (i.e. 1a, 1b, 1d, Eb and Ec) would play specific and local roles that remain 
to be explored. 
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Protacanthopterygii
Acanthopterygii
Ostariophysi
Perciformes
Scorpaeniformes
Pleuronectiformes
Tetraodontiformes
Mugiliformes
Cypriniformes
Siluriformes
Acanthuroidei
Labroidei
Percoidei
Ictaluridae
Clariidae
Serranidae
Scianidae
Percidae
Moronidae
Centrarchidae
Sparidae
Osteichthyes
Amphibia
Aves
Mammalia
Vertebrata
Pimephales promelas FW
Megalobrama amblycephala FW
Megalobrama terminalis FW
Gymnocypris przewalskii FW
Danio rerio FW
Devario aequipinnatus FW
Cyprinus carpio FW B
Cirrhinus molitorella FW
Spinibarbus sinensis FW
Ctenopharyngodon idella FW
Carassius auratus FW
Ictalurus punctatus FW
Clarias macrocephalus FW B
Tetraodon nigroviridis FW B
Mugil cephalus FW B SW
Cottus kazika FW B SW
Myoxocephalus scorpius B SW
Paralichthys olivaceus SW
Oreochromis mossambicus FW B
Siganus guttatus B SW
Epinephelus coioides B SW
Umbrina cirrosa B SW
Perca flavescens FW B
Perca fluviatilis FW B
Dicentrarchus labrax FW B SW
Micropterus salmoides FW
Sparus aurata B SW
Acanthopagrus latus FW B SW
Acanthopagrus schlegeli B SW
Salmo salar M
Oncorhynchus keta M
Oncorhynchus kisutch M
Oncorhynchus mykiss M
Oncorhynchus tschawytscha M
Xenopus laevis
Anser anser
Anas platyrhynchos
Meleagris gallopavo
Struthio camelus
Gallus gallus
Mus musculus
Homo sapiens
Osteichthyes
Amphibia
Aves
Mammalia
EcEba b c/Ea d
Transcripts occurrence Increasing
water salinity
 
Figure 3.20 - Species and vertebrate distribution of IGF-1 alternatively spliced transcripts. Taxonomic 
tree of represented species; taxonomic data were retrieved (10-27-2006) from the Integrated Taxonomic 
Information System at www.itis.usda.gov and fish salinity environment data were retrieved from 
FishBase website at www.fishbase.org; a, b, c and d indicate IGF-1a, IGF-1b, IGF-1c and IGF-1d 
transcripts, respectively; Eb and Ec indicate the mammalian specific IGF-1 transcripts; grey boxes 
indicate the presence of a transcript in a species below, table indicates the distribution of IGF-1 transcripts 
in vertebrates taxons. 
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4. Discussion 
4.1. Metavanadate and decavanadate differently affect VSa13 cells 
The effects of vanadium on bone biology have been extensively studied in 
mammalian in vivo and in vitro systems [50,117-119,122,156], but, to our knowledge, 
no studies have been performed using bone-derived systems of aquatic vertebrate origin. 
One of the goals of this study was to analyze, for the first time, the effects of different 
vanadate oligomers on the proliferation and differentiation/mineralization of fish bone-
derived cell lines since the composition of vanadate solutions is very sensitive to 
vanadate concentration, pH, buffer, and other compounds used in biochemical studies 
[53,55,57,64,65,157]. Therefore, it was of primary importance to precisely characterize 
the species that can interact with a system before attempting to understand the effects 
promoted by vanadate solutions. Unlike metavanadate, containing several 
oxovanadates, decavanadate solutions contain mainly decameric vanadate species 
(V10). However, V10 is unstable in solution at pH 7, and decomposes into monomeric 
vanadate with half-life times of approximately 2 hours [53]. In this regard, species 
present in decavanadate-DMEM solutions have been characterized and its effects on 
VSa13 cells compared with those of metavanadate. 
 
 
4.1.1. Differential effect of monomeric and decameric vanadate species on 
VSa13 cells upon short exposures 
51V NMR spectroscopy analysis of 1 and 5 mM vanadate solutions in DMEM, at pH 
7.0, revealed the presence of: (i) V1, V2, V4 and V5 oligomers in metavanadate 
solution; and (ii) V1 and V10 oligomers in decavanadate solution. According to this 
analysis, lower metavanadate concentrations favour the formation of V1 species, while 
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the proportion of V1:V10 species are maintained upon decavanadate solution dilution. 
However, broadening of monomeric species NMR signal in DMEM (from 80 Hz in 
previous studies [65] to 270 Hz) indicated putative interactions with compounds present 
in medium, such as glucose (25 mM) and piruvate (1 mM), or even interactions with 
several proteins also present in medium, as it has been proposed in previous studies 
[53,65]. The half-life of decameric species decomposition in DMEM was approximately 
150 minutes, a result which was in agreement with other decomposition kinetics 
determined in other systems [53], indicating that short exposure (less than 2.5 h) of 
VSa13 cells to decavanadate solutions would mainly result in effects caused by 
decameric species while long exposure (more than 2.5 h) would mainly result in effects 
caused by newly formed monomeric species. It was consequently not surprising to 
observe similar effects on cell proliferation and differentiation upon long exposure of 
decavanadate and metavanadate. On the contrary, short exposure of VSa13 cells to 
decavanadate was shown to be more toxic than for metavanadate. Considering that 
decavanadate solution contains 10 times less molecules (particularly in shorter exposure 
times, in which decameric species are predominant) than metavanadate (in which 
monomeric species are predominant), short-term toxicity of decavanadate is even more 
remarkable. This result is consistent with previous observations that decavanadate and 
metavanadate produce different oxidative stress levels in cardiac muscle in toadfish and 
gilthead seabream [54,56] and interact differently in vitro with specific proteins such as 
myosin and sarcoplasmic reticulum Ca2+-ATPase [53,65,158].  
Atomic absorption spectrometry analysis has revealed that vanadium differently 
accumulates in extracts from VSa13 cells treated with metavanadate or decavanadate 
solutions (less accumulation of vanadium after 1 and 2 h in decavanadate-treated cells), 
suggesting that the uptake mechanism for decameric species is probably inexistent or 
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less efficient. Although cellular accumulation of metavanadate has been previously 
demonstrated in mammalian systems, e.g. bovine kidney and Caco-2 cells [159,160], 
this process has never been related to the oligomerization of vanadium species until 
now. We propose that repeated exposures of the cells to vanadate may result in 
increasing intracellular accumulation of vanadium, possibly reaching concentrations 
toxic for cellular mechanisms. 
 
4.2. Vanadate insulin-like effects on VSa13 cells  
4.2.1. Insulin-like effects on VSa13 cells proliferation and ECM 
mineralization 
Vanadate (i.e. metavanadate and decavanadate) stimulates VSa13 cell proliferation 
while inhibiting differentiation/mineralization. Similar proliferative effects have been 
reported in mammalian bone-derived cell lines and associated with the activation of 
IR [122]. The absence of proliferative effect in VSa13 cells upon insulin treatment 
suggests that vanadate effect is probably not mediated through IR in fish cells, but 
possibly through IGF-1 receptor/signalling in agreement with the observed stimulation 
of VSa13 cell proliferation by IGF-1. Alternatively, vanadate stimulation of VSa13 cells 
growth could also be mediated by other TKR, such as cytosolic TKR, previously 
proposed as a mediator of vanadate metabolic effects in rat adipocytes [75,161] or 
PDGF receptors [122]. Insulin-like effects on VSa13 cell differentiation/ECM 
mineralization were inhibitory: ECM mineralization was mildly reduced (~30%) by 
insulin, strongly impaired (~88%) by vanadate (regardless of its oligomerization - 
monomeric or decameric), and nearly abolished when both insulin and vanadate were 
present. Inability of IGF-1 to regulate mineralization is likely to be related to the 
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absence of its receptor during this process. Recently, we have analyzed the levels of 
gene expression in VSa13 cells undergoing mineralization using a microarray 
containing approx. 20,000 seabream genes, including IGF-1 receptor (but not insulin 
receptor). Preliminary data indicated the presence of IGF-1R in proliferating cells and 
its absence in mineralizing cells, which further supports our hypothesis. Nevertheless, 
regarding the effect of vanadate, results are not in agreement with those obtained in 
mammalian bone-derived cells, where it was shown to stimulate ECM mineralization 
[122,133]. The reasons for this discrepancy are not clear. However, differences in 
vanadate effects could be species-related (mammalian versus fish) and/or cell type-
related (studies in mammalian were developed in osteoblast-like cell lines while fish 
VSa13 is a chondrocyte-like cell lines) 
 
4.2.2. MAPK pathway transduces vanadate stimulation of cell proliferation 
Prolonged exposure of VSa13 cells to low levels of metavanadate and decavanadate 
stimulated cell proliferation, in agreement with recent reports on the effect of 
ortovanadate and vanadium derivatives in mammalian bone-derived cell cultures 
MC3T3E1 and UMR106 [127-129,162], where vanadium effect was attributed to its 
ability to increase phosphotyrosine protein levels and to inhibit PTPase, thus regulating 
growth signalling pathways. Reversion of vanadate and IGF-1 proliferative effect by 
PD98059 demonstrated the involvement of the MAPK pathway in these mechanisms. 
Similar observations in mammalian osteoblast-like cell lines (i.e. MC3T3E1 and 
UMR106) [132,133], suggest a conservation of mechanisms of action throughout 
evolution and across bone cell types. Similar mechanisms (i.e. a key role of MAPK 
pathway in proliferative effect of IGF-1) have also been recently reported in the mouse 
chondrocyte ATDC5 cell line [108]. We propose on the basis of these results and those 
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reported in this study, a mechanism involving MAPK pathway that would regulate 
chondrocyte proliferation and also transduce vanadate effect (Figure 4.1). 
 
Figure 4.1 - Putative mechanisms of action for insulin, IGF-1 and vanadate in vertebrate chondrocyte 
cells. Circled 5 and 13 indicate pathways related to ATDC5 and VSa13 cell lines, respectively. Black, 
gray and dashed arrows indicate activated, moderately activated and putatively activated pathways, 
respectively. X indicates an absence of effect. V, vanadate. Raf, MEK and ERK are intermediates in the 
MAPK pathway. 
 
4.2.3. PI-3K\Ras\ERK pathway mediates insulin and vanadate impairment of 
VSa13 ECM mineralization 
The similarity in the anti-mineralogenic effects triggered by vanadate and insulin 
suggests that vanadate effect may occur through IR and/or signalling pathway, on the 
contrary to what has been proposed for its proliferative effect (i.e. involvement of 
IGF-1R and/or signalling pathway). The reversion of both insulin and vanadate effect 
by both PD98059 and wortmannin suggest a complex mechanism involving 2 signalling 
pathways, those of PI-3K and MAPK. We proposed, in agreement with recent results 
obtained in mouse MC3T3-E1 cells [163], that PI-3K\Ras\ERK pathway (a combination 
of MAPK and PI-3K pathways) may regulate VSa13 cell differentiation/ECM 
mineralization. We also propose, in agreement with recent results obtained in mouse 
ATDC5 chondrocyte cells [107,108], a mechanism involving PI-3K\Ras\ERK pathway 
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that would regulate chondrocyte differentiation/mineralization and transduce vanadate 
effect (Figure 4.1B)  
 
4.2.3. Vanadate affects ECM mineralization through inhibition of ALP 
activity  
Incomplete reversion of vanadate anti-mineralogenic effect by both PD98059 and 
wortmannin suggested that other differentiation/ECM mineralization-related 
mechanisms are affected by vanadate. ALP, by cleaving pyrophosphate, an inhibitor of 
ECM mineralization [93], and collagen, an essential structural component of ECM [94] 
are targets of choice for vanadate action. While vanadate treatments resulted in 
decreased ALP activity and increased collagen synthesis, insulin was unable to affect 
neither ALP nor collagen, suggesting that vanadate action on these two markers occurs 
through an IR-independent manner. We propose that vanadate not only inhibits ECM 
mineralization by interfering with intracellular Pi-3K/Ras/Erk signalling pathway, but 
also by interfering with ALP activity and pyrophosphate cleavage. Similar results, i.e. 
inhibition of ALP activity and stimulation of collagen synthesis by vanadate, have been 
reported in chicken [123] and mouse [117,125,133] bone-derived systems and we 
propose the conservation of these mechanisms throughout evolution and across bone 
cell types. 
 
4.3. Insulin-like effects in chondrocyte-like versus osteoblast-like cells 
4.3.1. IGF-1 stimulates both chondrocyte and osteoblast proliferation in fish 
IGF-1, but not insulin, exhibited similar proliferative effects in both VSa16 and 
VSa13 cells, suggesting that IGF-1 growth-related mechanisms are probably conserved 
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across bone cell types. This hypothesis is consistent with data reported in mammalian 
osteoblast-like (e.g. MG-63) [95,96] and chondrocyte-like (ATDC5) cell 
lines [107,108], further demonstrating the conservation of mechanisms across species 
and throughout evolution. However, insulin incapacity to stimulate VSa13 and VSa16 
cell proliferation contrasted with its stimulatory effects in mammalian chondrocyte- and 
osteoblast-like cell lines [104,107], suggesting a differential role for this peptide in fish 
and mammalian bone. In a similar manner, vanadate inefficacy to stimulate VSa16 cell 
proliferation also contrasted with its stimulatory effects in VSa13 cells and mammalian 
osteoblast-like cell lines (MC3T3-E1 and UMR106 cells) [127], which could indicate 
that either vanadate was unable to interact with intracellular targets (i.e. possible 
incapacity to enter cells), or its targets were absent during VSa16 cells proliferation. 
Further studies involving vanadium accumulation in VSa16 cell extracts and 
investigating signalling pathways mediating IGF-1 effects would need to be performed 
in order to explain these discrepancies. 
 
4.3.2. IGF-1 and vanadate inhibit ECM mineralization of both fish 
chondrocyte-like and osteoblast-like cell lines  
IGF-1 inhibition of ECM mineralization in VSa16 cells is consistent with similar 
effects observed in VSa13 cells. However, in opposition to what has been observed in 
the fish chondrocyte-like cells, these results suggest that IR is absent during ECM 
mineralization of the fish osteoblast-like cell line. Although, results are inconsistent 
with data showing mineralogenic effect of IGF-1 in mammals in vitro and in vivo 
[16,20,95,96], probably indicating that mechanisms have not been conserved across 
species, it was also recently demonstrated that mineral deposition in MC3T3-E1 
cultures (also pre-osteoblasts) can be seriously hampered through ERK 
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activation (which is associated to insulin and IGF-1) [163]. We propose, in the light of 
all these data that IGF-1 stimulates proliferation of both chondrocytes and osteoblasts 
while it only affects osteoblast differentiation/ECM mineralization, a role played by 
insulin in chondrocytes. Finally, the severe anti-mineralogenic effect of vanadate on 
VSa13 cells through insulin/IGF-1 signalling pathways activation, as well as ALP 
activity inhibition, suggest the involvement of similar mechanisms of action in VSa16 
cells. Further studies analyzing insulin and IGF-1 signalling, ALP activity and collagen 
synthesis as putative targets for vanadate action in VSa16 cells should be carried out. 
 
4.4. Putative roles for alternatively spliced transcripts of IGF-1 in seabream 
Recent reports on the existence of multiple forms of proIGF-1 in vertebrates have 
stimulated the interest of the scientific community in understanding its biological role, 
which remains largely controversial [155,164-173]. In this work, multiple proIGF-1 
transcripts in the gilthead seabream have been identified. These transcripts are 
alternatively spliced within the region encoding the E domain and exhibit different 
patterns of expression during fish development and in adult tissues. In silico analysis 
revealed that alternative splicing is a common feature for IGF-1 expression in most 
vertebrates and identified taxon-specific transcripts. 
 
4.4.1. Seabream IGF-1: one gene, several transcripts 
Three alternatively spliced IGF-1 transcripts (IGF-1a, 1b and 1c) and corresponding 
gene have been identified in gilthead seabream through this work. A transcript, similar 
to seabream IGF-1a, was already available [152], but with what appears to have been an 
error in stop codon identification, and only a partial 3’UTR. In addition, two transcripts 
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(IGF-1b and 1c) were newly identified, as was the partial IGF-1 gene sequence. 
Alternative splicing was shown to occur within the sequence encoding the E domain, 
thus resulting in pro-peptides of different sizes. The IGF-1 alternative splicing identified 
in seabream resulted from the use of alternative donor sites in exon 3 and entire 
skipping of exon 4, consistent with previous observations in Salmonids and flounder 
[169,174]. In mammals, similar alternative splicing mechanisms have been shown to be 
at the origin of the different proIGF-1 variants (mammalian IGF-1Ea is similar to teleost 
IGF-1c) [155]. Based on alternative splicing mechanisms observed in Salmonids, a 
fourth transcript was predicted in seabream (IGF-1d; Figure 3.17 A). IGF-1d has 
however never been detected and is, therefore, either weakly or not expressed in 
seabream, or its expression is restricted to sites not explored in this work. IGF-1d 
variant could also be related to the existence of a second IGF-1 gene as in Salmonids, 
and consequently be absent in seabream where available evidence does not support the 
existence of 2 genes. However, existing data in Salmonids does not allow the 
association of any of the variants to a specific gene [174]. The presence of 2 genes in 
these species may be the consequence of (i) the fish-specific whole-genome duplication 
event that occurred in the teleost lineage after divergence from tetrapods, approximately 
420 million years ago [175], the duplicated gene would then have been lost in seabream, 
or (ii) a recent whole-genome duplication event occurring 25-100 million years ago in 
the common ancestor of all salmonids [176]. High similarities between variants in 
Salmonids seem to indicate however that IGF-1 is more likely to have derived from a 
recent duplication event, in agreement with the second hypothesis. It has also been 
hypothesized that IGF-1 and IGF-2 genes may have diverged in the first whole-genome 
duplication event (420 million years ago) although this hypothesis has been ruled out in 
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a previous study performed in S. acanthias, in which two IGF-like peptides have been 
identified: one more similar to vertebrate IGF-1 and the other similar to IGF-2 [177].  
 
4.4.2. The proIGF-1 variants are tightly regulated during seabream 
development 
One of the goals of this study was to determine the expression profile of proIGF-1 
variants during seabream development. Results have indicated: a) basal levels of IGF-1c 
expression in larval stages and strong up-regulation after hatching; b) onset of IGF-1b 
expression immediately after hatching and remaining at low levels; and c) onset of 
IGF-1a expression at 20 DAH and remaining at intermediate levels (when compared to 
IGF-1c). A similar analysis, although not quantitative, has been performed in coho 
salmon [170]: IGF-1b, IGF-1c and IGF-1d isoforms were detected in 6 week-old 
embryos and thereafter, and shown to be mainly expressed in liver, muscle and brain. 
The analysis of seabream proIGF-1 expression patterns during development suggests 
that IGF-1 pro-peptides may be involved in specific organ formation and/or 
development. Endocrine system, which has been shown to be active early in 
development, and GH initial expression at 3 DAH in seabream [178,179] are coincident 
with first detection of IGF-1b and strong up-regulation of IGF-1c. In the same period, it 
has been also observed in seabream an onset of mineralization (2 DAH) [140], primitive 
digestive tract differentiation (3-6 DAH) [179], red muscle development (from 1 DAH) 
[180]. Later in development, IGF-1a first appearance and second up-regulation of IGF-
1c were coincident with previously observed intensification of tissue calcification 
(20 DAH) [139]. An intensification of IGF-1c expression, from 20 to 48 DAH, was 
observed during a period previously associated to increase in white muscle formation 
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(35 DAH until juvenile). The endocrine system has been previously shown to directly 
regulate IGF-1 expression (through GH) in vertebrates [171,181], which in part may 
explain IGF-1b and IGF-1c transcripts regulation after hatching. In mammals, its 
deficiency has been associated to smaller structures and osteoporosis but no specific 
variants have been related to these effects in fish. IGF-1 down-regulation in fish scales 
has been associated to decreased bone cell activity (osteoblast and osteoclast) [182]. In 
the present study, we hypothesize that different proIGF-1 isoforms may have different 
functions in fish bone development, with IGF-1c and IGF-1b assuming specific roles at 
the onset of mineralization, while IGF-1a could be more related to periods of intensive 
calcification. However, additional functional analysis is required to verify this 
hypothesis (e.g. different IGF-1 variants peptides effects in bone-derived cell lines, 
namely in VSa13 and VSa16 cells). In mammals, specific IGF-1 alternative transcripts 
have been shown to be involved in muscle formation [155,168,183], but in fish no 
specific functions have been attributed to any variant. In coho salmon, however, 
multiple IGF-1 transcripts have been detected in muscle [170], indicating a probable 
important role, as in mammals.  
 
4.4.3. Variants of proIGF-1 in adult seabream tissues: systemic versus 
autocrine/paracrine modes of action 
Various physiological mechanisms have been associated with IGF-1 action in 
mammals. It includes: i) stem cell differentiation into adipocyte and metabolic 
mechanisms of fasting and re-feeding in adipose tissue [25,26]; ii) pancreatic β-cell 
proliferation [27] and insulin release [29]; and iii) regulation of bone mineral density in 
developing structures [18]. Pattern of IGF-1 expression in adult seabream (i.e. main 
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expression is in liver, adipose tissue and pancreas; relatively high expression in calcified 
tissues) is in agreement with the reported role of mammalian IGF-1 in these processes. 
ProIGF-1 peptide resulting from IGF-1c (or E domain itself), the main transcript in liver 
(expression levels are 2-4 times higher than those for variants 1a and 1b), is likely to be 
involved in important physiological processes upon its release into circulation, an 
hypothesis consistent with previous observations in mammals, in which a systemic 
mode of action was demonstrated for IGF-1-Ea, the IGF-1c-like isoform in mammals 
[155]. It is hereby proposed that IGF-1c isoform assumes a similar role in seabream. 
Also of interest is our finding of relatively high IGF-1c expression in calcified tissues, 
which may indicate an autocrine/paracrine role of this variant in bone formation or 
metabolism. Following the same idea, variants 1a and 1b would assume local functions. 
Testing this hypothesis requires functional analysis, and again treatments with 
synthesized proIGF-1 or E domains variant peptides in isolated systems (e.g. in VSa13 
and VSa16 cells) are suggested. 
 
4.4.4. Mechanisms of IGF-1 alternative splicing in vertebrates are taxon-
specific 
Our in silico analysis of IGF-1 alternative splicing in vertebrates, indicates that a 
retention of IGF-1c/Ea has occurred in all taxa, suggesting that in fish, as in mammals, 
this variant may assume a systemic role, while other isoforms would play specific roles, 
a possibility that should be further explored. In order to identify these putative 
unexplored roles, taxonomic distribution of IGF-1 variants was tentatively related with 
various environmental adaptations or species characteristics. The distribution of IGF-1a 
and 1b in bony fish indicated a possible role in adaptations to different water salinities 
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(Figure 3.20). To test this hypothesis, analysis of IGF-1 variants expression during 
salinity adaptation is suggested. Since seabream which is a partially euryhaline species, 
it is proposed a study in which gene expression is analyzed upon specimen incubation in 
hypo-, iso- and hyperosmotic waters. In salmonids, IGF-1 potential role in 
osmoregulation has been previously studied and an up-regulation of IGF-1 expression in 
gills has been observed during seawater adaptation and smoltification process [184]. 
However, this process was never related to a specific IGF-1 variant and therefore this 
hypothesis could be tested  by analyzing the expression of the different variants when 
specimens inhabit either rivers or seawater. Possible mechanisms, such as 
Na+/K+ ATPase regulation in gills, which has been previously related to IGF-1 [185], 
could also be correlated to expression of specific IGF-1 variants through the use of 
functional assays. 
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5. Conclusions and future perspectives 
In this work, insulin-like activities of vanadate, insulin and IGF-1 were investigated 
in fish chondrocyte-like (VSa13) and osteoblast-like (VSa16) cell lines. Vanadate was 
shown to display different toxic effects and rates of intracellular accumulation 
according to its oligomerization state. Vanadate (independently of its oligomerization 
state) was shown to stimulate chondrocyte but not osteoblast cell proliferation, while 
strongly inhibiting differentiation/ECM mineralization in both cell types. IGF-1, but not 
insulin, stimulated cell proliferation of both cell type and inhibited cell 
differentiation/ECM mineralization of osteoblast cells. On the contrary, insulin, but not 
IGF-1, was shown to inhibit differentiation/ECM mineralization of chondrocyte cells. 
MAPK signalling pathway has been associated with the proliferative effect of vanadate 
and IGF-1 on chondrocyte cells, while PI-3K/Ras/ERK pathway has been associated 
with their anti-mineralogenic effect. Vanadate was shown to affect chondrocyte 
differentiation/ECM mineralization not only by interfering with intracellular signalling 
pathways but also by inhibiting alkaline phosphatase activity, which is crucial to 
prevent pyrophosphate inhibition of mineral deposition.  Accordingly, we proposed that 
vanadate could affect chondrocyte proliferation through IGF-1 receptor/signalling 
pathway and chondrocyte differentiation through insulin receptor/signalling pathway.  
In light of our results we proposed the conservation, throughout evolution, of those 
mechanisms regulating chondrocyte proliferation and differentiation and demonstrated 
the suitability of the fish VSa13 cell line to investigate mechanisms related to 
chondrogenesis in vertebrates. Although more data will be necessary to ascertain this 
hypothesis, we have hereby provided evidence towards the conservation of mechanisms 
involved in the IGF-1 dependent proliferative effect, across bone cell types and 
throughout evolution.  
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Finally, we report the existence of 3 transcripts for seabream IGF-1, alternatively 
spliced in the E domain, and their tight regulation during development and in adult 
tissues. We have tentatively associated the different isoforms (i.e. the pro-peptide or the 
E domain) to specific functions: IGF-1a and IGF-1b would be involved in the regulation 
of late developmental events (e.g. muscle and bone formation, and/or osmoregulation in 
teleosts), while IGF-1c would assume a systemic mode of action. Altogether, these 
results give new insights on bone-related insulin-like effects and further demonstrate the 
suitability of fish to study vertebrate development. 
Although this work reports, for the first time, a detailed analysis of the  insulin-like 
activities of IGF-1 and vanadate on the proliferation and ECM mineralization of fish 
chondrocyte-like and osteoblast-like cells, and provides new insights on the 
mechanisms (i.e. signalling and alternative targets) involved, there are still uncertainties 
that we would like to further investigate, such as the presence/activation of insulin and 
IGF-1 receptors during treatments, and/or the activation of downstream intermediates of 
PI-3K and MAPK pathways (e.g. phosphorylated forms of Akt and ERK). Although this 
could be performed through Western-blot analysis, there are no commercially available 
antibodies for these proteins in fish, therefore these experiments would require testing 
antibodies specific for the mammalian counterparts.  
In VSa16 cells, the putative involvement of signalling pathways and other targets in 
insulin-like activities promoted by vanadate and IGF-1 are currently being investigated 
and preliminary results indicate involvement of MAPK in proliferative effects and 
PI-3K in anti-mineralogenic action.  
Additionally, we are also performing microarray analysis using RNA samples from 
VSa13 and VSa16 cells during proliferation and ECM mineralization, and 4 x 44 k 
Agilent microarray slides specific for over 20.000 seabream genes. Preliminary results 
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in VSa13 cells indicate (i) 737 positive (up-regulated) and 587 negative 
(down-regulated) genes in control versus ECM mineralized cells, (ii) 207 positive and 
379 negative genes in ECM mineralized versus ECM mineralized cells in the presence 
of vanadate, and (iii) 1710 positive and 2330 negative genes in control versus vanadate 
treated cells. We are currently identifying the most relevant genes (in terms of fold 
change and statistical significance) and its patterns of expression.  
Concerning proIGF-1 alternative splicing, it would be interesting to investigate the 
activity of the distinct variants during VSa13 and VSa16 cell proliferation and ECM 
mineralization. Considering that adaptation to different water salinities was one of the 
putative roles identified for these variants in the course of this work, it would be 
important to analyze proIGF-1 alternative transcripts expression during incubation of 
seabream in different water salinities. 
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Appendices 
Appendix I – Medium and solutions compositions 
Table AI.1 – Composition of DME medium used in cell culture. 
DMEM (Invitrogen reference 21969-035) 
Inorganic salts: Concentration (mM) 
Calcium chloride 1.80 
Ferric nitrate 2.48 x 10-4 
Magnesium sulfate 0.81 
Potassium chloride 5.33 
Sodium bicarbonate 44.05 
Sodium chloride 110.34 
Sodium phosphate monobasic 0.92 
Amino acids:  
Glycine 0.40 
L-Arginine HCl 0.40 
L-Cystine 2HCl 0.20 
L-Histidine HCl-H2O 0.20 
L-Isoleucine 0.80 
L-Leucine 0.80 
L-Lysine HCl 0.80 
L-Methionine 0.20 
L-Phenylalanine 0.40 
L-Serine 0.40 
L-Threonine 0.80 
L-Tryptophan 7.84 x 10-2 
L-Tyrosine 0.40 
L-Valine 0.80 
Vitamins:  
Choline chloride 2.86 x 10-2 
D-Calcium pantothenate 8.39 x 10-3 
Folic acid 9.07 x 10-3 
i-Inositol 4.00 x 10-2 
Niacinamide 3.28 x 10-2 
Pyridoxine hydrochloride 1.96 x 10-2 
Riboflavin 1.06 x 10-3 
Thiamine hydrochloride 1.19 x 10-2 
Other components:  
D-Glucose 25.00 
Phenol red 3.99 x 10-2 
Sodium pyruvate 1.00 
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Table AI.2 – Composition of solutions used in cell culture. 
PBS 1X 
Component: Concentration 
Sodium chloride 137.00 mM 
Potassium chloride 2.70 mM 
Sodium phosphate dibasic 8.10 mM 
Potassium phosphate monobasic 1.47 mM 
pH 7.4 
Solution T  
Component: Concentration 
Sodium chloride 137.00 mM 
Potassium chloride 2.70 mM 
Sodium phosphate dibasic 15.80 mM 
Potassium phosphate monobasic 1.23 mM 
EDTA 1.10 mM 
Trypsin (Invitrogen) 0.2% 
pH 7.4 
 
Table AI.3 – Composition of RNA extraction buffers. 
 
 
 
 
 
 
 
Trizol 
Component: Quantity / final concentration 
Guanidinium-HCl 4.00 M 
Sodium acetate 0.05 M 
Dithiothreitol 2.50 x 10-3 M 
n-Lauryl-sarcosine (sodium salt) 0.25% 
Saturated phenol pH 4.0 1 volume 
Solution D 
Component: Quantity 
Guanidinium isothiocyanate 250 g 
0.75 M Sodium citrate pH 7.0 17.6 ml 
10% (w/v) n-Lauryl-sarcosine (sodium salt) 26.4 ml 
RNase-free water 293.0 ml 
β-mercaptoethanol 360 µl / 50 ml of solution D 
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Table AI.4 – Composition of ALP buffer. 
 
Table AI.5 – Composition of collagen staining solutions. 
 
Table AI.6 – Composition of SSC solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALP reaction buffer 
Component: Concentration 
Glycine 55.00 mM 
Magnesium chloride 0.55 mM 
pH 10.5 
Bouin’s fluid 
Component: Volume 
Saturated picric acid solution 15 ml 
35% (w/v) formaldehyde 5 ml 
Glacial acetic acid 1 ml 
Sirius red staining solution  
Component: Quantity 
Sirius red dye (F3BA; Chroma) 10 mg 
Saturated picric acid solution 10 ml 
SSC 10X 
Component: Concentration 
Sodium citrate 0.15 M 
Sodium chloride 1.50 M 
pH 7.0 
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Appendix II – Primers 
Table AII.1 – PCR primers used in cloning of seabream IGF-1, identification of alternative splicing 
variants and gene expression analysis in development and adult tissues. 
Primer names Primer sequence (5’ to 3’) 
Sparus aurata IGF-1 gene primers: 
IGF-1RV1 GCTAGACATCCCCACGGGTCTCCGCAAGA 
IGF-1FW1 GTGACATTGCCCGCATCTCATCCTC 
IGF-1FW2 TGGGGATGTCTAGCGCTCTTTCCTTTC 
IGF-1RV2 TCCATTCGCTCCGTCCCTACATTC 
IGF-1FW3 GGCATTGTGGACGAGTGCTGCTTCC 
IGF-1FW4 TGTGAGCTGCGGCGTCTGGAGATGTAC 
Commercial primers: 
oligo-d(T)-adapter ACGCGTCGACCTCGAGATCGATG(T)13 
universal adapter ACGCGTCGACCTCGAGATCGATG 
MarAP1 CCATCCTAATACGACTCACTATAGGGC 
MarAP2 ACTCACTATAGGGCTCGAGCGGC 
GWAP1 GTAATACGACTCACTATAGGGC 
GWAP2 ACTATAGGGCACGCGTGGT 
 
Table AII.2 – Primers used in qPCR gene expression analysis in seabream development, adult tissues 
and VSa13 cells samples. 
Primer names Primer sequence (5’ to 3’) 
Seabream IGF-1 gene primers: 
IGF-1ABC_FW ACAGAATGTAGGGACGGAGCGAATGGAC 
IGF-1A_FW AGGACAGCACAGCAGCCAGACAAGAC 
IGF-1AB_FW AGTCATTCATCCTTCAAGGAAGTGCATCC 
IGF-1ABC_RV TTCGGACCATTGTTAGCCTCCTCTCTG 
IGF1FW145 TCGACACGCTGCAGTTTGTGTGTGG 
IGF1RV145 GCACAGTACATCTCCAGACGCCGCA 
Seabream housekeeping genes primers: 
ActinFW CTTCCTCGGTATGGAGTCCTGCGG 
ActinRV TCCTGCTTGCTGATCCACATCTGCT 
RPL27aFW AAGAGGAACACAACTCACTGCCCCAC 
RPL27aRV GCTTGCCTTTGCCCAGAACTTTGTAG 
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Appendix III – Methods complementary information 
Table AIII.1 – Development stages and feeding calendar. 
Development stage: 
UE Embryo Larvae Juvenile 
Number of cells HAF DAH 
1 8 512 10 14 18 24 3 6 10 20 37 48 67 82 130
Feeding: 
Unfed Rotifers Artemia Selco/dry food
Note: UE means unfertilized eggs 
 
 
Table AIII.2 – BSA standard stock solution, milliQ water, samples and Bradford reagent quantities used 
in protein quantification assay in each cuvette.  
Protein quantity 
(µg) 
Volume stock 
solution or 
sample (µl) 
Volume milliQ 
water (µl) 
Volume 
Bradford 
reagent (µl) 
Standards (BSA 2 mg/ml stock solution) 
0 0 800 200 
1 0.5 799.5 200 
2 1 799 200 
4 2 798 200 
8 4 796 200 
10 5 795 200 
15 7.5 792.5 200 
20 10 790 200 
Sample (S) or extraction/purification buffer (B) 
S 10 790 200 
B 10 790 200 
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Appendix IV – Results and discussion complementary information 
 
Figure AIV.1 – MTS assay linearity test in VSa13 cell line. Different quantities of cells were seeded in 
96-well plates (150 µl cell suspension / well) and incubated approximately 6 hours at 37ºC and 5 % CO2 
for surface attaching; 20 µl of MTS/ phenazine methosulfate reagent mixture (see section 2.5) were added 
to cultures, incubated for 1 hour and absorbance measured at 490 nm wavelength in a Bio-rad Benchmark 
microplate reader; well culture medium and reagent was considered as blank and subtracted to measured 
absorbances.  
 
 
Figure AIV.2 - Viability of VSa13 cells after 8 days growth with wortmannin and PD98059. VSa13 cells 
were seeded in 96-well plates at 1.5×103 cells/well then either left untreated (control), treated with 5, 100 
and 250 µM PD98059, or treated with 0.1, 0.5 and 5 µM wortmannin. Cell viability was evaluated at 
appropriate time using MTS assay. Values are the mean of at least three independent experiments.  
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Figure AIV.3 - IGF-1 sequences (cDNA/EST) retrieved from GenBank (in October 2006) using BLAST 
facilities at NCBI (www.ncbi.nih.gov).  
1, Pimephales promelas IGF-1b from AY533140.  
2, Megalobrama amblycephala IGF-1b from AF332865. 
3, Megalobrama terminalis IGF-1b from AY247412. 
4, Gymnocypris przewalskii IGF-1b from AY919608. 
5, Danio rerio IGF-1b from BC114262, NM_131825, AF314545, AF268051, DT080649 and BF717691. 
6, Danio aequipinnatus IGF-1b from DQ221105. 
7, Cyprinus carpio IGF-1b from D83271, S82374 and D83272. 
8, Cirrhinus molitorella IGF-1b from AY987045 and AY069945. 
9, Spinibarbus sinensis IGF-1b from DQ449027. 
10, Ctenopharyngodon idella IGF-1b from AF247658.  
11, Carassius auratus IGF-1b from AF001005, AF001006 and AF216775 
12, Ictalurus punctatus IGF-1b from AY353852. 
13, Clarias macrocephalus IGF-1c from X79077 and X79244. 
14, Tetraodon nigroviridis IGF-1a from CR653867. 
15, Mugil cephalus IGF-1a from AY427954. 
16, Cottus kazika IGF-1a from AB079539. 
17, Myoxocephalus scorpius IGF-1a from Y12583. 
18, Paralichthys olivaceus IGF-1a from AJ010603 and AF061278 
19, Paralichthys olivaceus IGF-1b from AJ010602.  
20, Oreochromis mossambicus IGF-1a from Y10830, Y18690 and AF033796. 
21, Siganus guttatus IGF-1a from AY198184. 
22, Epinephelus coioides IGF-1a from AY776159 and AY513719. 
23, Umbrina cirrosa IGF-1a from AY941254. 
24, Perca flavescens IGF-1a from AY332492. 
25, Perca fluviatilis IGF-1a from AJ586907. 
26, Perca fluviatilis IGF-1b from AJ586908. 
27, Dicentrarchus labrax IGF-1a from AY800248, DQ105655, AJ579342 and AY847777. 
28, Micropterus salmoides IGF-1a from DQ666526.  
29, Acanthopagrus latus IGF-1a from AY608674. 
30, Acanthopagrus schlegeli IGF-1a from AF030573.  
31, Salmo salar IGF-1a from M81904. 
32, Oncorhynchus keta IGF-1a from S70778 and AH004580. 
33, Oncorhynchus kisutch IGF-1a from M81913. 
34, Oncorhynchus kisutch IGF-1c from M81911. 
35, Oncorhynchus kisutch IGF-1d from M81912 and M32792. 
36, Oncorhynchus mykiss IGF-1a from CA381456. 
37, Oncorhynchus mykiss IGF-1d from M95183. 
38, Oncorhynchus tschawytscha IGF-1a from U15960 and U14536. 
39, Oncorhynchus tschawytscha IGF-1b from U15961. 
40, Oncorhynchus tschawytscha IGF-1c from U15962. 
41, Xenopus laevis IGF-1c from M29857.  
42, Anser anser IGF-1c from DQ662932 and DQ490222. 
43, Anas platyrhynchos IGF-1c from AB061721 and DQ168593. 
44, Meleagris gallopavo IGF-1c from AF074980. 
45, Struthio camelus IGF-1c from AB035804. 
46, Gallus gallus IGF-1c from NM_001004384, BU454475 and CT485883. 
47, Mus musculus IGF-1-Ea (similar to IGF-1c) from X04480, AF440694, AK081019, AK165471, 
AK155435, AY878192, W96836, CN694804, CD241297, BI714882, BI440109, BF719517, BI441115, 
BG071465, BY732820, AA245300, AI526955, AA451360, BI144500, AA867155, AA690767, 
AA461866, BQ568928, BI714981, BI714874, BI715603, BI715465, BI715475, BI676839, DV043357, 
CF585817, CF585816, BI328661, AW493459, BQ567564, CB589117, BI731538, CA456022, 
AI326648, CA494190, AA277619, AA096666, AI573421, BI221656, AW413016 and AI314558. 
48, Mus musculus IGF-1-Eb from NM_184052 and BY748273. 
49, Mus musculus IGF-1-Ec (also lnown as MGF) from CT010364, NM_010512, X04482, AY878192, 
AW495481, AI503976, AI265629, AW146128, BF383724, CB846321, AI604642, CA491066 and 
AI119218.  
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50, Homo sapiens IGF-1-Ea (similar to IGF-1c) from X56773, CR541861, X00173, AB209184, M27544, 
M29644, NM_000618, M37484, BP423487, DB259587, AL599807, BY800109, AA542914, BM984670, 
AA913900, DR005306, AI248089 and CB959991. 
51, Homo sapiens IGF-1-Eb from M11568, X56774 and AI401719. 
52, Homo sapiens IGF-1-Ec (also kown as MGF) from U40870. 
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Abstract Vanadium, a trace metal known to accu-
mulate in bone and to mimic insulin, has been shown
to regulate mammalian bone formation using in vitro
and in vivo systems. In the present work, short- and
long-term effects of metavanadate (containing mono-
meric, dimeric, tetrameric and pentameric vanadate
species) and decavanadate (containing decameric
vanadate species) solutions on the mineralization of
a fish bone-derived cell line (VSa13) were studied
and compared to that of insulin. After 2 h of
incubation with vanadate (10 μM in monomeric
vanadate), metavanadate exhibited higher accumula-
tion rates than decavanadate (6.85±0.40 versus 3.95±
0.10 μg V/g of protein, respectively) in fish VSa13
cells and was also shown to be less toxic when
applied for short periods. In longer treatments with
both metavanadate and decavanadate solutions, sim-
ilar effects were promoted: stimulation of cell
proliferation and strong impairment (75%) of extra-
cellular matrix (ECM) mineralization. The effect of
both vanadate solutions (5 μM in monomeric vana-
date), on ECM mineralization was increased in the
presence of insulin (10 nM). It is concluded that
chronic treatment with both vanadate solutions stimu-
lated fish VSa13 cells proliferation and prevented
ECM mineralization. Newly developed VSa13 fish
cells appeared to be appropriate in the characterization
of vanadate effects on vertebrate bone formation,
representing a good alternative to mammalian systems.
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Decavanadate . Insulin-mimetic properties .
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Introduction
Vanadium, an essential trace element found in animals
and higher plants (Anke 2004) and described to be
accumulated in mammalian bone (Etcheverry et al.
1984), has been shown to display important biological
effects in association with its physicochemical prop-
erties, e.g. insulin-like activity and regulation of
phosphatases and ATPases activity (Nielsen and
Uthus 1990). Vanadium, which easily transitions
between three oxidation states, namely, V(III), V(IV)
and V(V), has been proposed to be potentially
important for its role as a biometal (Rehder 1999,
2003). Vanadate (V(V)), which is the most stable
oxidation state in aerobic conditions, forms in
solution monomeric vanadate species with different
states of protonation, such as HVO24 or H2VO

4 ,
depending on pH value. However, at physiological
pH values and at millimolar range of concentrations,
several n-meric species (n=1 to 10), normally
ascribed as vanadate oligomers, can occur simulta-
neously in equilibrium, such as monomeric (V1),
dimeric (V2) and tetrameric (V4) vanadate species
(Amado et al. 1993). Eventually, even decameric (V10)
vanadate species can be formed upon medium
acidification (Aureliano and Gândara 2005). These
vanadate oligomers species have been shown to
interact with several proteins, thus affecting many
biological systems (Crans et al. 2004). For instance,
monomeric vanadate as been described to behave as a
phosphate analogue, inhibiting (or, in some cases,
stimulating) several phosphatases (acid, alkaline and
protein phosphatases), phosphorylases, ribonucleases
and ATPases (Crans et al. 2004). Conversely, other
vanadate oligomers, such as the decameric vanadate,
has been described to inhibit non-competitively
several enzymes, among others, proteins involved in
muscle contraction and regulation such as myosin
ATPase and sarcoplasmic reticulum calcium ATPase,
thus contributing for the several biological processes
influenced by vanadate (Aureliano and Madeira 1994;
Tiago et al. 2004; Aureliano and Gândara 2005).
The most important clinical effect of vanadium is
probably its ability to mimic or to enhance the effect
of insulin, as demonstrated in various in vivo and in
vitro studies using streptozocin-treated diabetic rats
(Heyliger et al. 1985; Meyerovitch et al. 1987) and
adipocyte cultures (Dubyak and Kleinzeller 1980;
Shechter and Karlish 1980). Insulin, a peptide that
binds to specific membrane tyrosine kinase receptors,
initiates intracellular signalling that either results in
the regulation of protein, lipid, carbohydrate and
mineral metabolism, or cell differentiation and prolif-
eration, depending on the involved pathways: phos-
phatidyl inositol-3 kinase (PI3-K) pathway for
metabolic effects or mitogen-activated protein kinase
(MAPK) pathway for cell proliferation and differen-
tiation effects (Cheatham and Kahn 1995; Cohick and
Clemmons 1993; LeRoith 2000). Vanadium insulin-
mimetic properties have been associated to the
activity of tyrosine phosphatases and consequent
activation of tyrosine kinase receptors, including the
insulin receptor (Goldwaser et al. 2000; Shechter et al.
1995; Shisheva and Shechter 1993). In vertebrates, a
major process regulated by insulin (and insulin-like
growth factor 1) is linear bone growth (McCarthy et al.
2000; Moriyama et al. 2000). Vanadate was also
shown to exhibit strong metabolic and mitogenic
effects, as demonstrated by in vitro studies using
mammalian bone-derived cell lines (and also using rat
calvaria and chondrocyte primary cultures) (Canalis
1985a; Kato et al. 1987; Lau et al. 1988). These effects
have been extensively studied using two mammalian
cell lines, MC3T3-E1 and UMR106, and important
features, such as tyrosine phosphorylation and activa-
tion of signalling mechanisms, have been character-
ized (Barrio and Etcheverry 2006; Cortizo and
Etcheverry 1995; Salice et al. 1999). Although
repetitively studied in mammals, vanadate effects have
not been investigated in marine vertebrates (e.g. fish
and amphibians), despite being recognized as the
second most abundant transition metal in seawater
(Rehder 2003).
In this paper, we describe the effects of two
different vanadate solutions on the growth and
mineralization performances of a gilthead seabream
bone-derived cell line (VSa13) recently developed in
our laboratory (Pombinho et al. 2004) and capable of
mineralizing its extracellular matrix.
Materials and methods
Dulbecco’s modified Eagle medium (DMEM), fetal
bovine serum (FBS), antibiotics (penicillin and
streptomycin), antimycotic (fungizone), trypsin-
EDTA solution and L-glutamine were purchased from
Invitrogen. Tissue culture dishes were purchased from
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Sarstedt or Nunc. CellTiter 96 non-radioactive prolif-
eration assay kit was purchased from Promega. All
other reagents were purchased from Sigma-Aldrich
unless otherwise stated.
Cell culture maintenance
Cultured cells were maintained in DMEM supple-
mented with 1% penicillin-streptomycin, 1% fungi-
zone, 2 mM L-glutamine and 10% FBS, and
incubated at 33°C in a 10% CO2 humidified atmo-
sphere. Confluent cell cultures were divided (1:2)
every 3–4 days using trypsin–EDTA solution.
Vanadate solution preparation
Metavanadate stock solution (50 mM, pH 6.7) was
prepared from ammonium metavanadate (NH4VO3).
Decavanadate stock solution was obtained by adjust-
ing the pH of the former solution to 4.0, as described
elsewhere (Aureliano and Madeira 1994). The ac-
quired characteristic orange color in decavanadate
solution upon acidification reveals the presence of
decameric vanadate species (V10). Decavanadate
stock solution was always adjusted to pH 7.0
immediately before using it. Both vanadate solutions
were stored at 4°C. Although total vanadate concen-
tration does not change, note that in case of
decavanadate solutions the concentration in decameric
vanadate species was effectively reduced 10-fold,
meaning that stock decavanadate solutions contain
5 mM decameric vanadate species. However, vana-
date concentrations are always given for monomeric
vanadate, i.e. total vanadate.
Characterization of vanadate solutions
The composition of both vanadate solutions was
analysed by 51V Nuclear Magnetic Resonance (NMR)
spectroscopy, as described elsewhere (Aureliano and
Madeira 1994). Briefly, the composition of vanadate
solutions upon dilution into DMEM was analysed in a
Bruker AM-400 spectrometer at 105.2 MHz equipped
with a 5-mm multinuclear inverse probe, using a 90°
pulse Fourier transform technique. Spectra were
acquired at room temperature using 0.5 ml of vanadate
samples in the medium, containing at least 10% D2O,
under the following conditions: spectral width
45,455 Hz, accumulation time 0.05 s and relaxation
delay 0.01 s. 51V NMR chemical shifts are reported
relative to an external reference of VOCl3 (0 ppm). The
relative areas of the several free or/and bound vanadate
resonances were integrated and the line widths were
obtained after subtracting the value (20 Hz) used in
line broadening. The concentration of each vanadate
oligomer Vx was calculated from the fractions of the
total integrated areas observed in the recorded spectra
as described (Equation 1). The symbol A corresponds
to the area measured for the x vanadate species with
the n aggregation number (number of vanadium
atoms), At, the sum of measured areas and [Vt]
corresponds to total vanadate concentration.
Vx½  ¼ AxAt 
Vt½ 
n
ð1Þ
The calculated concentrations of vanadate oligomers
were reproducible within 2–4%. For quantitative meas-
urements, all spectra parameters were kept constant.
Vanadate concentrations are always given for mono-
meric vanadate, i.e. total vanadium.
Unlike metavanadate, decavanadate solutions are
unstable. The partial deoligomerization of decameric
vanadate species present at the decavanadate solutions
upon dilution in DMEM medium was analysed by
ultraviolet/visible spectroscopy at 400 nm, as de-
scribed elsewhere (Soares et al. 2006).
Cell viability measurement
Cytotoxic and proliferative effects of vanadate olig-
omers on VSa13 cells were assessed through cell
viability analysis using the CellTiter 96 non-radioactive
proliferation assay kit according to the manufacturer’s
instructions. Tetrazolium reagent (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium; inner salt,MTS) and the electron-coupling
reagent, phenazine methosulfate, were mixed in solu-
tion in a 20:1 proportion. Once added to cell culture,
MTS is reduced into formazan by the dehydrogenase
enzyme found in metabolically active cells. Formazan
formation, which is proportional to the number of living
cells (Malich et al. 1997), was followed at 490 nm
in 96-well tissue culture dishes. Incubation with
20 μl of reagent mixture during 1 h was determined
to be the optimal conditions for VSa13 cell viability
measurement. Vanadate cytotoxic effects were studied
in confluent cell cultures (approximately 1.7×104 cells/
well) while effects on cell proliferation were investi-
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gated in low-density cell cultures (starting from
1.5×103 cells/well).
Vanadium accumulation measurement
Cells were cultured for 0, 1, 2, 4, 8 and 24 h in the
presence of 10 μM metavanadate or decavanadate. At
appropriate times, cell cultures were washed three
times with phosphate-buffered saline (PBS), supple-
mented with 1 ml of MilliQ water (Millipore) and
placed at −80°C for 10 h. Frozen cells were thawed at
room temperature for 15 min, collected using a cell
scraper and transferred into a 2-ml microcentrifuge
tube. Cell culture dishes were washed once with 1 ml
of MilliQ water and washing solution was transferred
into the microcentrifuge tube containing the initial
cell extract. Total protein content was quantified from
cell extracts using Bradford reagent. Samples were
then digested at 100°C with 30 μl of 65% HNO3 and
final solid residues dissolved in 5% HCl solution.
Vanadium concentration was determined by atomic
absorption spectrometry analysis using a GBC Avanta
atomic absorption spectrometer equipped with a GBC
GF 3000 graphite furnace system and a GBC PAL
3000 auto sampler working at a furnace program of
63 s with an argon gas flow of 3.0 L/min. The
vanadium lamp was operated at 318.2 nm, with slit
width of 0.2 nm, and the instrument was calibrated
against a series of solutions containing 12.5, 25, 37.5
and 50 ppb of vanadium. Calibrating standards were
obtained by successive dilutions of a standard
solution of vanadium 1002±2 mg/L (Merck). The
detection and quantification limits of the instrument
for these analysis conditions, determined according to
ISO 8466-1, were 5 and 11 ppb, respectively.
Extracellular matrix mineralization and nodule
detection
Cells were seeded in 24-well plates at 2×104 cells/well
and cultured in DMEM supplemented with 10% FBS.
To induce ECM mineralization, confluent cultures
received medium supplemented with 50 μg/mL of
L-ascorbic acid (vitamin C), 10mMβ -glycerophosphate
and 4 mM CaCl2 up to 4 weeks. Wherever appropriate,
cells were washed three times with PBS at 4°C, fixed
with 10% formaldehyde (in PBS) for 1 h at 4°C,
washed three times with distilled water, then incubated
with 5% silver nitrate for 30 min under ultraviolet
light. Relative levels of ECM mineralization were
determined by densitometric methods using Quantity 1
software (Bio-Rad).
Statistical analysis
The data were presented as average and standard
deviation of measurements taken at least in three
separate experiments. Statistical significance of data
was analysed wherever indicated by Student t test or
analysis of variance (ANOVA) analysis. Differences
were considered to be significant at P<0.05.
Results
Vanadate solutions characterization in DMEM
51V-NMR spectroscopy of 1 and 5 mM decavanadate
solutions in DMEM, at pH 7.0, revealed three signals
attributed to three specific vanadium atoms in V10
structure: V10A at −515 ppm, V10B at −498 ppm and
V10C at −425 ppm (Fig. 1a). Conversely, in 1 and
5 mM metavanadate solutions (Fig. 1a), detected
signals ascribed to mono- (V1), di- (V2), tetra- (V4)
and pentameric (V5) vanadate species, respectively,
at −556 ppm, −571 ppm, −579 ppm and at 587 ppm
(Fig. 1a). Monomeric NMR signal is clearly broad-
ened, with a half line-width value (270 Hz) approx.
3.4-fold of normal value (80 Hz), probably caused by
vanadate interactions with compounds present in
DMEM such as glucose (25 mM) and piruvate
(1 mM), or even interactions with several proteins
also present in the medium. For each metavanadate
concentration in DMEM (1 and 5 mM), different
amounts of mono (V1), di (V2), tetra (V4) and
pentameric (V5) species have been observed, that
corresponded to different species profiles (Fig. 1b).
While tetrameric species were predominant at 5 mM
metavanadate, monomeric vanadate was the major
specie in the lower concentration (Fig. 1b). Con-
versely, decameric vanadate species present in the
decavanadate solutions increased linearly with total
vanadate concentration (Fig. 1c).
Although 51V-NMR spectroscopy is an essential
technique for the analysis of vanadate oligomers
composition and interactions, approximately 1 h
acquisition time was necessary to obtain a clear
spectrum of 1 mM decavanadate solution (Fig. 1a).
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In this sense, 51V-NMR spectroscopy is not adequate to
follow the decomposition kinetics of decavanadate, in
particular for vanadate concentrations lower than 1 mM.
However, the disappearance of decameric vanadate
species can be easily followed by ultraviolet/visible
(UV/Vis) spectroscopy. Therefore, the stability of
decameric species in DMEM was analysed by UV/Vis,
at 33°C, using a 250 μM decavanadate solution (total
vanadium concentration, meaning 25 μM decameric
vanadate species). It was observed that in DMEM,
decameric species decompose through a first-order
kinetic, with a half-life time of 150 min (not shown).
Long- and short-term exposure to meta- and decavanadate
Cytotoxicity of vanadate oligomers on VSa13 cells was
tested in confluent cultures for either 15 days using
concentrations ranging from 0 to 250 μM (chronic
toxicity) or 4 h using a concentration of 1 mM (acute
toxicity). Prolonged exposure to meta- or decavanadate
similarly affected VSa13 cell viability (Fig. 2): treat-
ments with concentrations up to 7.5 μM did not
decrease cell viability (a slight increase was even
observed after 15 days), while treatments with concen-
trations from 10 to 250 μM seriously affected cell
viability, killing most of the cells at highest concen-
trations. On the contrary, short-term exposure to meta-
and decavanadate differentially affected VSa13 cell
viability (Fig. 3): While 1 mM decavanadate signifi-
cantly reduced cell viability after 2 hours, 1 mM
metavanadate showed no effects. After 4 hours, both
solutions significantly (according to ANOVA analysis)
reduced the cell viability to levels approximate to 50%.
This observation suggests that decameric vanadate
species, still present in culture medium after 2 h, are
likely to induce more toxicity effects than monomeric
vanadate species, certainly the most abundant vanadate
form found in culture medium after 4 h (half-life time
of decavanadate in DMEM was estimated at 2.5 h)
upon decameric vanadate disintegration.
Stimulation of cell proliferation by vanadate
Vanadate effect on VSa13 cell proliferation rate was
also investigated in dividing cultures (Fig. 4), and
both metavanadate and decavanadate exhibited simi-
lar effects (thus, only metavanadate results are
shown), i.e. a significant stimulation of proliferation
rate was observed for 7.5 μM concentration (accord-
Fig. 1 105.2 MHz 51V NMR spectra, at 22°C, of two vanadate
concentrations (total vanadate), namely, 1 and 5 mM of
decavanadate and metavanadate in DMEM, pH 7.1. (a) V1
and V2 signals correspond to monomeric (H2VO

4 ) and dimeric
(HV2O
3
7 and H2V2O
2
7 ) vanadate species, respectively,
irrespective of the protonation state, whereas V4 and V5
correspond to cyclic tetrameric (V4O
4
12 ) and pentameric
(V5O
5
15 ) vanadate species. V10A, V10B and V10C signals
correspond, respectively, to the V(2), V(1) and V(3) vanadium
atoms in the decameric vanadate specie (V10O
6
28 ). The
concentrations of each vanadium (V) species for metavanadate
(b) and decavanadate (c) solutions were calculated from the
fractions of the total integrated areas observed in the spectra.
For quantitative measurements, spectral parameters were kept
constant and the spectra were normalized regarding 5 mM
decavanadate spectra
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ing to ANOVA analysis). On the contrary, 10 nM
insulin (concentration used in mammalian bone-
derived cell line, Quarto et al. 1992), had no effect
on cell proliferation (Fig. 4) suggesting that vanadate,
despite proven insulin-mimetic properties, stimulates
cell proliferation. Nevertheless, no effects were
observed in cell proliferation using insulin concen-
trations up to 100 nM (not shown).
Metavanadate and decavanadate exhibit different rates
of accumulation in cells
The amount of vanadium accumulated within VSa13
cells was determined in confluent cultures treated
with 10 μM meta- or decavanadate for 0, 1, 2, 4,
8 and 24 h after subtraction of vanadium content
measured in non-treated cells (2.54±0.43 μg V/g of
protein) (Fig. 5). After 1 h of treatment, vanadium
accumulation was higher in cells treated with meta-
vanadate (4.61±0.29 μg V/g of protein) than in cells
treated with decavanadate (3.24±0.24 μg V/g of
protein), being the effect statistically significant
(according to Student’s t test). A similar, but more
pronounced, difference between meta- and decavana-
date-related vanadium accumulations was observed
after 2 h of treatment (6.85±0.4 μg and 3.95±0.1 μg
V/g of protein, respectively). Longer incubation times
resulted in a higher accumulation of vanadium
(approximately 18-fold increase above control value
after 24 h), but no significant differences were
observed between metavanadate and decavanadate
treated cells, as expected. These results suggest that
monomeric species enter VSa13 cells and accumulate
more easily than decameric species and that accumu-
lation rates become similar only when most of
decameric molecules are decomposed (half-life time
of decavanadate in DMEM was estimated at 2.5 h).
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Fig. 2 Long-term effect of metavanadate and decavanadate on
VSa13 cell viability. VSa13 cells were seeded in 96-well plates,
grown in DMEM until confluence then treated with metavana-
date (a) and decavanadate (b) using concentrations ranging
from 5 to 250 μM. Cell viability was evaluated at appropriate
times using MTS assay and is presented as the percentage of
control value (set to 100%). Values are the mean of at least
three independent experiments
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Fig. 3 Short-term effect of metavanadate and decavanadate on
VSa13 cell viability. VSa13 cells were seeded in 96-microwell
plates, grown in DMEM until confluence then treated with
1 mM metavanadate and decavanadate. Cell viability was
evaluated at appropriate times using MTS assay and is
presented as the percentage of control value (set to 100%).
Values are the mean of at least three independent experiments.
Asterisk indicates that values are statistically different in
comparison to the respective control (P<0.05 one-way
ANOVA). Dashed line indicates the half-life of decavanadate
in DMEM estimated at 2.5 h
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Vanadate and insulin decrease ECM mineralization
Vsa13 cells were cultured under mineralizing con-
ditions for 4 weeks. Then, extracellular matrix
mineralization was evaluated by densitometric analy-
sis of von Kossa staining. The effects of vanadate
(5 μM) and insulin (10 nM) on ECM mineralization
were tested separately or in combination (Fig. 6).
Vanadate 7.5 μM concentration was excluded from
this experiment because of cytotoxic effects observed
after 4 weeks of treatment (data not shown). Insulin,
metavanadate and decavanadate significantly de-
creased ECM mineralization (according to ANOVA
analysis), although to different extents: 31%, 74% and
78% decrease for insulin, meta- and decavanadate,
respectively. The combination of insulin with any of
the vanadate oligomers resulted in a more pronounced
decrease (88% and 86%, respectively), although not
significant (according to ANOVA analysis), suggest-
ing an additive effect. A lower concentration of
vanadate (2.5 μM) was also tested and shown to
exhibit a similar, but less pronounced, decrease (data
not shown) indicating a dose-dependent inhibition of
ECM mineralization by vanadate oligomers.
Discussion
The effects of vanadium on bone biology have been
extensively studied in several mammalian in vivo and
in vitro systems (Etcheverry and Cortizo 1998;
Shechter 1990), but, to our knowledge, no studies
have been performed using bone-derived systems of
aquatic vertebrate origin. In this study, we analyse, for
the first time, the effects different vanadate oligomers
have on bone-derived cell line mineralization. How-
ever, the composition of vanadate solutions is very
sensitive to vanadate concentration, pH, buffer and
other compounds used in biochemical studies. There-
fore, it is of primary importance to precisely charac-
terise the species that can interact with a system
before attempting to understand the effects promoted
by vanadate solutions. Unlike metavanadate contain-
ing several oxovanadates, decavanadate solutions
contain decameric vanadate species (V10). However,
V10 is unstable and decomposes into monomeric
vanadate with a half-life time of above 2 h in DMEM.
In this regard, effects of decavanadate were always
compared with those of metavanadate.
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Fig. 4 Effect of metavanadate and insulin on VSa13 cell
proliferation. VSa13 cells were seeded in 96-well plates at 1.5×
103 cell/well then treated with metavanadate using concen-
trations ranging from 2.5 to 7.5 μM or 10 nM insulin. Cell
proliferation was evaluated at appropriate times using MTS
assay. Values are the mean of at least three independent
experiments. Asterisk indicates that values are statistically
different in comparison to the respective control (P<0.05 one-
way ANOVA)
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Fig. 5 Vanadium accumulation in VSa13 cells upon vanadate
solutions exposure. VSa13 cells were seeded in 100-mm plates,
grown in DMEM until confluence then treated with 10 μM
metavanadate or decavanadate. At appropriate times, vanadium
content was determined by atomic absorption from cellular
extract and normalized with protein content. Vanadium content
measured in non-treated samples (2.54±0.43 μg V/g of protein)
was subtracted from each value. Asterisks indicate statistically
significant differences between metavanadate and decavanadate
according to Student’s test (**p<0.005 and ***p<0.001).
Values are the mean of at least three independent experiments.
Dashed line indicates the half-life of decavanadate in DMEM
estimated at 2.5 h
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Monomeric and decameric vanadate species affect
VSa13 cells differently
Prolonged exposure to low levels of meta- and
decavanadate similarly affected VSa13 cell viability
and proliferation, whereas short-term exposure to high
levels of decavanadate was more toxic than that of
metavanadate. In DMEM, decavanadate decomposes
into monomeric species with a half-life time of
∼150 min, suggesting that its long-term effects are
most probably caused by newly formed monomeric
species (as for metavanadate), whereas short-term
effects are likely caused by decameric vanadate
species. Considering that decavanadate solution con-
tains 10 times less molecules (particularly in shorter
exposure times, in which decameric species are
predominant) than metavanadate (in which monomer-
ic species are predominant), short-term toxicity of
decavanadate is even more remarkable. This result is
consistent with previous observations that decavana-
date and metavanadate produce different oxidative
stress levels in cardiac muscle in toadfish and gilthead
seabream (Aureliano et al. 2002; Soares et al. 2007)
and interact differently in vitro with specific proteins
such as myosin and sarcoplasmic reticulum Ca2+-
ATPase (Aureliano and Madeira 1994; Tiago et al.
2004; Aureliano and Gândara 2005). Prolonged
exposure to low levels of vanadate resulted in an
apparent increase in cell viability/number, an effect
that was previously observed in mammalian bone-
derived cell cultures (MC3T3E1 and UMR106)
(Barrio et al. 1997; Cortizo et al. 2000; Etcheverry
et al. 1997; Salice et al. 1999) and attributed to its
ability to increase phosphotyrosine protein levels and
to inhibit phosphotyrosine phosphatases, thus regu-
lating growth signalling pathways.
Although cellular accumulation of metavanadate has
been previously demonstrated in mammalian systems,
e.g. bovine kidney andCaco-2 cells (Bracken et al. 1985;
Yang et al. 2004), this process has never been analysed
in a comparative study with decavanadate. We present
evidences that vanadium differently accumulates in
VSa13 cells treated with metavanadate or decavanadate
solutions (decavanadate treatments resulted in signifi-
cantly lower vanadium accumulation at 1 and 2 h;
Fig. 5), which was probably caused by an inexistent or
a less efficient uptake mechanism for decameric species.
Vanadate stimulates VSa13 cell proliferation
Both vanadate oligomers exhibited a similar effect on
VSa13 growth rate, i.e. a stimulation of cell prolifer-
ation. A similar effect has been reported in mamma-
lian bone-derived cell lines and associated with the
activation of the insulin receptor. Insulin was shown
not to affect VSa13 cell proliferation, indicating that
either insulin receptor/signalling pathway is absent in
VSa13 cells (this hypothesis was later ruled out after
insulin was shown to affect ECM mineralization) or
vanadate stimulating effect is not mediated through
insulin signalling pathway. Several studies have
already proposed cytosolic tyrosine kinase receptor as
a mediator of vanadate proliferative effect (Shisheva
and Shechter 1992, 1993), and we propose that a
similar mechanism could occur in VSa13 cells.
Inhibition of ECM mineralization by vanadate
Mineralization of VSa13 extracellular matrix was
mildly reduced by insulin, strongly inhibited by
vanadate, regardless of its oligomerization (monomer-
ic or decameric), and even more strongly inhibited
Fig. 6 Effect of metavanadate, decavanadate and insulin on
extracellular matrix mineralization. VSa13 cells were seeded in
24-well plates, grown in DMEM until confluence then treated
for mineralization. Mineralizing cultures were subsequently
treated with 10 nM insulin (Ins), 5 μM metavanadate (MV),
5 μM decavanadate (DV), metavanadate and insulin (Ins+MV),
decavanadate and insulin (Ins+DV) or left untreated. Mineral
deposition was revealed by von Kossa staining and evaluated
by densitometric analysis. Pictures of von Kossa-stained VSa13
cells are presented above each treatment. Values are the mean
of at least three independent experiments. Asterisk indicates that
values are statistically different in comparison to the respective
control (P<0.05 one-way ANOVA)
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when both insulin and vanadate were present. Two
important regulatory effects have been associated with
vanadium osteogenic action in mammalian bone-
derived cells: the inhibition of alkaline phosphatase
activity and the stimulation of type I collagen
synthesis (Barrio and Etcheverry 2006; Canalis
1985b; Lau et al. 1988). Both processes are essential
to the correct mineralization of the extracellular
matrix of bone cells (Murshed et al. 2005), and it is
likely that vanadium effect on vertebrate bone
depends on the equilibrium between its stimulatory
and inhibitory properties. Vanadium derivatives were
previously shown to specifically activate insulin-
associated pathways (i.e. MAPK and PI-3K pathways)
through phosphorylation of common intermediates
such as extracellular signal-regulated kinase (ERK)
(Barrio and Etcheverry 2006). Moreover, vanadium
proliferative effect was reverted by specific inhibitors
of insulin-associated pathways. In one of those
studies, vanadyl (IV)-ascorbate, a vanadium complex,
significantly increased the rate and extent of mineral
deposition within the ECM of mouse MC3T3-E1
bone-derived cells and stimulated type I collagen
synthesis (Cortizo et al. 2006). These effects were
apparently related to both MAPK and PI-3K path-
ways activation and ERK increased phosphorylation.
In another study, it was described that the alkaline
phosphatase activity is inhibited in MC3T3-E1 cells
by a trehalose vanadyl complex independently of
regular insulin-associated pathways. Based on pub-
lished results, we suggest that vanadate inhibitory
effect on VSa13 ECM mineralization could be
associated with either direct interference of vanadium
into key processes such as alkaline phosphatase
activity, or indirect interference of vanadium into
insulin-associated pathways. Recently, it was shown
that the ECM mineralization of MC3T3-E1 cells is
inhibited by platelet-derived growth factor through
ERK activation (Kono et al. 2007). This result is, on
one hand, contradictory to a previous observation
where ECM mineralization of MC3T3-E1 cells was
stimulated by vanadium through ERK activation
(Cortizo et al. 2006), but, on the other hand, in total
agreement with the inhibition of VSa13 ECM
mineralization by vanadate, possibly through ERK
activation. The characterisation of the mechanisms
involved in vanadate inhibitory effect in VSa13 cell
line will need to be investigated in future studies.
Conclusion
Vanadate was shown here to accumulate within
VSa13 bone-derived cells, stimulating growth perfor-
mance through insulin-independent mechanisms and
preventing ECM mineralization probably through
multiple processes involving regulation that may or
may not depend on the activation of insulin-stimulated
pathways. The presence of decameric vanadate species
was also shown to produce differences (accumulation
and cytotoxicity) between meta- and decavanadate in
short-term exposure while acting similarly in pro-
longed exposure caused eventually by the decomposi-
tion of decavanadate into other oligomers. VSa13 cells
were shown to be a suitable model to study vanadium
mechanisms of action in vertebrate bone development
and to be a good alternative to mammalian systems.
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Abstract 
      Vanadate, one of the most relevant forms of vanadium 
in solution, has been associated with the regulation of 
various enzyme activities (e.g. phosphatases, ribonucleases, 
ATPases, etc.) and shown to exhibit important biological 
effects. Several in vivo and in vitro studies have 
clearly demonstrated that any deficiency or excess of 
vanadium can seriously affect bone formation and its 
metabolism. Bone-related effects result largely from 
vanadium insulin-mimetic capabilities mediated by 
specific inhibition of  protein tyrosine phosphatases 
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(PTPases) and consequent activation of tyrosine kinase receptors (e.g. insulin 
receptor). Although mammals have been repetitively shown to be appropriate 
models to study vanadate mechanisms of action, fish have recently emerged as 
alternative models. Fish has been recognized as suitable model to study 
vertebrate bone formation and the natural presence of high quantities of 
vanadium in water makes it even more suitable to investigate vanadium effect 
on bone formation. Recent data obtained using fish bone-derived cells 
revealed that micromolar concentrations (5 µM) of monomeric and decameric 
vanadate slightly stimulate growth performances while strongly inhibiting 
extracellular matrix mineralization through mechanisms involving both 
alkaline phosphatase and MAPK pathways. Recent data obtained in fish cells 
will be discussed here and further compared to results obtained in mammalian 
systems. 
 
1. Introduction 
 Vanadium is a trace element that has been shown to be essential for 
biological activity in various organisms [1-3]. In plants and algae, vanadium is 
directly involved in enzyme activity, acting as a cofactor in vanadium 
nitrogenases and vanadate-dependent haloperoxidases. In mammals, reduced 
doses of vanadium have been associated with poorly developed animals and 
higher rates of spontaneous abortion or mortality [4]. 
 Biological effects of vanadium in vertebrates, in particular in mammals, 
essentially come from its capacity to interfere with several key enzymes, such 
as ATPases, phosphorylases, phosphatases (alkaline, acid and protein 
phosphatases) and ribonucleases [2]. This interference has been attributed to 
vanadium oxidation states VV and VIV (vanadate and vanadyl, respectively), 
which exhibit some analogy with phosphate, although to different extents 
(strong for vanadate and weak for vanadyl). Inhibition of phosphatases by 
vanadate was attributed to the formation of good transition state analogues 
during enzymatic catalysis [2,5] and a similar mechanism was proposed for 
vanadyl although its geometry of coordination is somewhat different to that of 
phosphate [2]. 
 An important feature of vanadate resides in its capacity to promote distinct 
effects depending on its oligomerization (monomeric to decameric species 
according to pH and concentration [6]) as shown using in vitro and in vivo 
models [7-9]. For example, decameric species were shown, in fish, to induce 
higher oxidative stress, haemoglobin oxidation, stimulate antioxidant enzyme 
activities and generate more tissue damages than other oligomeric species [10-
12], while monomeric species apparently accumulated at higher rates and 
doses in cardiac muscle, red blood cells and plasma [13]. Aspects related with 
decavanadate in vivo effects are reviewed in Chapter 9 of this book. Decameric 
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species also revealed stronger inhibition and affinity for ATPases, in particular 
myosin ATPase and sarcoplasmic reticulum (SR) Ca2+- ATPase [9,14-16]. 
Decavanadate effects in the contractile system and in SR calcium pump are 
reviewed in Chapters 5 and 7 of this book, respectively. 
 The most important biological effect of vanadium is probably insulin 
mimicking. It was first demonstrated in the early 80’s, when vanadate and 
vanadyl treatments applied to isolated rat adipocytes [17,18] were shown to 
stimulate hexose transport, glucose oxidation and lipogenesis, as insulin [19]. 
Additional in vivo studies showed that oral administration of vanadate to 
streptozocin-treated diabetic rats (STZ rats) resulted in decreased blood 
glucose to normal levels [20,21], confirming its action as a substitute of 
insulin. Vanadate was consequently proposed as a possible therapeutic agent 
for diabetes mellitus (insulin-dependent). However, the therapeutic use of 
vanadate has been seriously hampered by its relatively high toxicity [22,23]. 
Recent efforts have therefore focused on the discovery of chelators, which 
would reduce vanadyl and vanadate toxicity while preserving its insulin-
mimetic properties [24]. 
 Insulin-mimetic properties of vanadium have been associated to specific 
inhibition of protein tyrosine phosphatases (PTPases) and consequent activation 
of receptor-associated protein tyrosine kinase (PTK), including that of insulin 
receptor [23,25,26]. Alternatively, non-receptor PTK, e.g. insulin receptor 
substrate 1 (IRS-1), or cytosolic PTK can be activated [27]. Two pathways 
involved in vanadate intracellular signalling have been identified, both 
resulting in distinct effects (Figure 1). A common feature of both pathways is 
the activation of PTK domain in IRS-1 through phosphorylation of tyrosines. 
While metabolic effects are mediated by phosphatidylinositol-3 kinase (PI-3K) 
activation, effects on cell proliferation and differentiation result from the 
activation of mitogen-responsive protein kinases (MAPK) [28]. Alternatively, 
specific insulin-like effects, e.g. glycogen synthase activation, have been 
associated to PI-3K/Ras/ERK activation [27]. 
 While most studies investigating vanadium effects have been performed in 
adipose tissue, bone has recently emerged as a system of interest after its 
regulation by insulin and IGF1 was demonstrated [1,29-31] and after vanadium 
was shown to accumulate in mammalian bones [32] and affect bone formation 
when absent from diet [4,33]. Accumulation of vanadium within bone, was 
first proposed to be related to a detoxification process [34,35]. Severe 
malformations occurring in bone of animals lacking vanadium however 
suggested that it could interact with specific growth factor-dependent 
signalling, in particular those known to control bone development: platelet-
derived growth factor (PDGF), fibroblast growth factors (FGF1 and 2), insulin, 
insulin-like growth factors (IGF1 and 2), transforming growth factors beta 
(TGF-β1, 2 and 3), and   bone morphogenetic proteins (BMP) [30,36]. Because  
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Figure 1.  Insulin signalling pathways and putative regulation by vanadium. Ins 
indicates insulin peptide; V indicates vanadium; α and β represent the subunits of 
insulin tyrosine kinase receptor; circled P represents phosphorylation of tyrosines in 
PTK domain within the β subunit of insulin receptor; PKB indicates protein kinase B, 
the activated intermediate in PI-3K pathway. GRB-2, Ras, MEK and ERK indicate 
intermediate adaptor proteins in MAPK pathways. 
 
insulin, IGFs and TGF-β bind to specific tyrosine kinase receptors and are 
involved in osteoblast differentiation, they have been therefore considered as 
putative targets for vanadium. Effects due to insulin and IGF mimicking action 
of vanadium, were first demonstrated in vitro by Canalis and colleagues, who 
showed that concentrations below 15 µM of sodium vanadate increased DNA 
synthesis and mitotic index of rat calvaria primary cultures [31]. Since then, 
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two mammalian cell lines, MC3T3-E1 (developed from newborn mouse 
calvaria, composed of pre-osteoblasts and able to mineralize extracellular 
matrix (ECM) [37]) and UMR106 (developed from rat osteosarcoma, 
composed of differentiated osteoblasts and unable to mineralize the ECM [38]) 
were shown to be particularly useful in understanding insulin and IGF 
mimicking effects of vanadium in bone and important features like tyrosine 
kinase receptors phosphorylation (with consequent activation) and activation 
of signalling mechanisms have been characterized [39].  
 Until recently, effects of vanadate on bone metabolism have been 
exclusively characterized in vitro using these two mammalian bone-derived 
cell lines [39]. The recent contribution of a fish-bone derived cell line to this 
characterization is hereby described and results obtained compared to those 
derived from studies on mammalian cell lines and its suitability as an in vitro 
model system to study these effects is further discussed. 
 
2. Mammalian cell lines as in vitro models to study 
vanadium mechanisms of action in bone 
 Primary cell cultures of rat and chicken calvaria were the first in vitro 
systems used to investigate vanadium insulin-like effects in bone [31,40] and 
have contributed to the characterization of osteogenic action of vanadium in 
mammals including the inhibition of alkaline phosphatase (ALP) activity and 
the stimulation of type-I collagen synthesis [39], two mechanisms essential to 
the correct mineralization of the extracellular matrix of bone cells [41]. 
Osteogenic actions of vanadate are also described in Chapter 13 of this book. 
The key role of growth factors, e.g. IGF1, and tyrosine protein phosphorylation 
in the mediation of vanadium action was later demonstrated using mouse 
MC3T3-E1 and rat UMR106 cell lines [39]. Osteoblastic differentiation of 
these cells, monitored through the measurement of ALP activity, was show to 
be inhibited by vanadate, vanadyl, hydroperoxo- and peroxo-vanadium, in 
agreement with previous observations in primary bone-derived cultures [42]. 
Interestingly, enzymatic activity of PTPases was also shown to be inhibited in 
treated cells, suggesting a probable signalling interference with insulin and 
other growth factors that bind to tyrosine kinase receptors. In more recent 
experiments, vanadate, vanadyl and pervanadate were shown to stimulate cell 
proliferation at low doses, while higher doses severely arrested growth [43]. 
Primitive vanadium complexes (vanadium oxalate, citrate, tartrate and 
nitrilotriacetate) tested in mammalian MC3T3-E1 and UMR106 bone-derived 
cell lines revealed effects similar to those of vanadate: stimulation of cell 
proliferation, glucose consumption and protein content. It is worth to note that 
both vanadate and vanadium nitriloacetate exhibited a stronger inhibition of 
UMR106 cells differentiation [44]. However, complex toxicity was still high. 
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 The new generation of vanadium complexes (e.g. bis(maltolato)oxovanadium 
(IV) - BMOV - and bis(maltolato)dioxovanadium(V) - BMV) also exhibited 
effects similar to those of vanadium but revealed lower toxicity rates (BMV). 
All treatments with these complexes promoted cell growth in a biphasic 
manner, as well as increased phosphorylation of tyrosine residues, consistent 
with previous observation of strong inhibition of PTPases. In addition, BMOV, 
like vanadate, strongly inhibited ALP activity [45,46]. Similar results have 
been observed when using vanadyl/aspirin complex [47,48]. Relevant 
information concerning vanadium regulatory mechanisms associated to insulin 
signalling pathways were obtained only recently. Involvement of MAPK and 
PI-3K pathways in vanadium osteogenic effects was investigated using two 
complexes, trehalose vanadyl (TreVO) and vanadyl ascorbate (VOAsc) [49,50] 
and specific inhibitors of these pathways. While stimulation of cell 
proliferation and type-I collagen synthesis were shown to be mediated by an 
insulin-dependent mechanism, stimulation of glucose consumption and 
inhibition of ALP activity were apparently mediated by an insulin-independent 
mechanism. Another important observation was the increased phosphorylation 
of key intermediates of these cascades upon vanadium treatments. One of the 
major subfamilies of the MAP kinases, the extracellular signal-regulated 
kinase (ERK), has been shown to be phosphorylated / activated in UMR106 
and MC3T3-E1 cells after vanadium treatments. This effect is apparently 
mediated by a PI-3K/ras/ERK (extracellular signal-regulated kinase) pathway 
[39]. This mechanism is probably essential to explain vanadium effect in bone 
and will be further discussed. 
 Although vanadium insulin-dependent and insulin-independent actions 
have been already described in mammalian bone-derived in vitro systems, 
there is a lack of information concerning other vertebrate bone-derived 
systems, in particular those derived from marine vertebrate species. 
 
3. Teleost fish bone-derived cell lines as an alternative 
to mammalian systems to study vanadium effects in 
bone 
 VSa13 bone-derived cell line has been recently developed from the 
vertebra of Sparus aurata, a marine teleost fish, and fully characterized [51]. 
This cell line is capable of mineralizing its extracellular matrix under 
appropriate culture conditions and has been associated to the chondrocyte 
lineage, as suggested by a relatively high expression of matrix gla protein (a 
calcification inhibitor normally produced by chondrocytes in cartilage), no 
expression of osteocalcin (an osteoblastic marker) and strong alcian blue 
staining (normally associated with cartilage extracellular matrix). The 
suitability of VSa13 cells to study in vitro vanadium insulin-like action on 
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bone was confirmed by its responsiveness to insulin treatments (10 nM insulin 
was shown to decrease by 25% the degree of ECM mineralization in VSa13 
cell [52]). To date, only vanadate oligomeric solutions have been tested in 
VSa13 cells. Metavanadate (containing n-meric species with n = 1-5) and 
decavanadate (n = 1 or 10) effects on VSa13 cells viability, growth, vanadium 
accumulation and ECM mineralization have been investigated [52]. Vanadate 
oligomerization did not originate differences in toxicity levels after prolonged 
exposures (metavanadate and decavanadate solutions were shown to be 
non-toxic at concentrations below 10 µM during 15 days). However, 
decameric species exhibited higher toxicity after 2 h of treatment using 1 mM 
concentration (acute toxicity). Similarly, accumulation of vanadium in VSa13 
cells was oligomerization-independent from 4 to 24 h but much slower for 
decavanadate within the first 2 h of treatment. These results were shown to be 
coherent with decameric species decomposition rate into monomeric species 
(half-life time of approximately 150 min), suggesting that decavanadate long-
term effects resulted mainly from monomeric species. However, in short-term 
treatments in which decameric species were still present in solution, vanadate 
was shown to accumulate much slower in cells, and to induce higher toxicities. 
These results reinforced the hypothesis of the higher toxicity of species highly 
oligomerized, which are probably formed in specific cellular environments 
(e.g. in which the pH is low). Merged results of long-term treatments by 
monomeric and decameric vanadate indicate that cell proliferation was 
stimulated (Figure 2) in a dose-dependent manner. The observation that insulin 
did not stimulate VSa13 cell proliferation (inset of Figure 2) suggested that 
mitogenic pathways may not be controlled by this hormone in these cells. It 
also suggested that vanadate effects on cell proliferation were not mediated 
through insulin signalling pathways, and possibly involving other PTK. 
 However, mineralization of VSa13 ECM was later shown to be negatively 
regulated by insulin [52] (Figure 3), demonstrating the presence of insulin 
receptors and signalling pathways in these cells. ECM mineralization was also 
inhibited by vanadate in VSa13 cells, and combined treatments with insulin 
and vanadate resulted in stronger inhibition (31%, 76% and 87% inhibition in 
cells treated with insulin, vanadate and insulin + vanadate, respectively; Figure 3). 
Effect of vanadium on ECM mineralization in mammals has been reported in a 
recent study [50]. Surprisingly, vanadyl(IV)-ascorbate complex strongly 
increased mineral deposition within ECM of MC3T3-E1 (up to 20-fold using 
concentrations from 5 to 25 µM). This result, at the opposite of that observed 
in fish bone-derived cells, was even more surprising considering the mild 
effects of vanadium on bone markers: ALP activity was maintained or slightly 
decreased and type-I collagen synthesis was only slightly increased 
(approximately 10%). The opposite effect of vanadium on ECM mineralization 
observed  in VSa13 and MC3T3- E1 cells may be related to the species studied  
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Figure 2. Vanadate and insulin effects on VSa13 cell proliferation. VSa13 cells were 
seeded in 96-well plates at 1.5×103 cell/well then treated with metavanadate and 
decavanadate using concentrations ranging from 2.5 to 7.5 µM. Cell viability was 
evaluated at appropriate times using MTS assay. Inset indicates vanadate (5 µM) effect 
on VSa13 cell proliferation compared with that of insulin (10 nM) after 12 days of 
treatment. Vanadate values are the mean of metavanadate and decavanadate merged 
data resulting from at least six independent experiments. Insulin values are the mean of 
at least 3 independent experiments. 
 
 
 
Figure 3. Effect of vanadate and insulin on VSa13 extracellular matrix (ECM) 
mineralization. Mineral deposition was revealed by von Kossa staining and evaluated 
by densitometric analysis. Values are the mean of metavanadate and decavanadate 
merged data resulting from at least six independent experiments. Asterisks indicate 
statistically significant differences compared to control (or between conditions) 
according to Student’s test (* p < 0.05, *** p < 0.001). 
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(fish versus mammal) or the cell types used (osteoblast versus chondrocyte) 
and will require additional studies in the future. 
 Data obtained from VSa13 cells suggested that vanadate effect on ECM 
mineralization probably involves insulin-signalling pathways, but the 
contribution of other mechanisms must also be considered. In that aspect, 
preliminary data obtained in VSa13 cells indicated a strong decrease in ALP 
activity in vanadate-treated cells during ECM mineralization (Figure 4; our 
unpublished results). ALP activity in VSa13 cells was demonstrated to be up 
regulated during ECM mineralization [51], which is consistent with a 
differentiation process, but treatments with 5 µM monomeric vanadate have 
shown to massively decrease this activity. Specific inhibitors should be tested, 
in order to evaluate to what extent, and which insulin signalling pathways are 
mediating vanadate inhibition of ECM mineralization. Preliminary data from 
experiments using MAPK and PI-3K inhibitors (PD98059 and wortmannin, 
respectively) have involved mitogenic pathways (possibly through PI-3K/ras/ 
MAPK signalling pathways). This issue will be further discussed in the next 
section of this chapter. 
 
 
 
Figure 4. Effect of vanadate and insulin on alkaline phosphatase (ALP) activity of 
VSa13 cells during extracellular matrix (ECM) mineralization. Extracts from ECM 
mineralized cells alternatively treated with either insulin alone or metavanadate alone, 
or both, were collected in 0,1% (v/v) Triton X-100; samples ALP activity was evaluated 
in 50 mM glycine plus 0.5 mM MgCl2 reaction buffer using 0.5 mM pNP-P (p-
nitrophenyl-phosphate) as substrate. Values are the mean of at least three independent 
experiments. Asterisks indicate statistically significant differences compared to control 
according to Student’s test (* p < 0.05, ** p < 0.01). 
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4. Mechanisms of action of vanadium in bone-derived 
cell lines 
 Different in vitro systems (different species and cell type) have been used to 
investigate proliferative and mineralogenic effects of vanadium. Available data 
(summarized in Table 1) suggest that vanadium may promote distinct effects 
depending on the system used. Although similar toxic and proliferative effects 
have been recognized in both systems (i.e. mammalian and fish), effects on ECM 
mineralization were contradictory (i.e. stimulation in mammalian cells and 
inhibition in fish cells). Interestingly, vanadium-treated MC3T3-E1 cells 
exhibited increased ERK phosphorylation. ERK activation by vanadium salts 
was previously demonstrated in experiments using Chinese hamster ovary cells 
overexpressing insulin receptor [27]. Stimulation of ras/ERK pathway mediated 
by PI-3K activation (resulting in the PI-3K/ras/ERK pathway) promoted 
important insulin-mimetic effects, e.g. glycogen synthesis and glucose 
homeostasis. Nevertheless, this pathway is commonly associated to growth 
promotion effects [53]. Recently, the ECM mineralization of MC3T3-E1 cells 
was show to be significantly inhibited by PDGF, also through the activation of 
ERK pathway. This result is, on one hand, in contradiction with the ERK-
dependent   mineralogenic effect of vanadium in MC3T3-E1, but, on the other hand, 
 
 
 
Figure 5. Effect of MAPK and PI-3K inhibitors on vanadate stimulation of VSa13 cells 
proliferation. VSa13 cells were seeded in 96-well plates at 1.5×103 cell/well then 
treated with 7.5 µM metavanadate Cell viability was evaluated at 8 days using MTS 
assay. Values are the mean of at least three independent experiments. Asterisks indicate 
statistically significant differences compared to control according to Student’s test       
(* p < 0.05, ** p < 0.01). 
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Table 1. Effects of vanadium on vertebrate bone-derived cell systems. 
 
Effects Mammalian Non-mammalian 
Cell line 
Name MC3T3-E1 UMR106 VSa13 
Origin Mouse calvaria 
Rat 
osteosarcoma 
Seabream 
vertebra 
Cell type Pre-osteoblastic 
Differentiated 
osteoblast Chondrocyte-like 
Vanadate acute toxicity (1 mM during 4 h) 
 ↓↓ [54] ↓ [54] ↓ [52]
Phenotype 
Proliferation ↑ * [44,46,49,50,55,56] ↑ [44,49,50,55,56] ↑↑ **[52]
ECM mineralization ↑↑↑ [50] NT ↓↓↓ [52]
Protein content ↑↑ [44] ↑ [44] ↑↑↑ [UR]
Cell differentiation 
ALP activity ↔ [50] ↓↓↓ [44,49,50,54,56] ↓↓↓ ** [UR]
Type-I collagen 
synthesis ↑ * 
[50] ↑↑↑ * [50] NT 
Other activities 
Glucose 
consumption ↑↑ ** 
[44] ↑↑↑ ** [44,49,56] NT 
PTPase ↓↓↓ [46] ↓↓↓ [50] NT 
ERK activation ↑ * [50] ↑ * [49,50] NT 
* indicates insulin-like effect; ** indicates non-insulin-like effect; NT indicates not 
tested; UR indicates unpublished result 
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in total agreement with the anti-mineralogenic effect of vanadium in VSa13. It also 
suggests that vanadium effect could be mediated in VSa13 through ERK/MAPK 
pathway, an hypothesis which is strengthened by preliminary data showing the 
reversion of vanadium effect on cell proliferation by PD98059, a specific inhibitor 
of MAPK pathway early events (Figure 5; our unpublished results). However, 
increased ERK phosphorylation in VSa13 cells is still to be confirmed. 
 Alkaline phosphatase (ALP) activity (and cell differentiation) was shown to 
be similarly affected by vanadium in  all systems. Preliminary data suggest that 
 
 
 
Figure 6. Vanadium putative regulation mechanisms for extracellular matrix (ECM) 
mineralization in VSa13 and MC3T3-E1 cells. ECMM indicates mineralized ECM; P 
indicates phosphorylation of ERK; V indicates vanadium; light grey arrows and dashed 
lines indicate vanadium putative effects in VSa13 cells; dark grey arrows and lines 
indicate PDGF effect in MC3T3-E1 cells; black dashed/dotted arrows indicate vanadium 
putative effects in MC3T3-E1 cells; dotted arrow indicates PI-3K/ras/MAPK pathway; 
below are represented micrographs of non-mineralized and mineralized VSa13 cells. 
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vanadate may not directly inhibit ALP activity in VSa13 cells (our unpublished 
result). We hypothesize that vanadate may affect indirectly the levels of ALP 
activity during ECM mineralization by down-regulating gene expression. A 
putative model for vanadium action during ECM mineralization is presented in 
Figure 6. 
 
5. Concluding remarks 
 This chapter presents a comprehensive collection of in vitro data regarding 
the effects of vanadium on bone metabolism in mammals. It also describes the 
recent work performed in fish bone-derived cells shown to respond to insulin, 
but also to be finely regulated by vanadate. In these cells, like in mammalian 
bone-derived cell lines, vanadate behaves as a growth factor, stimulating 
VSa13 cell proliferation through an insulin-independent mechanism. On the 
contrary, ECM mineralization of VSa13 cells is negatively regulated by insulin 
and vanadium, with a stronger inhibition resulting from the combination of 
both treatments. Based on previous studies, it is suggested that this effect may 
be mediated through activation of ERK pathway and consequent down-regulation 
of mineralization. However, in order to confirm specific involvement of this 
pathway further investigation will be necessary. Preliminary results in VSa13 
cells have so far indicated (1) the involvement of MAPK pathways in the 
vanadate effects on cell proliferation through a non-insulin related mechanism, 
and (2) the vanadate-dependent inhibition of cell differentiation through an effect 
on ALP activity. In general, it is important to notice that full characterization of 
vanadium effects in bone-derived systems will require further investigation, 
such as the analysis of: a) combined action of vanadium and other growth 
factors (e.g. IGF1, TGF-β); b) general gene expression during vanadium 
treatments (using microarray technology); c) specific bone-related gene 
expression; d) specific bone-related protein synthesis. The development of 
non-mammalian in vitro systems is likely to bring new insights on vanadium 
mechanisms of action in bone. 
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Edited by Lukas HuberAbstract We recently reported proliferative and anti-mineral-
ogenic eﬀects of vanadate on ﬁsh chondrocytes and here we
investigate the signalling pathways associated with these eﬀects.
Our data show that vanadate stimulates chondrocyte prolifera-
tion through the MAPK pathway, using signalling mechanisms
similar to those used by IGF-1, while it inhibits chondrocyte
diﬀerentiation/mineralization through a putative PI-3K/Ras/
Erk signalling, a pathway shared with insulin. Our data also
suggest that vanadate impairs ECM mineralization not only
by interfering with regulatory pathways but also by inhibiting
enzymatic activity of ALP. Finally, this work provides addi-
tional evidence for the conservation, throughout evolution, of
mechanisms regulating chondrocyte proliferation and diﬀerenti-
ation.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Vanadium; Insulin-like activity; Intracellular
signalling; In vitro mineralization; Bony ﬁsh;
Bone-derived cell line1. Introduction
Vanadium, mostly known for enhancing mechanical proper-
ties of alloy steels in the metal industry, has also been recog-
nized as an essential trace element for biological activity in
most living animals [1]. In mammals, vanadium has been
associated to a variety of insulin-like eﬀects [2] and its action
associated to the speciﬁc regulation of protein tyrosine
phosphatases and consequent activation of tyrosine kinase
receptors, including the insulin receptor [2,3]. A role for vana-
dium in bone formation has been demonstrated [4,5] but
mechanisms of action have remained largely unexplored. In vi-
tro studies, using calvaria primary cultures [6,7] and bone-de-
rived cell lines [5,8,9], have evidenced the regulation of bone-
related enzymes activity (e.g. alkaline phosphatase (ALP)
and protein tyrosine phosphatases), the stimulation of bone-
related protein synthesis (e.g. type I collagen), the alteration
of bone-related cell proliferation and extracellular matrixAbbreviations: ALP, alkaline phosphatase; ECM, extracellular matrix;
IGF-1, insulin-like growth factor 1; MAPK, mitogen-activated protein
kinase; PI-3K, phosphatidyl inositol-3 kinase
*Corresponding author. Fax: +351 289 800069.
E-mail address: vlaize@ualg.pt (V. Laize´).
0014-5793/$34.00  2008 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2008.03.025(ECM) mineralization, and the activation of insulin and insu-
lin-like growth factor 1 (IGF-1) signalling mechanisms [5,9] by
vanadium compounds. However, there is still much to unveil
in order to understand vanadium mechanisms of action in
bone.
In this study, wortmannin, a speciﬁc inhibitor of phosphati-
dyl inositol-3 kinase (PI-3K) pathway, and PD98059, a speciﬁc
inhibitor of mitogen-activated protein kinase (MAPK) have
been tested for their eﬀects on vanadium-associated alteration
of growth performances, ECM mineralization, ALP activity,
collagen synthesis in VSa13 cells.2. Materials and methods
2.1. Cell culture and ECM mineralization
VSa13 cells were cultured as described previously [10]. ECM miner-
alization was induced in conﬂuent cultures by supplementing medium
with 50 lg/ml of L-ascorbic acid, 10 mM b-glycerophosphate and
4 mM CaCl2. At appropriate times, mineral deposition was revealed
using the von Kossa staining method and quantiﬁed by densitometric
analysis [10]. Culture medium was renewed every 2 days in prolifera-
tion experiments and every 3.5 days in mineralization experiments.
Insulin (1–100 nM), IGF-1 (1–100 nM) and vanadate (2.5–7.5 lM)
treatments were applied at the time of medium renewal.2.2. Preparation of vanadate, PD98059, wortmannin, insulin and IGF-1
stock solutions
Vanadate solution (50 mM, pH 6–7) was prepared as described pre-
viously [8]. PD98059 and wortmannin were solubilised in DMSO at 6
and 10 mg/ml, respectively. Bovine insulin (Sigma–Aldrich) and Pag-
rus auratus IGF-1 (Novozymes GroPep) were solubilised in pH 2 water
at 10 lM and in pH 6 water at 0.1 mg/ml, respectively. Milli-Q water
(Millipore) was used to prepare vanadate, insulin and IGF-1 solutions.2.3. Measurement of cell proliferation
VSa13 cell proliferation was determined from cultures seeded in 96-
well plates at 1.5 · 103 cells/well using the CellTiter 96 non-radioactive
proliferation assay kit (Promega). At appropriate times, cells were
incubated for 1 h with 20 ll of reagent mixture then cell proliferation
was determined from absorbance at 490 nm.2.4. Measurement of ALP activity
VSa13 cells grown for 4 weeks under mineralizing conditions were
washed three times with phosphate-buﬀered saline (PBS), scrapped
oﬀ the plate into 500 ll of 0.1% Triton X-100 then centrifuged for
1 min at 16000 · g. ALP activity was determined at 37 C from initial
rates of p-nitrophenyl phosphate (p-NPP) hydrolysis into p-nitrophe-
nol (p-NP). Formation of p-NP was monitored at 405 nm from the fol-
lowing reaction mixture: 800 ll of reaction buﬀer (55 mM glycine and
0.55 mM MgCl2 at pH 10.5), 100 ll of 5 mM p-NPP and 100 ll of cell
extract supernatant. ALP activity was normalized with protein content
determined using Bradford reagent (Bio-Rad).ation of European Biochemical Societies.
1382 D.M. Tiago et al. / FEBS Letters 582 (2008) 1381–13852.5. Measurement of collagen content
VSa13 cells grown for 4 weeks under mineralizing conditions were
washed three times with PBS then stained with Sirius red dye
(F3BA; Chroma) as described previously [11]. Bound dye was solubi-
lised into 200 ll of 0.1 N NaOH and collagen content was determined
from absorbance at 550 nm.
2.6. Statistical analysis
Values are the mean of at least three separate experiments and are
presented with their standard deviation. Diﬀerences upon treatment
were analyzed by one-way ANOVA and considered signiﬁcant at
P < 0.05.3. Results and discussion
In vitro studies investigating vanadium insulin-like eﬀects
and speciﬁc targets in bone have been largely restricted to a
particular taxonomic group (i.e. mammals) and to particular
cell types (i.e. osteoblast-like and osteosarcoma cells). This
work evidences, for the ﬁrst time in a non-mammalian
in vitro system and using a chondrocyte-like cell line, the role
of MAPK and PI-3K pathways in the mediation of vanadate
eﬀects on proliferation and mineralization.
3.1. MAPK pathway mediates vanadate stimulation of VSa13
cell proliferation
Vanadate (2.5–7.5 lM), insulin (1–100 nM) and IGF-1 (1–
100 nM) were tested for their eﬀect on VSa13 cell growth. Both
vanadate and IGF-1, but not insulin, stimulated cell prolifera-
tion to a similar extent (strongest stimulation at 7.5 lM and
10 nM, respectively; Supplementary Figures 1 and 2 and
Fig. 1). Wortmannin and PD98059, known inhibitors of
PI-3K and MAPK pathways, respectively, were then tested
for their eﬀect on VSa13 cell proliferation and for their capac-
ity of reverting IGF-1 and vanadate stimulatory eﬀects. Divid-Fig. 1. Eﬀect of vanadate, insulin, IGF-1, wortmannin and PD98059 on V
1.5 · 103 cells/well then either left untreated or treated with PD98059, wor
proliferation was evaluated after 8 days using MTS assay. Asterisk indica
P < 0.05; one-way ANOVA).ing cultures of VSa13 cells were treated for 8 days with 0.1 lM
wortmannin, 100 lM PD98059 (non-toxic concentrations,
data not shown) in the presence or absence of insulin, vanadate
or IGF-1 (Fig. 1). PD98059, but not wortmannin, totally abol-
ished vanadate and IGF-1 stimulation of cell proliferation
(inhibitors alone had no eﬀect) suggesting that proliferation
of VSa13 cells is stimulated by vanadate through the activation
of the MAPK pathway. A similar contribution of the MAPK
pathway in the transduction of vanadate proliferative eﬀect
has been reported in mammalian osteoblast-like cells [12,13],
suggesting a conservation of mechanisms of action throughout
evolution and across bone cell types. The inability of insulin to
enhance VSa13 cell proliferation suggests that the activation of
MAPK pathway by vanadate would occur through an insulin
receptor-independent manner. Similarly, the stimulation of
VSa13 cell proliferation by IGF-1 through MAPK pathway
and to a similar extent, suggest that the activation of MAPK
pathway by vanadate could occur through IGF-1 receptor
and/or signalling pathway, although we cannot exclude that
other tyrosine kinase receptors (e.g. platelet-derived growth
factor (PDGF) receptor) may be involved [5]. Similar mecha-
nisms (i.e. those related to the proliferative eﬀect of IGF-1)
have been recently reported in the mouse chondrocyte ATDC5
cell line [14] and thus, based on those results as well as our data
reported in this study, we propose the existence of a mecha-
nism involving MAPK pathway that would regulate chondro-
cyte proliferation and transduce vanadate eﬀect (Fig. 5A).3.2. Putative PI-3K/Ras/Erk pathway mediates vanadate
impairment of VSa13 ECM mineralization
Wortmannin and PD98059 were then tested for their eﬀect
on VSa13 ECMmineralization and for their capacity of revert-
ing vanadate and insulin inhibitory eﬀects previously demon-
strated [8] and further conﬁrmed here. Mineralizing VSa13Sa13 cell proliferation. VSa13 cells were seeded in 96-well plates at
tmannin, vanadate, insulin or IGF-1, alone or in combinations. Cell
tes values statistically diﬀerent from corresponding controls (n P 3;
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100 lM PD98059, 10 nM IGF-1, 10 nM insulin, and/or 5 lM
vanadate, then evaluated for mineralization. While unaltered
by IGF-1, mineral deposition was increasingly impaired by
insulin (1.4-fold), vanadate (8-folds) and almost abolished by
a combination of both agents (Fig. 2). Apparent synergy be-
tween vanadate and insulin could suggest that diﬀerent signal-
ling pathways are involved in both mechanisms of action, or
that vanadate potentiates insulin action during mineralization,
e.g. by inhibiting PTPases, therefore increasing sensitivity of
insulin pathway as previously suggested [15]. Interestingly,
ECM of PD98059-treated cells, but not that of wortmannin-
treated cells, exhibited a signiﬁcant increase in mineral deposi-
tion (3.2-folds), suggesting a down-regulation of ECM
mineralization by MAPK pathway. We propose, in agreement
with recent results obtained in mouse ATDC5 chondrocyte
cells [14,16], that MAPK pathway may aﬀect ECM mineraliza-
tion of VSa13 cells by inhibiting cell diﬀerentiation. The role of
MAPK pathway in regulating VSa13 ECM mineralization was
further conﬁrmed by the reversion (100% and 72.5%, respec-
tively) of insulin and vanadate anti-mineralogenic eﬀects with
PD98059. Surprisingly, wortmannin also reverted (100% and
57.5%, respectively) insulin and vanadate anti-mineralogenic
eﬀects, suggesting a role for PI-3K pathway in regulating
VSa13 ECM mineralization. As expected, impairment of min-
eralization by the combined eﬀects of insulin and vanadate was
reverted to an extent similar to that observed for vanadate
alone. Altogether, these results suggest that both MAPK and
PI-3K pathways could mediate vanadate and insulin anti-min-
eralogenic eﬀects. We propose that regulation of VSa13 cell
diﬀerentiation/mineralization is exerted through the PI-3K/
Ras/Erk pathway (a combination of MAPK and PI-3K path-
ways), a ﬁnding that is in agreement with recent results ob-Fig. 2. Eﬀect of IGF-1, vanadate, insulin, wortmannin and PD98059 on VS
2 · 104 cells/well, grown until conﬂuence then treated for mineralization. M
insulin, vanadate, PD98059, or wortmannin, alone or in combinations. Min
evaluated by densitometry analysis. Mineralization data are presented as the
treated, treated with wortmannin and treated with PD98059). Asterisk indic
P < 0.05; one-way ANOVA).tained for mouse MC3T3-E1 cells [17]. We further propose,
based on overall available data as well as results reported in
this study, that a similar mechanism is responsible for trans-
ducing vanadate eﬀects (Fig. 5B). However, incomplete rever-
sion of vanadate anti-mineralogenic eﬀect by both PD98059
and wortmannin (83.2% reversion, result not shown) suggests
that other diﬀerentiation/mineralization-related mechanisms
are aﬀected by vanadate. ALP, by cleaving pyrophosphate,
an inhibitor of ECM mineralization [18], and collagen, an
essential structural component of ECM [19], were considered
as putative targets for vanadate action and further investi-
gated.
3.3. ALP activity is inhibited while collagen content is increased
by micromolar concentrations of vanadate
Enzymatic activity of ALP was ﬁrst determined in mineral-
ized cell cultures treated with 5 lM vanadate and/or 10 nM
insulin. Interestingly, a 40% increase in ALP activity was ob-
served following ECM mineralization, while activity remained
similar to non-mineralizing control cells upon vanadate treat-
ment (Fig. 3). In similar experiments, collagen content was
shown to increase by 57% in mineralized cultures and by an
additional 17% when those cultures were also treated with van-
adate (Fig. 4). The stimulation of both ALP activity and colla-
gen production in mineralized cultures is consistent with their
role in mineralization mechanisms. The inability of insulin to
aﬀect ALP activity and collagen production suggests that van-
adate action occurs through an insulin receptor-independent
manner. ALP activity was then measured in cellular extracts
of mineralized cultures (4 weeks) in the presence of increasing
concentrations of vanadate: activity was stimulated at low con-
centration (5 lM) while strongly inhibited at higher concentra-
tions (from 25 to 500 lM) of vanadate. We propose, ina13 ECM mineralization. VSa13 cells were seeded in 24-well plates at
ineralizing cultures were then left untreated or treated with IGF-1,
eral deposition was revealed after 4 weeks by von Kossa staining and
ratio between individual values and their corresponding controls (non-
ates values statistically diﬀerent from corresponding controls (n P 3;
Fig. 3. ALP activity in mineralized cell cultures treated with insulin and vanadate. VSa13 cells were seeded in 24-well plates at 2 · 104 cells/well,
grown until conﬂuence then treated for mineralization. Mineralizing cultures were then left untreated (control) or treated with insulin and/or
vanadate. ALP activity was measured in cell extracts after 4 weeks of treatment (left panel) or assayed in the presence of increasing concentration of
vanadate (right panel; values are normalized with ALP activity measured in the absence of vanadate). Asterisk indicates values statistically diﬀerent
from corresponding controls (n P 3; P < 0.05; one-way ANOVA).
Fig. 4. Collagen content in mineralized cell cultures treated with
insulin and/or vanadate. VSa13 cells were seeded in 24-well plates at
2 · 104 cells/well, grown until conﬂuence then treated for mineraliza-
tion. Mineralizing cultures were then left untreated (control) or treated
with insulin and/or vanadate. Total collagen content was determined
after 4 weeks of treatment through Sirius red staining. Asterisk
indicates values statistically diﬀerent from corresponding controls
(n P 3; P < 0.05; one-way ANOVA).
Fig. 5. Putative mechanisms of action for insulin, IGF-1 and vanadate in ver
ATDC5 and VSa13 cell lines, respectively. Black, gray and dashed arrows indi
respectively. X indicates an absence of eﬀect. V, vanadate. Raf, Mek and Er
1384 D.M. Tiago et al. / FEBS Letters 582 (2008) 1381–1385agreement with recent result demonstrating the accumulation
of vanadium in VSa13 cells [8], that although cultures were
treated with non-inhibitory concentrations of vanadate, these
may accumulate intracellularly and reach concentrations
inhibitory for ALP activity therefore aﬀecting mechanisms of
ECMmineralization. On the contrary, the increase of total col-
lagen content in vanadate-treated mineralized cultures (most
probably the result of increased type X collagen as observed
in diﬀerentiating ATDC5 chondrocyte cells [16]) can hardly ex-
plain the decrease of ECM mineralization since increased col-
lagen production is rather likely to beneﬁt ECM
mineralization. Similar results (i.e. inhibition of ALP activity
and/or stimulation of collagen synthesis) have been reported
in chicken [7] and mouse [6,12,20] bone-derived systems, sug-
gesting once again a conservation of mechanisms throughout
evolution and across bone cell types.4. Conclusions
Various evidences have been collected during this work to-
wards the involvement of MAPK and PI-3K/Ras/Erk path-tebrate chondrocyte cells. Circled 5 and 13 indicate pathways related to
cate activated, moderately activated and putatively activated pathways,
k are intermediates in the MAPK pathway.
D.M. Tiago et al. / FEBS Letters 582 (2008) 1381–1385 1385ways in vanadate proliferative and anti-mineralogenic eﬀects,
respectively, using a ﬁsh bone-derived cell line of the chondro-
cyte lineage. We propose that vanadate shares with IGF-1 the
signalling pathway regulating chondrocyte proliferation, while
it shares with insulin the signalling pathway regulating chon-
drocyte diﬀerentiation/mineralization. We also propose that
vanadate not only aﬀects ECM mineralization by activating
the PI-3K/Ras/Erk pathway but also inhibits the enzymatic
activity of ALP. Finally, this work provides strong evidence
for the conservation, throughout evolution, of those mecha-
nisms regulating chondrocyte proliferation and diﬀerentiation,
emphasizing the suitability of ﬁsh to investigate vertebrate
development, in particular mechanisms related to chondrogen-
esis.
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RSpliced variants of insulin-like growth factor 1 (IGF-1), a small peptide with a critical role in metabolismand growth, have been identiﬁed in various vertebrate species. However, despite recent functional data in
mammalian systems suggesting speciﬁc roles (e.g. in muscle formation) for their pro-peptides and/or E
domains, their function remains unclear. In this study, three alternatively spliced variants of Sparus aura-
ta proIGF-1 (1a, 1b, and 1c) were identiﬁed and their expression analyzed. In adult ﬁsh, IGF-1 gene
expression was observed in various soft tissues (highest levels in liver) and calciﬁed tissues, with IGF-
1c being always the most expressed isoform. In developing larvae, each isoform presented a speciﬁc
pattern of expression, characterized by different onset and extent and consistent with a possible role
of IGF-1a and 1b during early post-hatching events (e.g. bone or muscle formation), while IGF-1c would
be rather involved in early larvae formation but probably acts in concerted action with other isoforms at
later stages. We also propose that, in adults, IGF-1a and 1b isoforms may have a local action, while iso-
form 1c would assume a systemic action, as its mammalian counterpart. This hypothesis was further sup-
ported by in silico analysis of isoform distribution, revealing that only IGF-1c/Ea isoform has been
conserved throughout evolution and that other ﬁsh isoforms (i.e. 1a and 1b) may be associated with
mechanisms of osmoregulation. We ﬁnally propose that IGF-1 variants may exhibit different modes of
action (systemic or local) and may be involved in different developmental and adaptive mechanisms.
 2008 Published by Elsevier Inc.38E59
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R1. IntroductionIn vertebrates, body size and linear bone growth are regulated
by numerous and complex cellular signaling pathways controlled
by various growth factors and hormones (Canalis et al., 1993;
Efstratiadis, 1998; Qin et al., 2001). In this regulatory network,
insulin-like growth factor 1 (IGF-1) plays an essential role, regulat-
ing processes such as tissue homeostasis (e.g. bone), metabolism
(e.g. glucose) and organogenesis (including cell differentiation
and proliferation) (Powell-Braxton et al., 1993; D’Ercole et al.,
1996; McCarthy and Centrella, 2001) but it can also act in an auto-
crine/paracrine manner, regulating local processes (Schmid, 1995).
IGF-1 is mainly produced in liver, under the control of growth hor-
mone (GH) (Duguay et al., 1996; Ohlsson et al., 1998), but also oc-
curs in other tissues, e.g. brain, muscle, kidney, gut, and bone
(Moriyama et al., 2000). It is synthesized as a prepro-peptide con-
taining a signal peptide and ﬁve domains named B, C, A, D, and E.
Mature peptide is formed after the proteolytic cleavage of signal
peptide and E domain (Dupont and Holzenberger, 2003). Multiple
forms of proIGF-1 have been detected in mammals (Goldspink and79
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81
82
Elsevier Inc.
cela).
.M. et al., Alternatively splic
during early development ..Yang, 2004) and teleost ﬁsh (Duguay et al., 1992; Shamblott and
Chen, 1993; Wallis and Devlin, 1993; Tanaka et al., 1998), all
resulting from alternative splicing in the region coding for the E
domain. A generally accepted view on IGF-1 was that the E domain
had little or no biological activity other than its potential role in the
biosynthesis of mature peptides (Kuo and Chen, 2002). However,
recent works have clearly demonstrated the speciﬁcity of proIGF-
1 isoforms for particular tissues or cell types (Goldspink and Yang,
2004) suggesting otherwise. In human, isoform Ea assumes a sys-
temic role and is mostly expressed in the liver whereas isoform
Ec, also known as the mechano growth factor (MGF), is mostly ex-
pressed in muscle in response to mechanical stimuli and assumes
an autocrine/paracrine role. Functional analysis of these variants
showed that isoform Ec was more effective in promoting muscle
tissue repair and growth than IGF-1Ea (Goldspink and Yang
2004). In teleost ﬁsh (i.e. Salmonids and Japanese ﬂounder), four
different isoforms have been identiﬁed, shown to be either tis-
sue-speciﬁc or differentially stimulated by GH (Cao et al., 1989;
Duguay et al., 1992; Wallis and Devlin, 1993; Tanaka et al., 1998)
and associated (i.e. the recombinant E peptides) to cell prolifera-
tion/differentiation, angiogenesis and tumor growth (Tian et al.,
1999; Chen et al., 2002; Chun et al., 2006). However, despite an
increasing interest in understanding the physiological role of
proIGF-1 and E peptides, basic data such as a comprehensiveed transcripts of Sparus aurata insulin-like growth factor 1 are dif-
., Gen. Comp. Endocrinol. (2008), doi:10.1016/j.ygcen.2008.04.006
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Table 1
PCR primers used in this study
Primer names Primer sequence (50–30)
Sparus aurata IGF-1 gene primers
IGF-1RV1 GCTAGACATCCCCACGGGTCTCCGCAAGA
IGF-1FW1 GTGACATTGCCCGCATCTCATCCTC
IGF-1FW2 TGGGGATGTCTAGCGCTCTTTCCTTTC
IGF-1RV2 TCCATTCGCTCCGTCCCTACATTC
IGF-1FW3 GGCATTGTGGACGAGTGCTGCTTCC
IGF-1FW4 TGTGAGCTGCGGCGTCTGGAGATGTAC
IGF-1ABC_FW ACAGAATGTAGGGACGGAGCGAATGGAC
IGF-1A_FW AGGACAGCACAGCAGCCAGACAAGAC
IGF-1AB_FW AGTCATTCATCCTTCAAGGAAGTGCATCC
IGF-1ABC_RV TTCGGACCATTGTTAGCCTCCTCTCTG
Sparus aurata housekeeping gene primers
ActinFW CTTCCTCGGTATGGAGTCCTGCGG
ActinRV TCCTGCTTGCTGATCCACATCTGCT
RPL27aFW AAGAGGAACACAACTCACTGCCCCAC
RPL27aRV GCTTGCCTTTGCCCAGAACTTTGTAG
Commercial primers
Oligo-d(T)-adapter ACGCGTCGACCTCGAGATCGATG(T)13
Universal adapter ACGCGTCGACCTCGAGATCGATG
MarAP1 CCATCCTAATACGACTCACTATAGGGC
MarAP2 ACTCACTATAGGGCTCGAGCGGC
GWAP1 GTAATACGACTCACTATAGGGC
GWAP2 ACTATAGGGCACGCGTGGT
2 D.M. Tiago et al. / General and Comparative Endocrinology xxx (2008) xxx–xxx
YGCEN 10117 No. of Pages 9, Model 5G
6 May 2008 Disk Used
ARTICLE IN PRESSU
N
C
O
R
R
E
C
description of existing forms and characterization of their expres-
sion patterns are still lacking. In this paper, we report the existence
of three alternatively spliced IGF-1 transcripts in the gilthead sea-
bream (Sparus aurata) and characterize the expression patterns of
each variant in a wide selection of adult tissues and throughout
ﬁsh development. Furthermore, available E domain structures from
various vertebrates were compared from an evolutionary point of
view.
2. Materials and methods
2.1. Materials
Moloney murine leukemia virus reverse transcriptase (MMLV-RT), Taq DNA
polymerase and TOPO TA Cloning kit were purchased from Invitrogen (Carlsbad,
CA); [a-32P]dCTP, GFX PCR DNA and Gel Band Puriﬁcation kit, Rediprime II kit,
MicroSpin G-50 columns, Quick Prep Micro mRNA Puriﬁcation kit and Hybond-XL
nylon membrane were purchased from Amersham Biosciences (Piscataway, NJ);
RQ1 RNase-free DNase was purchased from Promega (Madison, WI); Advantage,
Marathon and GenomeWalker Universal kits were purchased from Clontech BD Bio-
sciences (Mountain View, CA); Real-time PCR iQ SYBR Green Supermix was pur-
chased from Bio-Rad (Hercules, CA). All other reagents were purchased from
Sigma-Aldrich (St. Louis, MO), unless otherwise stated.
2.2. Larvae, juvenile, and adult ﬁsh
Eggs collected from natural spawning of S. aurata (from January to March 2006)
were placed at 16 C in a closed recirculating system with 35 ppt salinity water.
Light was controlled with ﬂuorescent lamps, maintaining a 12:12 h light–dark pho-
toperiod. Hatching took place 48–56 h after fertilization (HAF; size of larvae was
approximately 3 mm). Developing larvae were fed with rotifers from 96 HAF to
20 days after hatching (DAH; approx. size 7–8 mm) and with newly hatched Art-
emia nauplii from 20 to 50 DAH (approx. size 15 mm). Rotifers and A. nauplii were
fed with microalgae Tetraselmis suecica and Isochrysis galbana. Selco (INVE, Dender-
mond, Belgium) was introduced into larval diet between 35 and 45 DAH through
the use of Selco-enriched A. nauplii. Dry food was introduced into larval diet be-
tween 45 and 70 DAH (approx. size 20 mm) through the use of Selco/dry food mix-
ture (50:50). After 70 DAH, larvae were maintained on a dry food diet. Deﬁnitive
morphology was reached at 90 DAH (approx. size 30 mm). Juvenile and adult ﬁsh
were reared at 16–20 C in 100-L tanks with a 12:12 h light–dark photoperiod, aer-
ation of 100 ml/min, and renewal ﬂow of 1 tank/day and fed with artiﬁcial food
(Sorgal, Porto, Portugal). When sampled for RNA preparation, eggs, larvae (in pools
of at least 10) and juvenile ﬁsh were washed in phosphate-buffered saline solution
and stored at 80 C in 5 ml of Trizol reagent. Tissues for RNA preparation were re-
moved from anesthetized (using 2-phenoxyethanol at 1:10,000 in seawater) then
decapitated adult ﬁsh, and stored at 80 C in 5 ml of guanidine thiocyanate
solution.
2.3. RNA preparation
Total RNA was extracted from selected tissues of adult seabream (3 males of ap-
prox. 0.5 kg and 1 female of approx. 2 kg; equal amount of male and female tissues
were mixed), and from eggs, larvae and juvenile using Trizol. Total RNA concentra-
tion was determined by spectrophotometry at 260 nm (GeneQuant, Pharmacia Bio-
tech, Sweden).
2.4. Construction of cDNA and genomic DNA libraries
Full-length cDNA library and genomic DNA libraries used in this work have
been previously developed in our laboratory using the Marathon cDNA Ampliﬁca-
tion kit and a pool of poly(A+) RNA from S. aurata liver, kidney, brain, and pituitary,
and using the GenomeWalker Universal kit and genomic DNA from S. aurata di-
gested with PvuII and ScaI, respectively. Libraries were constructed according to
manufacturer’s instructions.
2.5. DNA ampliﬁcation and cloning
Rapid ampliﬁcation of cDNA ends (RACE) and ampliﬁcation of full-length cDNAs
were performed by PCR using a 1:50 dilution of the Marathon cDNA library, Advan-
tage Klen Taq Polymerase mix and primers listed in Table 1. Ampliﬁcation of geno-
mic fragments was performed by PCR using GenomeWalker libraries, Advantage
Klen Taq Polymerase mix and primers listed in Table 1. PCR ampliﬁcations were per-
formed according to manufacturer’s instructions. PCR products were size-separated
by agarose gel electrophoresis, puriﬁed using the GFX PCR DNA and Gel Band Puri-
ﬁcation kit, and cloned into pCRII-TOPO vector. Final fragment identiﬁcation was
achieved by DNA sequencing (Macrogen, Seoul, South Korea) and comparative anal-
ysis using BLAST facilities at NCBI (http://www.ncbi.nih.gov).Please cite this article in press as: Tiago, D.M. et al., Alternatively splic
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GenBank database was searched using BLAST facilities at NCBI for sequences
showing similarities to IGF-1 transcripts. Species-speciﬁc sequences were ﬁrst clus-
tered then assembled using ContigExpress module of Vector NTI Suite 10 (Invitro-
gen) to generate, after manual correction, accurate consensus sequences. Virtual
transcripts and alternative splicing events were deduced from consensus sequences
using stringent overlap criteria.
2.7. Genomic Southern analysis
Aliquots (10 lg) of S. aurata genomic DNA, prepared using DNeasy Tissue kit
(QIAGEN, Hilden, Germany), were digested with 25 units of selected endonucleases
(BglI, BglII, EcoRI, HindIII, PstI, and ScaI) and DNA fragments were size-separated on
a 0.8% agarose gel for 10 h at 50 V. DNA was then transferred onto a Hybond-XL ny-
lon membrane by capillarity blotting with 10 standard saline citrate buffer (SSC;
1 SSC is 0.15 M NaCl and 15 mM sodium citrate, pH 7.0). IGF-1 cDNA probe
(199 bp corresponding to cDNA positions 357–555 bp) was radiolabeled with
[a-32P]dCTP (3000 Ci/ml) using the Rediprime II kit and puriﬁed from unincorpo-
rated nucleotides using MicroSpin G-50 columns. The hybridization was performed
overnight at 42 C in ULTRAhyb solution (Ambion, Austin, TX). Blots were washed
2  5 min in low stringency solution (2 SSC, 0.1% SDS) and 3  15 min in high
stringency solution (0.1 SSC, 0.1% SDS) at 60 C, then autoradiographed.
2.8. Analysis of gene expression levels by quantitative real-time PCR
Quantitative real-time PCR was performed using iCycler iQ system (Bio-Rad).
Total RNA (1 lg) from S. aurata unfertilized eggs, embryos, larvae, juveniles or adult
tissues was treated with RQ1 RNase-free DNase (Promega) then reverse-transcribed
at 37 C according to manufacturer’s instruction using MMLV-RT and speciﬁc re-
verse primers (Table 1). PCR ampliﬁcation of cDNA fragments was performed using
the iQ SYBR Green I mix, speciﬁc primers (Table 1) and 10 ng of reverse-transcribed
RNA. The following PCR conditions were used: an initial denaturation step at 95 C
for 4 min then 40–50 cycles of ampliﬁcation (each cycle is 30 s at 95 C, 30 s at
68 C). Fluorescence was measured at the end of each extension cycle in the
FAM-490 channel. Levels of IGF-1 gene expression were calculated using the DDCt
method and normalized using expression levels of b-actin or ribosomal protein
L27a (RPL27a) housekeeping genes in developmental samples and in adult samples,
respectively.
3. Results
3.1. Cloning of seabream IGF-1 transcripts
A 155-bp fragment was ﬁrst ampliﬁed by two rounds of RACE-
PCR using Marathon primers AP1 and AP2 combined with reverse
primer IGF-1RV1 (Table 1), designed according to the partial se-
quence published by Duguay et al. (1996). This fragment was se-ed transcripts of Sparus aurata insulin-like growth factor 1 are dif-
., Gen. Comp. Endocrinol. (2008), doi:10.1016/j.ygcen.2008.04.006
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ARTICLE IN PRESSquenced, identiﬁed as the 50 end of seabream IGF-1 cDNA, and then
used to design the forward speciﬁc primer IGF-1FW1 (Table 1).
Using this primer and Marathon primer AP1, two fragments of
2204 and 2285 bp were ampliﬁed by PCR. Both fragments were se-
quenced and identiﬁed as full-length IGF-1 cDNAs, then termed
IGF-1a (longer transcript; Accession No. AY996779) and IGF-1b
(shorter transcript; Accession No. EF688015). The comparison of
both sequences identiﬁed a region of 81 bp present in IGF-1a but
absent in IGF-1b (Fig. 1) and localized in the sequence coding for
E domain (from nt 492 to nt 572). Speciﬁc primers were designed
in order to detect additional IGF-1 transcripts. Using primer sets
IGF-1FW1/AP1 and IGF-1FW2/IGF-1RV2 (Table 1), a third fragment
was ampliﬁed and termed IGF-1c (Accession No. EF688016). The
comparison of IGF-1c sequence with that of IGF-1a identiﬁed a re-
gion of 117 bp present in IGF-1a but absent in IGF-1c (Fig. 1) andU
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R
E
C
T
Fig. 1. Sparus aurata IGF-1 full-length cDNA and deduced amino acid sequences. Light gr
indicate the B domain; dark gray box and white letters indicate the C domain; white box i
box and white letters indicate the E domain; asterisks indicate the stop codon; black ar
transcript but absent in transcripts IGF-1b and IGF-1c (alternative GT donor splice site is
region present in transcripts IGF-1a and IGF-1b but absent in transcript IGF-1c; putativ
Please cite this article in press as: Tiago, D.M. et al., Alternatively splic
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localized in the sequence coding for E domain (from nt 492 to nt
608). No polyadenylation signal has been clearly identiﬁed but a
putative one has been underlined in Fig. 1. All transcripts identiﬁed
in this study as S. aurata IGF-1 encode peptides containing the six
canonical domains (Moriyama et al., 2000) but exhibiting different
sizes for the E domain: 74, 47, and 35 aa for IGF-1a, 1b, and 1c,
respectively.
3.2. IGF-1 gene occurrence and structure
In order to determine whether the identiﬁed transcripts origi-
nated from alternative splicing of a single IGF-1 gene or from sev-
eral genes, S. aurata genome was analyzed by Southern blot. Probe
was designed within putative exon 3 (determined by comparison
of seabream cDNA with zebraﬁsh, salmon and ﬂounder IGF-1E
D
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O
ay box and black letters indicate the signal peptide; dark gray box and black letters
ndicates the A domain; light gray box and white letters indicate the D domain; black
rows set the boundaries of the 81-bp alternatively spliced region present in IGF-1a
bold-underlined); gray arrows set the boundaries of the 36-bp alternatively spliced
e polyadenylation signal sequence is underlined.
ed transcripts of Sparus aurata insulin-like growth factor 1 are dif-
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genes), which is present in all three transcripts, and found to con-
tain no restriction sites for the endonucleases used in this work to
digest genomic DNA. Accordingly, a single signal was detected in
each lane of the Southern blot (Fig. 2), suggesting the presence of
only one copy of IGF-1 gene in S. aurata genome and that IGF-1
transcripts were spliced variants. Using primer IGF-1FW3 and
IGF-1FW4, designed immediately upstream of the spliced regions,
in combination with GenomeWalker AP1 and AP2 primers, respec-
tively (Table 1), a genomic fragment of approximately 4600-bp was
ampliﬁed, sequenced and identiﬁed as partial seabream IGF-1 gene
(Accession No. DQ118098). This genomic fragment was compared
with each of the transcripts using the Spidey mRNA-to-genomic
alignment tool at NCBI, allowing the reconstruction of partial
IGF-1 gene structure (Fig. 3). Exon 3 (partial), exon 4, and exon 5
(containing 30UTR) were identiﬁed, coding for domains A (partial),
D and E, respectively (Fig. 3A). Spliced regions were localized with-
in exon 3 and exon 4 and shown to be removed through two differ-
ent splicing mechanisms: (1) alternative donor site (two functional
GT donor sites were localized 81 bp from each other) at the 30
extremity of exon 3, and (2) alternative skipping of the entire exon
4. In all cases, the phase of intron insertion was conserved (phase 0
according to (Patthy, 1987) thus maintaining the same reading
frame.
3.3. Expression of IGF-1 transcripts during development and in adult
seabream
Relative expression of alternatively spliced transcripts was
measured by real-time PCR in developing and adult seabream
using three sets of variant-speciﬁc primers (Table 1 and Fig. 3):
set 1 (IGF-1ABC) to amplify all isoforms, set 2 (IGF-1A) to amplify
IGF-1a, and set 3 (IGF-1AB) to amplify simultaneously IGF-1a and
IGF-1b (Fig. 3B). IGF-1b relative gene expression was determined
by subtracting values from set 2 to those from set 3 while relative
levels of IGF-1c gene expression were determined by subtracting
values from set 3 to those of set 1 (Figs. 4 and 5). IGF-1c was ex-
pressed at basal levels in unfertilized eggs and during early devel-
opment (embryo) while strongly up-regulated (around 30-fold) in
hatched larvae. Levels of IGF-1c expression remained high in juve-U
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Fig. 2. Southern blot analysis of S. aurata genomic DNA. A 199-bp radiolabeled
probe speciﬁc for exon 3 was used for hybridization; restriction enzymes used to
digest genomic DNA (BglI, BglII, EcoRI, HindIII, PstI, and ScaI) are indicated above
each lane; DNA marker sizes are indicated in the right.
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nile ﬁsh. IGF-1a transcript was ﬁrst detected in larvae at 20 DAH,
exhibiting intermediate levels of expression that remained stable
throughout larval and juvenile development. IGF-1b transcript
was detected soon after hatching but the levels remained low
throughout larval and juvenile development. All three transcripts
clearly exhibited different patterns of gene expression during
development (different onset and extent), suggesting different
roles during this particular process in ﬁsh. Differential expression
of spliced variants was also observed in adult tissues. IGF-1c was
by far the most expressed transcript in all adult tissues, exhibiting
highest levels of expression in liver, adipose tissue and pancreas,
and moderate levels in brain, gall bladder, spleen and most of
the calciﬁed tissues, including poorly calciﬁed branchial arches
and gills. Both IGF-1a and IGF-1b were poorly expressed in most
tissues analyzed, with the exception of liver.
4. Discussion
Recent reports on the existence of multiple forms of IGF-1 pro-
peptides (or E peptides) in vertebrates have increased the interest
of the scientiﬁc community in understanding its biological role,
which remains largely controversial (Duguay et al., 1992, 1994;
Tian et al., 1999; Chen et al., 2002; Goldspink and Yang, 2004;
Chun et al., 2006).
4.1. Seabream IGF-1: one gene, several transcripts
Three alternatively spliced IGF-1 transcripts (IGF-1a, 1b, and 1c)
have been identiﬁed in gilthead seabream. A transcript similar to
seabream IGF-1a was already available (Duguay et al., 1996), but
with what appears to have been an error in termination codon
identiﬁcation and a partial 30UTR. Alternative splicing mechanisms
identiﬁed in seabream IGF-1 (alternative donor sites in exon 3 and
entire skipping of exon 4) are consistent with those previously ob-
served in Salmonids and ﬂounder (Wallis and Devlin, 1993; Tanaka
et al., 1998), as well as in mammals (Goldspink and Yang, 2004).
Based on these similarities, a fourth transcript was predicted in
seabream (IGF-1d; Fig. 3). IGF-1d has however never been detected
yet and is, therefore, either weakly or not expressed in seabream,
or its expression is restricted to sites not explored in this work.
IGF-1d variant could also be related to the existence of a second
IGF-1 gene as in Salmonids (note that existing data in Salmonids
does not allow the association of any of the variants to a speciﬁc
gene), and consequently be absent in seabream where available
evidence does not support the existence of two genes.
4.2. Expression of IGF-1 spliced variants is tightly regulated during
seabream development
Seabream IGF-1 variants have been shown in this study to exhi-
bit different onset and extent of expression during development. A
similar analysis, although not quantitative, has been performed in
Coho salmon (Duguay et al., 1992): IGF-1b, IGF-1c, and IGF-1d iso-
forms were detected in 6-week-old embryos and thereafter, and
shown to be mainly expressed in liver, muscle, and brain. Expres-
sion patterns of seabream IGF-1 variants during development sug-
gest that either pro-peptides or E domains may be involved in
speciﬁc organ formation and/or development. The early develop-
ment of the endocrine system in seabream (Funkenstein and Co-
hen, 1996; Falk-Petersen, 2005) and the known regulation of IGF-
1 gene expression (through growth hormone) by the endocrine
system in vertebrates (Duguay et al., 1994; Ohlsson et al., 1998)
may be related, in part, to the expression patterns of IGF-1b and
IGF-1c transcripts during seabream early development. Similarly,
the early onset of calciﬁcation in seabream and the later ampliﬁca-
tion of tissue mineralization (Pinto et al., 2001, 2003) and the pro-ed transcripts of Sparus aurata insulin-like growth factor 1 are dif-
., Gen. Comp. Endocrinol. (2008), doi:10.1016/j.ygcen.2008.04.006
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Fig. 3. Schematic representation of S. aurata partial IGF-1 gene and related cDNAs. (A) Exons and domains are represented by boxes; introns are represented by solid thick
lines; light gray boxes indicate exon 3 and related domains, dark gray boxes indicate exon 4 and related domains and white boxes indicate exon 5 and related domains; boxes
with dashed lines indicate putative alternative transcripts; alternative splicing events in exon 3 and exon 4 are represented by solid and dashed lines; primers used for real-
time PCR ampliﬁcation of alternative transcripts are indicated above IGF-1a cDNA. (B) Real-time PCR fragments and primers used to amplify them; ﬁrst primer set is speciﬁc
for IGF-1a transcript and ampliﬁes a 258-bp fragment; second primer set is speciﬁc for IGF-1a and IGF-1b transcripts and ampliﬁes a 201-bp fragment; third primer set
ampliﬁes a 134-bp fragment common to all three transcripts.
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Fig. 5. Relative IGF-1 gene expression in S. aurata tissues measured by real-time PCR. IGF-1 gene expression was normalized using housekeeping gene RPL27a; asterisks
indicate that transcripts were not detected; values represent the mean of results obtained in at least three independent real-time PCR experiments.
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Bikle et al., 2001; Zhang et al., 2002) and ﬁsh (Suzuki and Hattori,
2003) may be related, in part, to the expression patterns of IGF-1
transcripts during seabream development. Association of IGF-1
with muscle formation (red and white muscle formation at 1 and
35 DAH, respectively (Ayala et al., 1999) is consistent with identi-
ﬁcation of various spliced transcripts in the muscle of Coho salmon
(Duguay et al., 1992) and seabream (this study), and with its role in
muscle formation in mammals (Goldspink and Yang, 2004). How-
ever, additional experiments (e.g. phenotype analysis of develop-
ing larvae or cultured cells where expression of each of the IGF-1
precursors has been altered, or the determination of sites of gene
expression by in situ hybridization using transcript-speciﬁc probes)
will need to be performed to conﬁrm the role of IGF-1 in these
processes.
4.3. Systemic versus autocrine/paracrine action of IGF-1 spliced
variants in seabream
Various physiological mechanisms have been associated with
IGF-1 action in mammals. It includes: (i) stem cell differentiation
into adipocyte andmetabolic mechanisms of fasting and re-feeding
in adipose tissue (Bertile and Raclot, 2004; Otto and Lane, 2005);
(ii) pancreatic b-cell proliferation (Kulkarni, 2005) and insulin re-
lease (Hill et al., 1997); and (iii) regulation of bone mineral density
in developing structures (Canalis, 1993). Pattern of IGF-1 expres-
sion in adult seabream (i.e. main expression is in liver, adipose tis-
sue and pancreas; relatively high expression in calciﬁed tissues) isPlease cite this article in press as: Tiago, D.M. et al., Alternatively splic
ferentially expressed in adult tissues and during early development ..in agreement with the reported role of mammalian IGF-1 in these
processes. IGF-1c propeptide (or E peptide alone), which transcript
is predominant in liver (expression levels are 2–4 times higher
than those for variants 1a and 1b), is likely to be involved in impor-
tant physiological processes upon its release into circulation, a
hypothesis consistent with previous observations in mammals, in
which a systemic mode of action was demonstrated for IGF-1-Ea,
the IGF-1c-like isoform in mammals (Goldspink and Yang, 2004).
We propose that IGF-1c isoform assumes a similar role in sea-
bream, and following the same idea, that variants 1a and 1b would
assume local functions. Also of interest is our ﬁnding of relatively
high IGF-1c expression in calciﬁed tissues, which may indicate a
role of this variant in bone formation or metabolism.
4.4. Mechanisms of IGF-1 alternative splicing in vertebrates are taxon-
speciﬁc
In order to understand the occurrence of IGF-1 variants in adult
tissues and during seabream development, orthologous sequences
have been searched within GenBank sequence data base using
Blast facilities at NCBI. Positive search results were considered to
be members of the IGF-1 family if they showed signiﬁcant se-
quence similarity to any of the previously identiﬁed members
and if this similarity extended throughout the protein. Our search
identiﬁed various sequences previously identiﬁed as IGF-1 and
numerous ESTs (a total of 154 sequences), from which we could
identify/reconstruct 52 IGF-1-related cDNAs (see Supplementary
data in Fig. S1) from 41 species representing most classes of verte-ed transcripts of Sparus aurata insulin-like growth factor 1 are dif-
., Gen. Comp. Endocrinol. (2008), doi:10.1016/j.ygcen.2008.04.006
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ARTICLE IN PRESSbrates (i.e. mammals, birds, amphibians and bony ﬁsh). An IGF-1-
like sequence was also identiﬁed in a cartilaginous ﬁsh (Squalus
acanthias) but homology with other IGF-1 sequences, in particular
within the E domain, was weak making its identiﬁcation dubious.
Consequently, no sequence from cartilaginous ﬁsh was included
in our analysis. While all available sequences from bony ﬁsh, birds
and amphibians were analyzed, only sequences from human and
mouse were processed for mammals, since almost nearly complete
sets of sequences exist for both species. Four alternatively spliced
IGF-1 transcripts were identiﬁed in bony ﬁsh: IGF-1a, 1b, 1c, andU
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identiﬁed in birds and amphibians. Finally, three IGF-1 variants
were identiﬁed in mammals, one spliced as seabream IGF-1c
(IGF-1–Ea), and two variants speciﬁc to this taxonomic group:
IGF-1–Eb, which includes exons 4 and 5 in the E domain, and
IGF-1–Ec, which includes exons 4, partial 5 and 6 (Goldspink and
Yang, 2004). Analysis of the distribution of IGF-1 variants in ﬁsh
taxonomic subgroups revealed that (i) IGF-1a transcript was spe-
ciﬁc of the Acanthopterygii and Protacanthopterygii, (ii) IGF-1b
transcript was mainly found in Ostariophysi (also observed inE
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few Acanthopterygii and Protacanthopterygii), (iii) IGF-1c was
identiﬁed only in gilthead seabream and Salmonids, and (iv) IGF-
1d, the rarest variant, was exclusively found in Salmonids
(Oncorhynchus kisutch and Oncorhynchus mykiss). However, due to
the limited genetic information available in public databases for
this taxonomic group, we cannot exclude that IGF-1 isoform distri-
bution presented here may be incomplete. Finally, isoforms 1a, 1b,
and 1d were shown to be speciﬁc for bony ﬁsh, while isoforms Eb
and Ec were found exclusively in mammals. On the contrary, IGF-
1c/Ea variant was common to all vertebrate taxa and the only one
present in amphibians and birds (Fig. 6B). We propose that 1c/Ea
propeptide would play a systemic role in ﬁsh as shown in mam-
mals (or would have acquired this role throughout evolution),
while other propeptides (i.e. 1a, 1b, 1d, Eb, and Ec) would play spe-
ciﬁc and local roles that remain to be explored in future studies.
The strong occurrence of IGF-1a and 1b in ﬁsh inhabiting waters
of different salinities (Fig. 6A) and the up-regulation of IGF-1
expression in salmon gills during seawater adaptation and smoltif-
ication process (Sakamoto et al., 1995) could suggest a role for
these variants in osmoregulation. In order to test this hypothesis,
additional experiments, such as analysis of IGF-1 expression during
adaptation of gilthead seabream, which is euryhaline, to different
water salinities should be carried out in studies similar to those de-
scribed for striped bass (Tipsmark et al., 2007).
4.5. Conclusion
Three seabream IGF-1 alternative transcripts have been iden-
tiﬁed and extensively analyzed by quantitative real-time PCR in
developing and adult specimens. In general, a tight regulation
of these transcripts’ expression was observed, and we propose
that different E domains, associated or not to a mature peptide,
assume speciﬁc functions. We hypothesize that: (a) IGF-1a and
IGF-1b are involved in the regulation of late developmental
events (e.g. muscle and bone formation); (b) IGF-1c participates
in early developmental events, and in later events in concerted
action with IGF-1a and IGF-1b; and (c) IGF-1c isoform is associ-
ated to a systemic mode of action. Finally, occurrence of differ-
ent IGF-1 variants in teleosts could be associated with
osmoregulatory processes.
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